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Delirium in Patients admitted to the Intensive Care
Definition of Delirium
The word delirium is derived from the Latin “lira” meaning track or trail. De-
lirium can be translated in terms of “derailment” or “to get off track”. Delirium is a 
psycho-organic disorder, which implies that a physical cause underlies the cognitive 
dysfunction, whereas the symptoms are psychological. According to the Diagnostic 
and Statistical Manual of Mental Disorders (DSM-IV) the diagnostic criteria for 
delirium are (1):
• Acute onset (hours or, days) and often fluctuating throughout the day
• Disturbances in consciousness: reduced clarity of awareness of the environment 
with a decreased attention span, reduced ability to focus, sustain and shift 
attention
• Change in cognition (memory deficit, disorientation, language disturbance) or 
the development of a perceptual disturbance that is not accounted for by a pre-
existing, established, or evolving dementia
• From the history, physical examination, or laboratory findings there is 
evidence that the perceptual disturbance is caused by the direct physiological 
consequences of a general medical condition. 
Incidence of Delirium in Intensive Care Patients
Delirium is a serious condition in hospitalized patients, including the critically ill 
patients in the Intensive Care Unit (ICU). In ICU patients, reported incidences range 
widely between 11-89% (2-4). These large differences in delirium incidence rates 
may be related to differences in ICU patient case-mix and is likely related to the 
intensity of the screenings and different methods of screening (5).
Three subtypes of delirium can be distinguished (4):
1. Hyperactive subtype: the patient is hyperalert or agitated
2. Hypoactive subtype: the patient is hypoalert or lethargic  
3. Alternating or mixed subtype: characterized by alternating hyper- and 
hypoactive symptoms.
The hyperactive subtype, usually associated with delusions, hallucinations, 
agitation and disorientation, occurs in approximately 1-2% of patients with delirium 
(4). The hypoactive subtype, characterized by lethargy, psychomotor slowing and 
inappropriate speech or mood, occurs in approximately 35% of patients with 
delirium (4). In intensive care patients with delirium, the alternating or mixed 
subtype has the highest incidence rate, and represents up to 60-70% of all cases 
of delirium. Especially, the hypoactive subtype is difficult to recognize and the 
Delirium in Intensive Care Patients
12
Introduction and outline of this thesis
13
incidence/prevalence is therefore likely to be underreported. Because of the 
fluctuating course of delirium it can be assumed that the alternating subtype is also 
underreported. 
Detection of Delirium in Intensive Care Patients
The gold standard for diagnosing delirium is the examination by a psychiatrist/
neurologist or geriatrician, who assesses delirium based on the above-mentioned 
DSM-IV criteria. In clinical ICU practice this is barely feasible, especially considering 
the fluctuating course of delirium and the fact that symptoms are more often 
manifest outside office hours, after sundown (1;6). The most practical solution to this 
problem is recognition of delirium by the attending nurse. After all, of all caregivers, 
nurses spend most hours at the patient’s bedside and are in the best position to 
closely observe the patient’s behaviour for longer periods. However, evidence 
indicates that nurses, as well as physicians, often fail to identify delirium, especially 
the hypoactive- and the alternating subtypes (7). According to Inouye et al. (8), the 
most important reason for this is the lack of a practical delirium assess tool. Other 
studies confirm this, showing that if ICU patients are not screened for delirium in 
a standard manner, 60 to 70% of patients with delirium are missed by ICU nurses 
and physicians (9;10). As a result several assessment tools for ICU patients have 
been developed that facilitate early detection of delirium by professionals other 
than psychiatrists, neurologists or geriatrician. Of these delirium assessment tools 
for ICU patients the Intensive Care Delirium Screening Checklist (ICDSC) developed 
by Bergeron (11) and the Confusion Assessment Method-Intensive Care Unit (CAM-
ICU) designed by Ely et al. (12) are the most frequently used tools. The ICDSC is an 
observational instrument consisting of eight items with a sensitivity of 99% and 
a specificity of 64% (11). This implies that in 36% of the patients the test result 
show ‘delirium’, while DSM-IV criteria indicate that the patients are not suffering 
from delirium. The CAM-ICU, when used by dedicated research nurses, has a 
better performance with a sensitivity of 95-100% and a specificity of 93-98% (13). 
Worldwide, the CAM-ICU is the best validated and most frequently used delirium 
assessment instrument in ICU patients by non-psychiatrists. 
The effects of implementation of the CAM-ICU on the treatment of delirium are 
unknown. It appears plausible that if a delirium assessment tool is implemented 
in daily practice, more delirious patients will be recognized which consequently 
affects the delirium treatment but this needs to be studied. 
In daily clinical practice the attending ICU nurses, not research nurses, use the 
CAM-ICU to screen their patient. The sensitivity and specificity of the CAM-ICU when 
executed by the attending nurse compared with the ‘gold standard’ is currently 
unknown and is examined in this thesis. 
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A disadvantage of the CAM-ICU is that it is a momentary test executed only once 
to 3 times a day. Because of the fluctuating course of delirium, this can lead to a 
false negative result. If the nurse or physician suspects delirium, the patient should 
be tested more frequently. Although there is no evidence for the optimal number 
of times a day patients should be screened, it is unlikely that assessing patients only 
once a day would be sufficient. 
Given this drawback of momentary tests it would be interesting to explore other 
possibilities to diagnose delirium. For many diseases specific laboratory tests are 
available to aid the diagnosis. Currently, no laboratory test is available to diagnose 
the disorder delirium. We therefore investigated the possibility to find a fingerprint 
for delirium using proteomics techniques. 
Impact of Delirium in Intensive Care Patients
The occurrence of delirium is associated with serious health problems. 
Independent of age and severity of illness (14), delirious patients have a longer 
duration of mechanical ventilation, ICU stay, and in-hospital stay than non-delirious 
patients (13;15). It is unknown whether these short-term consequences are similar 
in all patient categories and if there are differences between the delirium subtypes. 
Patients suffering from delirium have a significantly higher mortality rate than 
patients without delirium and delirium is reported as an independent predictor of 
mortality (16). Observational data show that each day a delirium continues, the risk 
of persisting cognitive disorders and death increases with approximately 10% (13). 
Although there are several long-term health related quality of life (HRQoL) studies 
performed in ICU patients (17-19), little is known about the effects of delirium on 
long-term quality of life. Therefore we explored the effect of delirium on long-term 
health related quality of life and on cognitive functions. 
Prediction and Prevention of Delirium in Intensive Care Patients
In view of the impact of delirium there is a clear need for prevention, as well as for 
effective treatment. Prevention can play an important role in reducing the incidence 
of delirium, in addition to reducing the subsequent harm of delirium in ICU patients. 
Prevention of delirium is likely most efficient and effective in ICU patients with the 
highest risk for developing delirium. To determine which patients have a high risk 
for delirium a prediction model would be necessary. Such a delirium prediction 
model is available for hospitalized patients (20), but a delirium prediction model for 
ICU patients is currently lacking. 
If we had a prediction model that would allow us to identify high risk patients, 
which preventive measures should be taken? There is some evidence that 
preventive measures can be effective (21;22). A multicomponent prevention 
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strategy was effective in reducing the delirium incidence and duration (21) and a 
low dose of prophylactic haloperidol resulted in a decrease in severity and duration 
of delirium and shortened the length of stay in-hospital (22). However, the two 
studies indicating this were performed in hospitalized elderly patients and not in 
ICU patients. Interestingly, in a retrospective cohort study a lower hospital mortality 
rate was found in mechanically ventilated ICU patients who received haloperidol 
compared with patients who were not treated with haloperidol (23), thus suggesting 
haloperidol may protect ICU patients in some way. Nevertheless, to date no delirium 
prevention studies have been performed in ICU patients. Therefore, in this thesis 
we describe the development and validation of a delirium prediction model for ICU 
patients and the effect of prophylactic use of haloperidol in ICU patients with a high 
risk for delirium.
Role of Biomarkers in Delirium in Intensive Care Patients
Finally, the aetiology of delirium is far from clear. A large diversity of factors are 
related to delirium and the pathogenesis of delirium is likely to be multifactorial (24-
26). Several pathways may contribute to the development of delirium (25;27;28), 
the most important being the cholinergic, the serotonergic and the inflammatory 
pathway. The cholinergic pathway, with acetylcholine as its neurotransmitter, plays 
a role in consciousness and activation of cholinergic neurons is associated with 
dreaming, hallucinations (29) and delirium (28). The serotonergic pathway with 
serotonin as the principal neurotransmitter modulates mood, wakefulness and 
cognition (30). The inflammatory pathway also plays a role in the onset of delirium. 
For example, administration of the cytokine interleukin-2 results in delirium (31;32). 
More recently it was shown that several other proinflammatory cytokines are 
associated with the onset of delirium in elderly patients (27). The inflammatory 
pathway may even be more important in critically ill intensive care patients, since 
these patients suffer from more systemic inflammation than non-ICU patients. 
One can hypothesize that the end-products of these different pathways exert 
direct injurious effects to the cells of the central nerve system and that these toxic 
effects can be detected through increased levels of brain specific proteins. To date, 
no studies are performed in which elevated levels of brain specific proteins are 
related to delirium. Also the role of inflammation in delirium in ICU patients is not 
investigated yet. In this thesis we determined the effect of several pro- and anti-
inflammatory cytokines on brain function and cognition in healthy volunteers. In 
addition, we determined the role of these cytokines and the role of brain specific 
proteins in delirious ICU patients with and without evidence of an infection.
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In summary, the aims of this thesis are:
• To gain more insight into the diagnosis of delirium in ICU patients using the 
confusion assessment tool and to explore if delirium can be diagnosed with 
other tools apart from the existing delirium assessment tools; 
• To determine the impact of delirium on several short- and long-term health 
related consequences; 
• To determine if delirium in ICU patients can be predicted and prevented;
• To explore the role of biomarkers in delirium in ICU patients.
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Outline of this thesis
This thesis consists of four parts. PART ONE is focussed on the Detection of Delirium 
in Intensive Care Patients. In Chapter 2 we describe a tailored implementation 
strategy, which was used to implement the validated confusion assessment method 
for ICU (CAM-ICU) patients. We evaluated this implementation strategy on several 
outcome measures and we studied the effect on the treatment of delirious patients. 
In the original studies of the CAM-ICU, the assessment tool had a high sensitivity 
and specificity when used by dedicated research nurses. In a multicentre study in 
the Netherlands (Chapter 3) we determined the performance of the CAM-ICU when 
used by ICU-nurses in daily practice. In Chapter 4 we describe a prospective study 
in which we explored the possibility to find a fingerprint of delirium markers in the 
urine of patients following cardiac surgery using urinary proteomics.
In PART TWO we determined the Impact of Delirium in Intensive Care Patients. 
First, we focused on the delirium incidence in several admission categories of 
intensive care patients and short-term consequences of delirium such as duration 
of mechanical ventilation, unplanned removal of tubes and catheters, length of stay 
in the ICU and hospital (Chapter 5). In this study we also determined to what extent 
delirium contributes to these short-term consequences. Knowing that delirium is 
a significant predictor for mortality, in Chapter 6 we examined if adding delirium 
as an additional variable to the acute physiology and chronic health evaluation 
(APACHE-II) score would improve the predictive estimate of the model. Chapter 7 
describes the impact of delirium on long-term health related quality of life and 
cognitive functioning of ICU survivors.
PART THREE focuses on the Prediction and Prevention of Delirium in Intensive Care 
Patients. In Chapter 8 we examined the possibility to develop a delirium prediction 
model for ICU patients with predictors which are readily available within 24 hours 
after ICU admission to enable identification of high risk patients. When it would be 
possible to develop and to validate such a delirium prediction model it would be of 
interest to implement this model in daily practice and to consequently examine the 
effects of preventive measures taken in patients with a high risk for delirium. The 
effects of preventive treatment with a low dose haloperidol were examined in high 
risk patients in Chapter 9.
Delirium in Intensive Care Patients
19
The last part of this thesis, PART FOUR, examined the Role of Biomarkers related 
to Delirium in Intensive Care Patients. We explored the role of several pro- and 
anti-inflammatory cytokines on brain function (measured by EEG), cognitive 
functioning and brain specific proteins in an experimental human endotoxemia 
model (Chapter 10). In Chapter 11 associations of various markers of inflammation 
and brain specific proteins with delirium in patients with or without infection/SIRS 
criteria and their relation to long-term cognitive function are described.
In the general discussion, conclusions and future directives in Chapter 12 the 
results described in this thesis are summarized and our findings are discussed in 
view of several methodological issues,  clinical consequences and aims for future 
research.
Introduction and outline of this thesis
1

PART ONE
Detection of Delirium 
in Intensive Care Patients
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Implementation of 
a delirium assessment tool 
in the ICU can influence 
haloperidol use
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Abstract
Introduction
In critically ill patients, delirium is a serious and frequent disorder that is associated 
with a prolonged intensive care and hospital stay and an increased morbidity and 
mortality. Without the use of a delirium screening instrument, delirium is often 
missed by ICU nurses and physicians. The effects of implementation of a screening 
method on haloperidol use is not known. The purpose of this study was to evaluate 
the implementation of the confusion assessment method-ICU (CAM-ICU) and the 
effect of its use on frequency and duration of haloperidol use.
Methods
We used a tailored implementation strategy focused on potential barriers. We 
measured CAM-ICU compliance, interrater reliability, and delirium knowledge, and 
compared the haloperidol use, as a proxy for delirium incidence, before and after 
the implementation of the CAM-ICU.
Results
Compliance and delirium knowledge increased from 77% to 92% and from 6.2 
to 7.4, respectively (both, p <.0001). The interrater reliability increased from 0.78 
to 0.89. More patients were treated with haloperidol (9.9% to 14.8%, p < .001), 
however with a lower dose (18 to 6 mg, p = 0.01) and for a shorter time period 
(5 [IQR:2-9] to 3 [IQR:1-5] days, p = .02).
Conclusions
With a tailored implementation strategy, a delirium assessment tool was 
successfully introduced in the ICU with the main goals achieved within four months. 
Early detection of delirium in critically ill patients increases the number of patients 
that receive treatment with haloperidol, however with a lower dose and for a 
shorter time period.
Delirium in Intensive Care Patients
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Introduction
Delirium is a common psychiatric disorder in critically ill patients. It has an acute 
onset and combines cognitive and attention defects with a fluctuating consciousness 
(1). It is associated with a prolonged intensive care and hospital stay and an increased 
morbidity and mortality (2-4)
Although there has been increasing interest in delirium in the past five years, 
standard screening of patients in daily practice is still not common, resulting in an 
underestimation of the problem. Previous studies showed that, without the use 
of a screening instrument, more than 60% of patients with delirium are missed by 
ICU nurses and more than 70% by physicians (5;6). It can therefore be assumed 
that delirious patients are not sufficiently treated if they are not recognized. The 
incidence rate in critically ill patients varies between 11% and 87%, depending on 
the study design, methods for assessment, and differences in population (2;4;7-9).
Although there is no evidence that the use of a delirium assessment tool results in 
improvement of outcome, early recognition of delirium is important for adequate 
and early treatment. Therefore routine screening of patients is necessary. In addition, 
because of the fluctuating clinical signs and symptoms of delirium, screening should 
be performed at least once every 8 to 12 hours (10;11). A delirium assessment tool 
should therefore be quick and easy to use with a high interrater reliability. 
The Dutch guidelines Delirium in the Intensive Care recommends the screening 
of all ICU patients with a reliable and validated delirium screening instrument 
(van Eijk MJJ, Spronk PE, van den Boogaard MHWA, Kuiper MA, Smit EGM, Slooter 
AJC. Delirium op de Intensive Care, unpublished data), such as the intensive care 
delirium screening checklist (ICDSC) (12) or the confusion assessment method-ICU 
(CAM-ICU) (13). 
The treatment of delirium is based on removing the underlying somatic disorder 
frequently combined with pharmacological therapy. Although there is no clear 
evidence that treatment improves the prognosis of delirious ICU patients (14), and 
haloperidol has significant side effects (15;16), haloperidol is the most commonly 
recommended pharmacological agent (17). As screening will probably increase 
the number of patients diagnosed with delirium, it could also increase the use 
of haloperidol. In view of this, it is important to determine the effect of the 
implementation of a screening instrument on the use of haloperidol. 
The first aim of our study was to evaluate our strategy for the implementation 
of the CAM-ICU. Therefore, the compliance with scoring of the CAM-ICU, the 
interrater reliability, and improvement in delirium knowledge of the nurses were 
used as indicators for successful implementation. We assumed that a larger number 
of delirious patients would be detected with the use of the CAM-ICU, in comparison 
2
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with previous periods without the standard use of a screening tool. The second aim 
of our study was therefore to assess how the CAM-ICU influences the frequency 
and duration of haloperidol use, which may be considered to be a proxy for the 
delirium incidence and duration. 
Material and methods
This study was conducted in the Radboud University Nijmegen Medical Centre, 
the Netherlands, a 960-bed university hospital that includes a level 3 (highest level) 
ICU with 40 beds divided over four adult wards and one paediatric ward. Annually 
2000 to 2500 (cardiothoracic surgery, neurosurgical, medical, surgical, and trauma) 
patients are admitted.
The local Institutional Review Board of Arnhem-Nijmegen indicated that for this 
study no approval was required and no informed consent from patients was needed. 
Nurses and the implementation of the CAM-ICU 
Although the ICDSC and the CAM-ICU are suitable delirium screening instruments, 
we preferred to implement the CAM-ICU above the ICDSC because of the higher 
sensitivity and specificity, and because the CAM-ICU is translated and validated in 
Dutch (18). The CAM-ICU is an easy to perform assessment tool for ICU nurses, which 
consists of a two-step approach model (13) [see Additional data file 1]. Before the 
implementation of the CAM-ICU, identification of delirious patients was based on 
the judgement of the attending ICU physician, and a delirium screening instrument 
was not used. Due to the potential importance of unrecognised delirium, we 
decided that this should be changed to a situation where regular and systematic 
assessment of delirium was performed by ICU nurses with specific knowledge of 
delirium recognition. Therefore, we introduced the CAM-ICU as an instrument for 
early recognition of delirium and started with the implementation on all four adult 
ICU wards in December 2007.
Implementation of a delirium assessment tool in daily practice introduces an 
essential change for ICU nurses. As there is no single best method for implementing 
an innovation in all settings (19), it is important to identify potential barriers and 
facilitators in this particular setting. For a good adaptation of a delirium screening 
instrument it is important to tailor the implementation strategy to these facilitators 
and barriers (20). Furthermore, support from the organisation and medical and 
nursing staff participation is important for a successful implementation (21).
Our implementation strategy [see Additional data file 2] was focused on potential 
barriers and facilitators for screening with the CAM-ICU (Table 1), which were 
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identified during several, unstructured, interviews with the nursing and medical 
staff.
Table 1 Identified potential barriers and facilitators during interviews
Table 1. Identified potential barriers and facilitators during interviews  
Implementation barriers  Implementation facilitators 
1. Lack of knowledge concerning delirium   1. Patient data management system  
2. Inavailability of the assessment tool   2. Senior nurses 
3. To fill in the delirium assessment tool 
on paper three times a day 
(‘paperwork’)  
3. Support of medical and nursing staff  
4. Time to perform the assessment   4. Delirium researcher  
 
 
We integrated the CAM-ICU algorithm in our patient data management system, 
which is available at all bedside computers. Because of the fluctuating course of 
delirium every patient had to be assessed minimally once in every eight-hour shift, 
according to the CAM-ICU manual (22;22). If the mental status changed after an 
assessment, an additional assessment had to be performed. Patients were excluded 
from screening when they had a Richmond agitation sedation score (RASS) of –4 
or -5 (13), were unable to understand Dutch, were severely mentally disabled, or 
suffered from a serious receptive aphasia. All necessary testing tools (attention 
screening pictures and disorganized thinking questions) were made available at 
every bed. The computer notified the nurse about the outcome of the CAM-ICU 
screening, that is, delirious or not.Evidence-based interventions (23) included in the 
implementation strategy were: education; educational outreach visits; reminders 
and feedback; and leadership. Education and educational outreach visits 
All ICU nurses were trained in the use of the CAM-ICU and performed a knowledge 
test prior to the training. The education consisted of a one-hour group training 
prior to the implementation of the CAM-ICU. During this training, information 
about delirium features, recognition, and delirium types was given. Furthermore, 
specific information was given about the CAM-ICU. We used educational material 
from the delirium website (22) such as the training video and the Harvard CAM-
ICU flow sheet. We appointed ‘delirium key-nurses’, who received supplementary 
training, for further instruction and introduction of the CAM-ICU in their unit. In 
addition, posters with the Harvard CAM-ICU flow sheet were distributed to nurses 
and the medical staff. Also, the medical staff was informed about delirium and the 
CAM-ICU. Supplementary individual training on the job (by MvdB, and the ‘delirium 
key-nurses’) started one month after the implementation and was given whenever 
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screening compliance and interrater reliability dropped below the stated aim. The 
focus during this training on the job was on the most common mismatches, that 
is feature 1A and 1B [see Additional data file 1]. Determination of the presence of 
cognitive function disturbances and the fluctuating nature of consciousness were 
the most difficult points for the ICU nurses. Individual problems with the assessment 
were addressed by focusing the training on the difficulties experienced during 
observations.
Reminders and feedback 
When a delirium assessment was not carried out, a pop-up appeared on the 
bedside computer as a reminder for the nurse. The CAM-ICU scoring rate, that 
is the screening compliance, and the interrater reliability were measured. The 
results were evaluated with the delirium key-nurses and the nursing staff, twice a 
week as parameters of a successful implementation. Feedback about results and 
performance of the CAM-ICU was supplied weekly by e-mail and during monthly 
clinical meetings. 
Leadership 
The medical and nursing staff committed themselves to, and supported the 
implementation of the delirium assessment tool, as agreed upon during the 
information meeting and was reported during feedback of the key nurses. One project 
leader was responsible and supervised the implementation process (MvdB). Prior to 
the implementation, the CAM-ICU was introduced to the medical staff. Two months 
after the implementation, the presence of delirium became a standard part of the 
daily multidisciplinary meeting, in which all patients are discussed. All ICU wards were 
visited daily by the project leader to identify problems concerning the performance 
and compliance of the assessment tool and for personal or group feedback.
Chosen indicators of a successful implementation were: regular assessment of 
all ICU patients defined as a screening compliance of more than 80%; interrater 
reliability score of more than 0.80; and improvement of the level of knowledge 
concerning delirium.
The compliance was calculated as the percentage of performed assessments 
per day of the total number of assessments that should have been performed. 
Interrater reliability tests were performed several times during the first month 
after the implementation and twice a week during and after the training on the job 
period. For this the CAM-ICU score assessed by the ICU nurse was compared with 
the CAM-ICU score assessed by an expert psychiatric nurse (GR). The maximum 
period between the two assessments was one hour and patients were chosen 
randomly. Patients who were excluded from screening with the CAM-ICU were 
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also excluded from the interrater reliability testing. We developed a non-validated 
written delirium knowledge test that had to be completed in 10 minutes prior 
to the delirium training and consisted of 10 mixed open and closed questions. A 
similar post-training test was performed four months later. ‘Delirium knowledge’ 
is expressed on a scale of 0 to 10. The implementation period started in December 
2007 and ended in March 2008, after reaching the indicators of care improvement 
(Figure 1). The nursing staff consists of 140 nurses of which 18 (13%) were ICU nurses 
in training. The patients and haloperidol treatment 
As delirium incidence rates before the use of the assessment tool were not available, 
we used the frequency of haloperidol use as a proxy for delirium incidence. Data 
of all patients who were treated with haloperidol are available through our patient 
data management system. As a general rule, in our ICU all patients diagnosed with 
delirium are treated with haloperidol and delirium is the only reason for prescribing 
haloperidol.
Figure 1 Implementation flow chart 
The duration of haloperidol treatment was used as a proxy for the duration of 
the delirious period. For the incidence rate of a four-month period (March until 
June 2008) after the implementation, the CAM-ICU results were compared with the 
haloperidol use during the same period of the two previous years. We compared 
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the total number of all consecutive patients treated with haloperidol, total days of 
treatment, and the total dose of administered haloperidol per patient and per day. 
Statistical analyses 
All data analyses were performed with SPSS 16.0 (SPSS Inc., Chicago, IL, USA). 
Normally distributed data (demographic data, knowledge level, and the scorings 
rate) were tested parametrically (Student’s t-test, repeated measurement analysis 
of variance). Data concerning the treatment with haloperidol were not normally 
distributed and were tested non-parametrically with the Friedman test and the 
Kruskal-Wallis one-way analysis of variance test. Interrater reliability of the outcome 
of screening, that is delirious or non-delirious, was calculated with the Cohen’s 
Kappa statistic. 
Results
Evaluation of implementation and nurses 
In the first month of the implementation period the interrater reliability was 0.78 
(n = 25, 95% confidence interval (CI): 0.5 to 1.0) and following intensive training on 
the job of almost all ICU nurses this increased to 0.89 (n = 47, 95% CI: 0.75 to 1.0).
In the first month after the implementation the compliance of screening with 
the CAM-ICU was 77% and increased significantly to 92% (repeated measurement 
analysis of variance, p <.0001) after four months. Scoring rate of the nurses at the 
pre-course delirium knowledge test was 6.2 ± 1.7 (n = 136) and increased significantly 
to 7.4 ± 1.2 (n = 122) four months later (Student’s t-test, p = .0001). 
Haloperidol treatment and patients 
With the exception of a small, but statistically significant difference in the Acute 
Physiology and Chronic Health Evaluation-II (APACHE-II) score, the demographic 
variables of the patients did not differ between the three years (Table 2). In the same 
period in 2006 and 2007, 13 (10%) and 20 (13%) patients per month were treated 
with haloperidol, respectively (Table 3). Following the implementation period, 
based on the CAM-ICU results, this increased significantly to 37 (23%) patients per 
month (p <.001) compared with the previous period without the use of the CAM-
ICU. All patients who received haloperidol in the period after the implementation in 
2008 were detected with the CAM-ICU as delirious patients.
From these 147 delirious patients, 25 (17%) had a hyperactive type, 47 (32%) a 
hypoactive type, and 74 patients (50.3%) had a mixed-type delirium. During this 
period 641 patients were admitted of which 74 patients were excluded from CAM-
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ICU screening. The most frequent reason was sustained coma (49%). To compare 
the effect on the detected incidence before and after the implementation of the 
CAM-ICU, we used the total of 641 patients, because of the lack of information of 
the patients in the period before the implementation. 
Table 2 Demographic variables of ICU-patients before and after implementation of CAM-ICU
Table 2. Demographic variables of ICU‐patients before and after implementation of CAM‐ICU 
Period 
Prior to 
implementation 
March to June 
2006 
Prior to 
implementation 
March to June 
2007 
After 
implementation 
March to June 
2008 
p value 
Number of 
patients 
512  589  641   
Age   57.5 ± 16.4  58.9 ± 16.6 59.5 ± 15.6  N.S.
Gender (M/F)  339/173  370/219 409/232  N.S.
APACHE‐II score  16.9 ± 7.0  17.1 ± 6.9 15.5 ± 6.5  .0001
Length of stay on 
ICU in days 
(median (IQR)) 
1.3 (0.8 to 5.9)  1.0 (1 to 5)  1.0 (1 to 3)  N.S. 
Admission type (n) 
Elective surgery 
Urgent surgery 
Medical 
 
214 (42%) 
106 (20%) 
192 (38%) 
283 (48%) 
96 (16%) 
210 (36%) 
 
340 (53%) 
76 (12%) 
225 (35%) 
N.S. 
 
All values are means ± standard deviation unless otherwise reported. 
APACHE  II  =  Acute  Physiology  and  Chronic  Health  Evaluation  II;  CAM‐ICU  =  confusion 
assessment  method‐intensive  care  unit;  F  =  female;  ICU  =  intensive  care  unit;  IQR  = 
interquartile range; M= male; N.S. = non‐significant. 
 
The median duration of treatment with haloperidol decreased from five 
(interquartile range (IQR) 2 to 9) to three days (IQR 1 to 5) after the implementation 
of the CAM-ICU (p = .02). The median total haloperidol dose per patient (during 
treatment) decreased from 18 mg (IQR 5 to 39.5) to 6 mg (IQR 2 to 19.5; p = .01). 
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Table 3 Effect of the implementation of the CAM-ICU in 2008 on delirium treatment
Table 3. Effect of the implementation of the CAM‐ICU in 2008 on delirium treatment 
  2006
(n = 512) 
2007
(n = 589) 
2008 
(n = 641) 
p value 
Total numbers of delirious patients (%) 51 (10%) 79 (13%) 147 (23%)  < .0001
Number of delirious patients per 
month  
13   20  37  < .0001 
Total dose of haloperidol per patient 
(mg) 
n = total number of patients treated 
with haloperidol 
18 (5 to 40)
 
(n = 52) 
12.5 (3 to 30)
 
(n = 80) 
6 (2 to 20) 
 
(n = 147) 
.01
 
Duration of treatment (days)  5 (2 to 9) 3 (2 to 9) 3 (1 to 5)  .02
All values are medians (interquartile range) unless other reported. CAM‐ICU = confusion 
assessment method‐intensive care unit. 
Discussion
In a relatively short period of four months, we successfully implemented a 
validated delirium assessment tool in our daily practice on the ICU. Following the 
implementation of the CAM-ICU, more patients were treated with haloperidol, 
but with a lower dose and for a shorter period of time when compared with the 
same period in the two previous years. Almost two times more delirious patients 
were detected with the use of the CAM-ICU. Our results indicate that successful 
implementation of the CAM-ICU is possible and, importantly, that this results in 
shorter and lower dosed haloperidol treatment.
The implementation of the CAM-ICU 
We feel that several aspects of our implementation strategy are responsible for this 
success. First, we used a multifaceted model with evidence-based interventions. 
Although we did not measure the effect of the separate interventions, previous 
studies showed that education and feedback with reminders are very effective 
interventions (23). Second, it is important to focus the implementation strategy on 
potential barriers that can be expected in daily practice (19), which will differ from 
hospital to hospital and from ward to ward. We therefore gathered information 
about these potential barriers prior to the actual implementation. Based on this 
information, we used the facilitators of our organization and integrated the CAM-
ICU in our patient data management system. Although it took some time to develop 
the integrated CAM-ICU, it was easier to use and included a reminder when the 
assessment had not been performed at the end of the shift. The key-nurses played 
an important role in supporting the group and therefore were pivotal. They were 
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also particularly helpful in bedside training of the ICU nurses, their direct colleagues. 
A final point of interest is the cooperation with the medical staff. We noticed that it 
is important that the CAM-ICU score is part of the daily evaluation of the patient and 
that it is also important to react adequately to a positive delirious score by treating 
the patient. Therefore, it is also important to inform the medical staff during the 
implementation (education) and give them regular feedback on the results of the 
implementation (compliance, interrater reliability, and delirium knowledge level). 
As these interventions are tailored to the barriers found in this study they should 
not be used as a blueprint for implementation but could serve as a guideline.
Although the CAM-ICU appears to be relatively simple to use and a relatively short 
training period should result in a reliable performance of the CAM-ICU (11;13), our 
study demonstrates that an intensive implementation strategy results in a further 
improvement of its performance. We aimed for a group interrater reliability score 
of at least 0.8, which can be considered a desirable (24) and attainable goal for 
the CAM-ICU (13). Evidently, it is of utmost importance to test the reliability of 
the assessment by the ICU nurses, because a false-positive diagnosis may result 
in unnecessary treatment and vice versa. Therefore, in our view, it is necessary to 
perform interrater reliability tests and analyse the mismatches to be able to give 
adequate feedback. Unfortunately, and surprisingly, not much attention is given to 
this aspect in the literature and many new screening and treatment policies appear 
to be implemented without it. 
Although a high interrater reliability is important for the performance of the CAM-
ICU, a screening tool will only be effective when the compliance with its use is also 
high. Although we did not formally measure the nursing workload, it is clear that 
the screening of patients with the CAM-ICU results in some additional work for 
the nurses. Our experience is that the mean screening time of the patients with 
the CAM-ICU is two to five minutes, which is comparable with that mentioned by 
Ely and colleagues (13). Based on a study by Soja and colleagues (25) we chose an 
80% compliance with the CAM-ICU as a feasible and acceptable aim for a successful 
implementation. Scoring all patients three times a day during their whole stay on 
the ICU is hardly realistic. Moreover, an optimal compliance is unknown. We are 
convinced that the intensive feedback and support of the project leader and the 
medical and nursing staff played an important role in achieving a high compliance. 
Haloperidol treatment and patients 
One could argue that haloperidol use is not a good proxy for the incidence of 
delirium because it is also used to treat other disorders such as serious psychoses, 
severe excitement, and anxiety (26). However, these disorders are rarely observed in 
our ICU or not treated with haloperidol. In the case of agitation in patients without 
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a protected airway we use a low dose of propofol, if necessary in combination 
with oxazepam. Therefore we are confident that in our ICU only delirious patients 
are treated with haloperidol and that the observed difference in haloperidol use 
between the compared treatment periods can only be attributed to differences in 
delirium detection rate. 
Despite the fact that we found a higher incidence of delirious patients with the 
CAM-ICU than without the use of a screening instrument, the incidence in our 
population is low. A possible explanation is that the study was performed in all 
consecutive patients, with no selection of high-risk patient groups. Including 
patients that were admitted to our ICU following elective surgery may also partly 
explain why the APACHE II score is lower compared with other studies that reported 
higher APACHE II scores associated with a higher incidence of delirium (13;27;28). 
It is assumed that the regular use of a delirium assessment tool results in a 
higher detection rate of delirious patients, especially patients with a hypoactive 
delirium. Naturally, this could result in more haloperidol use. Given the potential 
side effects of the drug, the absence of clear evidence that presence of hypoactive 
delirium is associated with poor patient outcome and that the use of a delirium 
assessment tool improves the outcome of the ICU patient, one might argue that 
an increase in haloperidol use is not desirable. On the other hand, an earlier and 
improved recognition of delirious patients may make it easier to treat the delirium 
with lower doses of haloperidol. To our knowledge, the influence of performing 
the CAM-ICU on the total amount of haloperidol used per patient has not been 
studied before. It appears plausible that, besides the earlier detection of delirious 
patients, also recovery from the delirious period could be detected earlier with 
the use of a delirium assessment tool. As a result, haloperidol treatment would 
be stopped earlier. Our data confirm these assumptions. It is also possible that the 
early treatment of delirium could result in shortening of the delirious period, but 
this assumption needs further study.
Conclusions
Tailoring our implementation strategy to the needs of the ICU was successful. 
The main goals were achieved within a relatively short time. Early recognition of 
delirium with the CAM-ICU has become a standard component of daily care by the 
nurses in our ICU and contributes to the quality of care. In addition, early detection 
of delirium leads to lower dosage and shorter periods of haloperidol treatment in 
critically ill patients. 
Delirium in Intensive Care Patients
35
Acknowledgements
The authors would like to thank J. Schoemaker and J. van der Velde for their 
excellent work of integrating the CAM-ICU in our patient data management system, 
and all the ‘delirium key-nurses’ for their work and assistance to come to this 
successful implementation.
References
1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 4th ed. 
Washington D.C.: 1994.
2. Dubois MJ, Bergeron N, Dumont M, Dial S, Skrobik Y. Delirium in an intensive care unit: a study of risk 
factors. Intensive Care Med 2001 Aug;27(8):1297-304.
3. Ely EW, Gautam S, Margolin R, Francis J, May L, Speroff T, et al. The impact of delirium in the intensive care 
unit on hospital length of stay. Intensive Care Med 2001 Dec;27(12):1892-900.
4. Ely EW, Shintani A, Truman B, Speroff T, Gordon SM, Harrell FE, Jr., et al. Delirium as a predictor of mortality 
in mechanically ventilated patients in the intensive care unit. JAMA: Journal of the American Medical 
Association 2004 Jul 14;292(2):168-9.
5. Immers HE, Schuurmans MJ, van de Bijl JJ. Recognition of delirium in ICU patients: a diagnostic study of the 
NEECHAM confusion scale in ICU patients. BMC Nurs 2005;4:7.
6. Masterclass Delirium: A clinical overview:  Inouye SK, (Aug 4, 2008).
7. Aldemir M, Ozen S, Kara IH, Sir A, Bac B. Predisposing factors for delirium in the surgical intensive care unit. 
Crit Care 2001 Oct;5(5):265-70.
8. McNicoll L, Pisani MA, Zhang Y, Ely EW, Siegel MD, Inouye SK. Delirium in the intensive care unit: occurrence 
and clinical course in older patients. J Am Geriatr Soc 2003 May;51(5):591-8.
9. Ouimet S, Kavanagh BP, Gottfried SB, Skrobik Y. Incidence, risk factors and consequences of ICU delirium. 
Intensive Care Med 2007 Jan;33(1):66-73.
10. Hart RP, Levenson JL, Sessler CN, Best AM, Schwartz SM, Rutherford LE. Validation of a cognitive test for 
delirium in medical ICU patients. Psychosomatics 1996 Nov;37(6):533-46.
11. Pun BT, Gordon SM, Peterson JF, Shintani AK, Jackson JC, Foss J, et al. Large-scale implementation of 
sedation and delirium monitoring in the intensive care unit: a report from two medical centers. Crit Care 
Med 2005 Jun;33(6):1199-205.
12. Bergeron N, Dubois MJ, Dumont M, Dial S, Skrobik Y. Intensive Care Delirium Screening Checklist: evaluation 
of a new screening tool. Intensive Care Med 2001 May;27(5):859-64.
13. Ely EW, Inouye SK, Bernard GR, Gordon S, Francis J, May L, et al. Delirium in mechanically ventilated 
patients: validity and reliability of the confusion assessment method for the intensive care unit (CAM-ICU). 
JAMA 2001 Dec 5;286(21):2703-10.
14. Lonergan E, Britton AM, Luxenberg J, Wyller T. Antipsychotics for delirium. Cochrane Database Syst Rev 
2007;(2):CD005594.
15. Justo D, Prokhorov V, Heller K, Zeltser D. Torsade de pointes induced by psychotropic drugs and the 
prevalence of its risk factors. Acta Psychiatr Scand 2005 Mar;111(3):171-6.
16. Settle EC, Jr., Ayd FJ, Jr. Haloperidol: a quarter century of experience. J Clin Psychiatry 1983 
Dec;44(12):440-8.
17. Jacobi J, Fraser GL, Coursin DB, Riker RR, Fontaine D, Wittbrodt ET, et al. Clinical practice guidelines for the 
sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med 2002 Jan;30(1):119-41.
18. Vreeswijk R, Toornvliet A, Honing M, Bakker K, de Man T, Daas G, et al. Validation of the Dutch version of the 
Implementation of a delirium assessment tool in the ICU 
can influence haloperidol use
2
36
Confusion Assessment Method (CAM-ICU) for delirium screening in the Intensive Care Unit. Netherlands 
Journal of Critical Care 2009;13(2):73-8.
19. Grol R, Wensing M. Implementation; effective improvement of patient care (in Dutch: Implementatie; 
Effectieve verbetering van de patiëntenzorg). 3th ed. Maarssen: Elsevier Gezondheidszorg; 2006.
20. Bosch M, van der WT, Wensing M, Grol R. Tailoring quality improvement interventions to identified barriers: 
a multiple case analysis. J Eval Clin Pract 2007 Apr;13(2):161-8.
21. Crist L. Outcomes system implementation for subacute care. Nurs Case Manag 1997 Jan;2(1):33-41.
22. CAM-ICU Training Manual and Video.  [http://www.icudelirium.org/delirium/CAMICUTraining.html] 
23. Dijkstra R, Wensing M, Thomas R, Akkermans R, Braspenning J, Grimshaw J, et al. The relationship between 
organisational characteristics and the effects of clinical guidelines on medical performance in hospitals, a 
meta-analysis. BMC Health Serv Res 2006;6:53.
24. Polit DF, Beck CT. Assessing Measurement Quality in Quantitative Studies. Nursing Research; Generating and 
assessing Evidence for Nursing Practice. 8th ed. Philadelphia: Lippincott Williams&Wilkins; 2008. p. 449-74.
25. Soja SL, Pandharipande PP, Fleming SB, Cotton BA, Miller LR, Weaver SG, et al. Implementation, reliability 
testing, and compliance monitoring of the Confusion Assessment Method for the Intensive Care Unit in 
trauma patients. Intensive Care Med 2008 Jul;34(7):1263-8.
26. Devlin JW, Nava S, Fong JJ, Bahhady I, Hill NS. Survey of sedation practices during noninvasive positive-
pressure ventilation to treat acute respiratory failure. Crit Care Med 2007 Oct;35(10):2298-302.
27. Page VJ, Navarange S, Gama S, McAuley DF. Routine delirium monitoring in a UK critical care unit. Crit Care 
2009 Feb 9;13(1):R16.
28. Pisani MA, Araujo KL, Van Ness PH, Zhang Y, Ely EW, Inouye SK. A research algorithm to improve detection of 
delirium in the intensive care unit. Crit Care 2006;10(4):R121.
Delirium in Intensive Care Patients
37
Appendix 1  CAM-ICU worksheet
Appendix 1  CAM‐ICU worksheet 
Feature 1: Acute Onset or Fluctuating Course 
Positive if answer ‘ yes’ to either 1A or 1B 
Positive  Negative 
1A: Is the pt. different than his/her baseline mental status?
                                          Or 
1B: Has the patient had any fluctuation in mental status in the past          
      24 hours as evidence by fluctuation on a sedation scale (e.g.   
      RASS) GCS, or previous delirium assessment 
Yes  No
Feature 2: Inattention 
Positive if either score for 2A or 2B is less than 8. 
Attempt the ASE letters first. If pt. Is able to perform this test and the score 
is clear, record this score and move to Feature 3. If pt. Is unable to perform 
this test or the test score is unclear, then perform the ASE pictures. If you 
perform both tests, use the ASE pictures’ results to score the Feature 
Positive  Negative 
2A: ASE letters: record score (enter NT for not tested)
Directions: Say to the patient, “I am going to read you a series of 10 letters. 
When you hear the letter ‘A’ indicate by squeezing my hand”. Read letters 
from the following letter list in a normal tone. 
            SAVEAHAART  
Scoring: errors are counted when patient fails to squeeze on the letter ‘A’ 
and when the patient squeezes on any letter other than ‘A’. 
Score (out of 10):‐‐‐‐‐‐‐‐‐‐‐ 
2B: ASE pictures: record score (enter NT when not tested)
Directions are included on the picture packets.  Score (out of 10):‐‐‐‐‐‐‐‐‐‐‐‐ 
Feature 3: Disorganized thinking 
Positive if the combined score is less than 4 
Positive  Negative 
3A: Yes/No Questions 
(Use either Set A or  B, alternate on consecutive days if necessary): 
Set A                                              Set B  
1. Will a stone float on water?       1. Will a leaf float on water? 
2. Are there fish in the sea?          2. Are there elephants in the sea?                  
3. Does one pound weigh more    3. Do two pounds weight more     
    than two pounds?                          than one pound? 
4. Can you use a hammer to        4. Can you use a hammer to cut  
    pound a nail?                                wood?  
Score_____(patient earns 1 point for each correct answer out of 4) 
 
3B: Command 
Say to patient: “Hold up this many fingers”(examiner holds two fingers in 
front of patient) “Now do the same thing with the other hand”(not 
repeating the number of fingers). *If pt. Is unable to move both arms, for 
the second part of the command ask patient “Add one more finger”) 
Score_____(Patient earns 1 point if able to successfully complete the 
entire command) 
Combined Score (3A=3B): ______ 
(out of 5) 
Feature 4: Altered level of consciousness 
Positive if the actual RASS score is anything other than “0” (zero) 
Positive  Negative 
Overall CAM‐ICU (Features 1 and 2 and either Feature 3 or 4): Positive  Negative
With permission of the authors. 
Copyright © 2002, E. Wesley Ely, MD, MPH and Vanderbilt University, all rights reserved 
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Appendix 2 Textbox: Implementation strategy
Appendix 2 Textbox: Implementation strategy  
Interventions for the CAM‐ICU implementation. We:  
1. made an inventory of potential facilitators and barriers of our organization 
 
 
 
 
  
2. tailored the implementation strategy to the potential barriers and opportunities
3. set clear and feasible targets for a successful implementation
4. computerized the CAM‐ICU algorithm in our system and made it user friendly
5. integrated reminders for screening in the computerized CAM‐ICU  
6. equipped every bed with all necessary tools for the assessment performance
7. appointed  delirium  ‘key‐nurses’  for  dissemination  of  delirium  knowledge  and 
assistance during the implementation 
8. involved medical and nursing staff in the implementation
9. performed  interrater  reliability  tests  and  provided  extra  training  on  the  job  on 
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Abstract
Rationale
Delirium is often unrecognized in Intensive Care Unit (ICU) patients and associated 
with poor outcome. Screening for ICU delirium is recommended by several medical 
organizations to improve early diagnosis and treatment. The Confusion Assessment 
Method for the ICU (CAM-ICU) has high sensitivity and specificity for delirium when 
administered by research nurses. However, test characteristics of the CAM-ICU as 
performed in routine practice are unclear.
Objective
To investigate the diagnostic value of the CAM-ICU in daily practice.
Methods
Teams of three delirium experts including psychiatrists, geriatricians and 
neurologists visited ten ICUs twice. Based on cognitive examination, inspection of 
medical files and DSM-IV-TR criteria for delirium, the expert teams classified patients 
as awake and not delirious, delirious or comatose. This served as gold standard 
to which the CAM-ICU as performed by the bedside ICU-nurses was compared. 
Assessors were unaware of each-others conclusions.
Main results
Fifteen delirium experts assessed 282 patients of whom 101 (36%) were comatose 
and excluded. In the remaining 181 (64%) patients, the CAM-ICU had a sensitivity 
of 47% (95% Confidence Interval (CI) 35% - 58%), specificity of 98% (95% CI 93% - 
100%), positive predictive value of 95% (95% CI 80% - 99%) and negative predictive 
value of 72% (95% CI 64% - 79%). The positive likelihood ratio was 24.7 (95% CI 6.1-
100) and the negative likelihood ratio 0.5 (95% CI 0.4-0.8). 
Conclusions
Specificity of the CAM-ICU as performed in routine practice appears to be high but 
sensitivity low. This hampers early detection of delirium by the CAM-ICU. 
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Introduction
Delirium is characterized by an acute disturbance of consciousness and attention 
with cognitive or perceptual changes and often a fluctuating course (1). It is common 
in Intensive Care Unit (ICU) patients, with an incidence during ICU stay ranging up 
to 89% (2-8). In ICU patients, delirium is associated with poor outcome, including 
increased mortality, increased ICU and hospital length of stay, more cognitive 
impairment after hospital discharge and higher health-care related costs (4;9-11). 
Despite its frequency and impact, delirium in the ICU goes often unrecognized 
which hampers early treatment (12). The clinical impression of ICU physicians and 
nurses whether or not an ICU patient was delirious had a sensitivity of 29% and 35% 
respectively, compared to the conclusion of delirium experts (13;14). To improve 
early recognition of delirium, several easy-to-use screening methods have been 
developed (15), such as the Confusion Assessment Method adopted for the Intensive 
Care Unit (CAM-ICU)(16) and the Intensive Care Delirium Screening Checklist (ICDSC)
(17). Of these, the CAM-ICU had higher sensitivity (64%; specificity 88%)  than the 
ICDSC (sensitivity 43%; specificity 95%) within the same population of mixed ICU 
patients (13), and is therefore the most frequently used delirium detection tool(18).
Several medical organizations, including the Society of Critical Care Medicine 
(SCCM) and the American Psychiatric Association (APA), advise standard screening 
for delirium in critically ill patients (12;19). The CAM-ICU showed high sensitivity 
(range 97%-100%) and specificity (range 89%-100%) in several validation studies 
(16;20-22). It should however be noted that all these investigation were performed in 
research settings (16;20-22), which may differ from day-to-day critical care (23). Test 
characteristics of the CAM-ICU as performed by bedside ICU nurses are unknown. 
The aim of this study was to investigate the diagnostic value of the CAM-ICU when 
performed by bedside ICU nurses in routine daily practice. Some of the results of 
this study have been previously reported in the form of an abstract (24-26). 
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Methods
Design and Setting
This prospective multicenter study was performed in ten ICUs of university, 
teaching and rural hospitals in the Netherlands, which were selected based on 
a previous nation-wide survey on the use of delirium monitoring (18). The study 
population consisted of mixed medical and surgical ICU patients who were admitted 
to one of the participating ICUs during visits of delirium experts, as described below. 
Patients who were unable to speak Dutch or English, and those who could not be 
examined due to logistic reasons were excluded. This study was approved by the 
institutional review board of the University Medical Center Utrecht and a waiver for 
informed consent was obtained.
Implementation of the CAM-ICU
Investigators in each participating center completed a questionnaire concerning the 
implementation of the CAM-ICU at their ICU. They registered whether lectures had 
been given to nurses preceding implementation in the daily routine of that specific 
ICU, and whether written information was provided explaining the use of the CAM-
ICU. Furthermore, local investigators were asked if individual bedside training had 
been given to the nurses and whether the ICU physicians always or regularly used 
the CAM-ICU results at their daily rounds. Lastly, the local investigators registered 
compliance rate of the CAM-ICU in daily practice. 
Delirium assessment 
During visits to the participating centers, a group of three experts made rounds 
along all admitted ICU patients at that time. One of these experts was either a 
research-physician (MMJvE) or a nurse-scientist (MvdB), who guaranteed that 
all assessments and study-procedures were performed uniformly. The other two 
experts were, in different combinations guaranteeing a multidisciplinary team, 
psychiatrists (n=5), geriatricians (n=4) or neurologists (n=4), who had on average 
16 years (standard deviation (SD) 5) clinical experience after their medical specialist 
registration and who saw an estimated 20 (mean; SD 8) delirious patients monthly. 
To guarantee blinding for CAM-ICU scores of preceding days, experts were not 
allowed to evaluate patients in their own center. The expert groups assessed the 
patients using the Diagnostic Statistic Manual, 4th edition (DSM-IV-TR) (1) criteria 
for delirium, based on clinical assessment for cognitive dysfunction and a review of 
the medical charts, but remained blinded to reported CAM-ICU scores. The group 
of experts classified each patient as: 1) awake and not delirious; 2) delirious or 3) 
comatose, i.e. not assessable due to a low level of consciousness. If they diagnosed 
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a patient as delirious they had to classify whether they thought the patient suffered 
from a hypoactive-, a hyperactive- or a mixed type of delirium. The expert groups 
remained blinded for the CAM-ICU as scored by the nurses throughout the visit. 
The bedside nurses assessed all patients using the Dutch version of the CAM-ICU 
(22) within three hours of the expert assessment, without extra training for this 
study. We further registered the CAM-ICU scores on the day before and the day 
after the experts visits. The ICU nurses were blinded for the assessment by the 
expert groups and received no notice before the study visits were made. 
Other data collection 
Local investigators supplied data on age, gender, Acute Physiology and Chronic 
Health Evaluation (APACHE) II score, admitting discipline and the (in)ability to verbally 
communicate (e.g. intubation or tracheotomy) at the moment of assessment. The 
timing of the administration of psychoactive medication (for example antipsychotics, 
opiates or benzodiazepines) and the timing of assessment by the expert group and 
the bedside nurse were also noted by the local investigator.
Statistical analysis 
After exclusion of patients who were non-assessable by either the expert groups 
or the nurses, we calculated the sensitivity, specificity, positive predictive value 
and negative predictive value for the CAM-ICU, based on 2x2 tables, with the 
classification of the expert groups as reference. Furthermore, as delirium may vary 
in time, we analyzed test characteristics using RASS and CAM-ICU results from the 
day before and the day after the experts visits, based on the following classification: 
‘always RASS < -3 during this 48 hours period’, or ‘never a positive CAM-ICU during 
this 48 hours period’ or ‘a positive CAM-ICU at one or more moments during this 48 
hours period’, and the reference described above. Pre-specified stratified analyses 
were performed on type of delirium (hypoactive-, hyperactive- or mixed type), 
study center and ability of verbal communication. Agreement between the CAM-
ICU results and the expert groups was computed with Cohen’s kappa coefficient (κ). 
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Results
Between April 2009 and April 2010 all 10 participating centers were attended 
twice. The expert groups visited 306 different patients of whom 282 (92%) were 
assessable as either awake and not-delirious, or delirious or comatose. We excluded 
14 patients (5%) who could not speak Dutch or English. Ten patients (3%) could 
not be assessed because they underwent an examination or a procedure when the 
expert group made their round. The average age in the included patients was 59 
years (SD 18) and the average APACHE II score was 18.6 (SD 7.5), see Table 1. 
Table 1 Characteristics of the study population  
Table 1. Characteristics of the study population  
 
Characteristic 
Total 
(n=282) 
Delirium* 
(n= 80) 
No delirium* 
(n=106) 
Coma* 
(n=96) 
Age (years), mean (SD)  59 (18)  62 (15)  59 (16)  57 (21) 
Gender, male, n (%)  172 (61 %)  54 (68%)  64 (60%)  54 (56%) 
APACHE‐II score, mean (SD)  18.6 (7.5)  20.1 (7.0)  16.2 (6.9)  20.2 (7.8) 
Admitting discipline, n (%) 
- Internal medicine 
- General surgery 
- Cardiology / cardiothoracic surgery 
- Neurology / neurosurgery 
 
96 (34%) 
90 (32%) 
 
62 (22%) 
34 (12%) 
 
29 (36%) 
23 (29%) 
 
21 (25%) 
7 (10%) 
 
37 (36%) 
29 (26%) 
 
24 (22%) 
16 (16%) 
 
30 (31%) 
38 (40%) 
 
17 (17%) 
11 (12%) 
Able to communicate verbally, n (%)  107 (38%)  36 (45%)  71 (67%)  0 (0%) 
Definition of abbreviations: APACHE = Acute Physiology and Chronic Health Evaluation; 
SD = Standard Deviation.  
*As defined by DSM‐IV‐TR criteria and assessed by experts. 
 
The participating centers admitted on average 1545 patients a year (SD 500) and 
had, on average, 25 beds (SD 12) all with capability for mechanical ventilation (see 
Table 2). All ICUs worked according to closed format formula with on average 9 
(SD 3) intensivists. Concerning the implementation of the CAM-ICU, all participating 
ICUs reported to have provided lectures and written information to their nurses 
before its introduction. The majority of centers (60%) offered individual bedside 
teaching before or during the introduction of the CAM-ICU. 
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Table 2 Characteristics of the participating ICUs Table 2. Characteristics of the participating ICUs
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Beds per center, n  33  10  32  12  10  24  50  32  30  10 
Intensivists (full‐time equivalents) per center, n   20  4  11  5  4  7  19  11  10  4 
Annually admissions per center, n  2,250  600  2,500 640  800  1,456  1,952 2,000  2,000  713 
Time from implementation CAM‐ICU to participation in study, months  36  48  36  24  12  36  12  12  24  12 
Lectures given   Y  Y  Y  Y  Y  Y  Y  Y  Y  Y 
Written information available  Y  Y  Y  Y  Y  Y  Y  Y  Y  Y 
Individual bedside training  Y  Y  Y  N  N  Y  N  N  Y  Y 
Duration of individual training, minutes  20  30  10  N/A  N/A  20  N/A  N/A  20  10 
Use of dedicated training nurses   Y  Y  N  Y  N  N  Y  N  N  N 
Standard use of CAM‐ICU in daily decision making  A A  R A  R  R  R  R  R  R 
Trained nurses, %  95%  95%  80%  N/A  N/A  90%  N/A  N/A  80%  90% 
Compliance to the daily CAM‐ICU, %  93%  95%  90%  70%  90%  80%  95%  80%  85%  95% 
Frequency of CAM‐ICU per day  3  3  3  3  2  2  2  2  3  2 
Definition of abbreviations: A = always; CAM‐ICU = Confusion Assessment Method for the Intensive Care Unit; N = no; N/A = not applicable; R = 
regularly; Y = yes. 
 
In three out of ten participating centers, CAM-ICU test results as performed by the 
ICU nurse, were always part of the standard evaluation by the attending intensivist. 
In the other centers, CAM-ICU results were regularly used. The average time from 
implementation of the CAM-ICU to participation in this study was two years (SD 0.5). 
The expert groups reached consensus in all 282 cases, who were classified as 
awake and not-delirious (n=106, 38%), delirious (n=80, 28%) or comatose (n=96, 
34%, Table 3). 
Table 3 Overall classification of the study populationTable 3. Overall classification of the study population
   
Delirium* 
 
No delirium* 
 
Coma* 
   
Total 
CAM‐ICU positive  35  2  7    44 
CAM‐ICU negative  40  104  15    159 
RASS < ‐3  5  0  74    79 
           
Total  80  106  96    282 
Definition of abbreviations: CAM‐ICU = Confusion Assessment Method for the Intensive 
Care Unit administered by the bedside nurse; RASS = Richmond Agitation and Sedation 
score.  *According to the delirium experts and DSM‐IV‐TR criteria. 
 
Of these 282 patients, 159 (56%) patients were scored CAM-ICU negative by the 
bedside nurses, 44 subjects (16%) as CAM-ICU positive and 79 patients (28%) as 
RASS (Richmond Agitation and Sedation Score) < -3 (not assessable). In total, 101 
patients were identified as comatose, either by the expert groups or by the bedside 
nurses, and excluded to calculate sensitivity, specificity and predictive values of the 
CAM-ICU. The kappa score for agreement between CAM-ICU results and expert 
conclusions was κ = 0.63. 
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As shown in Table 4, delirium was detected in 75 out of 181 remaining patients by 
the experts. The CAM-ICU as administered by the bedside nurses was positive in 35 
of these 75 subjects. This yielded an overall sensitivity of 47% (95% CI 35% - 58%) 
and a specificity of 98% (95% CI 93% - 100%). The overall positive and negative 
predictive value (PPV and NPV) were 95% (95% CI 80% - 99%) and 72% (95% CI 
64% - 79%) respectively. The positive likelihood ratio was 24.7 (95% CI 6.1-100) and 
the negative likelihood ratio 0.5 (95% CI 0.4-0.8), see supplement Table S1. When 
this analysis was based on the RASS and CAM-ICU cores the day before, the day of, 
and the day after the expert assessment, we found the sensitivity to be 53% (95% CI 
41%-65%), the specificity 86% (95% CI 77%-92%), the PPV 73% (95% CI 60% - 83%) 
and the NPV 72% (95% CI 64%-79%).
Table 4 Test characteristics of the confusion assessment method for the Intensive Care Unit
Table 4. Test characteristics of the confusion assessment method for the Intensive Care Unit
(Sub‐) population (n)  Sensitivity (95% CI)  Specificity (95% CI)  PPV (95% CI)  NPV (95% CI) 
Total population (n=181)  47% (35%‐58%)  98% (93%‐100%)  95% (80%‐99%)  72% (64%‐79%)  
Psychoactive medication between assessments 
‐ Yes (n=46)   
‐ No (n=135) 
 
54% (33%‐74%) 
43% (30%‐58%) 
 
95% (75%‐99%) 
99% (93%‐100%) 
 
93% (64%‐99%) 
96% (76%‐100%) 
 
65% (47%‐81%) 
74% (64%‐82%) 
Delirium subtypes*
‐ Hypoactive (delirious n=36; not delirious  n=106) 
‐ Hyperactive (delirious n=7; not delirious n=106) 
‐ Mixed type (delirious n=32; not delirious n=106) 
 
31% (17%‐48%) 
100% (56%‐100%) 
53% (35%‐74%) 
 
98% (92%‐99%) 
98% (93%‐100%) 
98% (93%‐100%) 
 
85% (54%‐97%) 
78% (40%‐96%) 
90% (65%‐98%) 
 
81% (72%‐87%) 
100% (95%‐100%) 
87% (80%‐93%) 
Admitting discipline 
‐ Internal medicine (n=52) 
‐ General surgery (n=64) 
‐ Cardiology / cardiothoracic surgery (n=43) 
‐ Neurology / neurosurgery (n=22) 
 
54% (33%‐73%) 
38% (21%‐59%) 
58% (34%‐79%) 
17% (1%‐64%) 
 
96% (78%‐100%) 
97% (85%‐100%) 
100% (83%‐100%) 
100% (76%‐100%) 
 
93% (64%‐100%) 
91% (57%‐100%) 
100% (68%‐100%) 
100% (1%‐100%) 
 
69% (52%‐83%) 
70% (55%‐81%) 
75% (56%‐88%) 
76% (52%‐91%) 
Communication ability 
‐ Verbal communication possible (n=109) 
‐ Verbal communication not possible (n=72) 
 
42% (26%‐61%) 
50% (34%‐66%) 
 
99% (91%‐100%) 
97% (82%‐100%) 
 
93% (66%‐99%) 
95% (74%‐100%) 
 
79% (68%‐86%) 
61% (46%‐74%) 
Center (number of included patients) 
- A (n=26) 
- B (n=9) 
- C (n=34) 
- D (n=20) 
- E (n=10) 
- F (n=15) 
- G (n=26) 
- H (n=14) 
- I (n=20) 
- J (n=7) 
 
71% (42%‐90%) 
50% (4%‐91%) 
29% (10%‐58%) 
60% (17%‐93%) 
33% (2%‐87%) 
N/A 
44% (21%‐69%) 
80% (30%‐99%) 
44% (15%‐77%) 
N/A 
 
92% (60%‐100%) 
100% (46%‐100%) 
100% (80%‐100%) 
93% (66%‐100%) 
100% (56%‐100%) 
100% (31%‐100%) 
100% (66%‐100%) 
100% (63%‐100% 
100% (68%‐100%) 
100% (46%‐100%) 
 
91% (57%‐100%) 
100% (20%‐100%) 
100% (40%‐100%) 
75% (22%‐99%) 
100% (5%‐100%) 
N/A 
100% (56%‐100%) 
100% (40%‐100%) 
100% (39%‐100%) 
N/A 
 
73% (45%‐91%) 
71% (30%‐95%) 
67% (47%‐82%) 
88% (60%‐98%) 
78% (40%‐96%) 
20% (5%‐49%) 
53% (29%‐75%) 
90% (54%‐99%) 
69% (41%‐88%) 
71% (30%‐95%) 
Definitions of abbreviations: CAM‐ICU = Confusion Assessment Method for the Intensive Care Unit; CI = Confidence Interval; N/A = not applicable (no delirious 
patient identified); NPV = negative predictive value; PPV = positive predictive value.  *according to the expert groups 
The median duration between evaluation by the expert group and assessment 
with the CAM-ICU was 86 minutes (interquartile range (IQR) 41-168 minutes). 
Based on this interval, data were divided in quartiles and analyses were repeated. 
No substantial differences were found between the lowest quartile (interval less 
than 41 minutes: sensitivity 36% (95% CI 14%-64%); specificity 100% (95% CI 86% 
- 100%); PPV 100% (95% CI 46%-100%) and NPV 78% (95% CI 61%-89%) and the 
highest quartile (interval longer than 168 minutes: sensitivity 43% (95% CI 24%-
65%); specificity 95% (95% CI 74%-99%); PPV 90% (95% CI 57%-99%) and NPV 61% 
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(95% CI 42%-77%). In 31% of patients (n = 87) the evaluation of the experts preceded 
the assessment of the nurses; in 69% of patients (n = 195) the assessment of the 
nurses preceded the visit of the experts. When we compared test characteristics 
between these two groups, no substantial differences in sensitivity, specificity, PPV 
and NPV were found (data not shown).
All analyses were repeated after exclusion of 46 patients (25%) who had received 
psychoactive medication between both assessments, which did not differ from the 
above described overall results: sensitivity 43% (95% CI 30% - 58%); specificity 99% 
(95% CI 93% - 100%); PPV 96% (95% CI 76% - 100%) and NPV 74% (95% CI 64% - 82%). 
After stratification according to type of delirium, sensitivity of the CAM-ICU 
was lowest in the hypoactive subgroup (31%; 95% CI 17% - 48%), highest in the 
hyperactive delirious patients (100%; 95% CI 56% - 100%) and intermediate in the 
mixed type patients (53%; 95% CI 35% - 74%). As further shown in Table 4, the 
CAM-ICU showed particularly poor test characteristics in neurocritical care patients 
(sensitivity 17%; 95% CI 1% - 64%). Centers always using the CAM-ICU result to adapt 
clinical practice on a daily base showed better test characteristics than centers in 
which the CAM-ICU was regularly used, especially with regard to sensitivity (range 
50%-71% respectively 29%-80%).
Discussion
In summary, we found in this multicenter evaluation of daily practice, the CAM-ICU 
to have a sensitivity and specificity of 47% and 98% respectively and positive and 
negative predictive values of 95% and 72% respectively. Sensitivity was particularly 
poor in neurocritical care patients, in patients with hypoactive delirium and in 
centers where the test results were not always part of the standard evaluation by 
the attending intensivist. The sensitivity remained low when CAM-ICU results from 
a 48 hours period were considered.
The CAM-ICU in daily practice showed thus not quite as good test characteristics 
as presented in the original validation studies (16;20-22), where a limited number 
of specially trained research nurses performed the test and some categories of 
ICU patients were excluded (such as patients with a neurological disorder). The 
discrepancy in findings may also be due to inadequate training and/or by incomplete 
implementation of the CAM-ICU in daily routine. As training was comprehensive 
and did not essentially differ between centers, a possible explanation for our results 
may be that bedside nurses lack motivation to perform the CAM-ICU correctly if 
it is not standard to always evaluate the result in the treatment of their patients. 
However, even in centers where the test results were always part of the standard 
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evaluation by the intensivist, sensitivity was still substantially lower (50%-71%) than 
in the original validation studies (97%-100% (16;20-22)). 
Strengths of this study include the sample size. This study is the largest study on 
this topic, with 181 included non-comatose patients from ten different ICUs. Earlier 
CAM-ICU validation studies (16;20-22) included less patients (range 30-129) and had 
all a single-center design, potentially hampering external validity. Most importantly, 
in all previous studies, assessments were performed by a limited number of 
research nurses, whereas our investigation is an evaluation of daily life. The gold 
standard classification was made by multidisciplinary expert groups comprising 
physicians from other centers with significant expertise and experience in assessing 
patients with delirium. Furthermore, it was ensured that the assessments and study 
procedures by the expert groups were always performed similarly. As the expert 
groups were unaware of the CAM-ICU as registered by the bedside nurses, and 
bedside nurses were blinded to the examinations and conclusions of the expert 
groups, our findings are not subject to bias. 
This study has also some limitations. The classification of the type of delirium by 
the experts may have lacked accuracy as it was based on an assessment at a given 
moment in time, while delirium symptoms tend to fluctuate over the day.
Secondly, expert assessment and the CAM-ICU could not always be performed 
immediately after each other. As delirium tends to fluctuate during the course of 
the day, discrepancies between the two assessments might result from differences 
in clinical presentation over time. However, our results were not related to the 
time interval in between assessments, did not change when we excluded patients 
who had received psychoactive medication in between evaluations and were 
essentially similar when we stratified on the order of the assessments. Therefore 
our findings seem not to be subject to bias. Moreover, time between assessments 
was comparable to the original validation studies (16;20). 
Thirdly, we stratified our results according to study center and related these 
findings to differences in training and implementation. These observations should 
however be interpreted with caution as the number of patients per center was small 
and the exact process of training and implementation was difficult to objectify. 
Fourthly, a possible concern is the generalizability of our findings. The participating 
centers were selected from all Dutch ICU’s based on a previous survey on routine 
delirium monitoring(18). As these centers represent the ICUs were delirium 
monitoring was implemented earliest, these centers most likely are the most active 
sites with regard to delirium care. It seems therefore unlikely that our selection of 
study centers has negatively influenced test characteristics of the CAM-ICU. 
High sensitivity is an essential feature for a screening instrument, because 
screening is about to identify all patients with the disease. In our study, sensitivity 
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of the CAM-ICU was overall 47% and 31% for hypoactive delirium, the delirium 
subtype most difficult to recognize for ICU physicians (13). This low sensitivity of 
the CAM-ICU hampers its use as a screening instrument for delirium in critically ill 
patients. The specificity and the positive predictive value were however high. The 
higher sensitivity of the CAM-ICU found in centers always using the CAM-ICU results 
in daily care suggests that this may be a necessary condition for achieving adequate 
implementation in daily practice. Furthermore, sensitivity may be increased by 
combining CAM-ICU results with observations described in nursing files (27). Results 
from clinical efficacy trials often contradict with results from ‘real-world’ analyses 
(23). In this study we have shown that this may also apply for screening instruments. 
In conclusion, in this multicenter study, specificity of the CAM-ICU as performed 
in daily critical care appears to be high but sensitivity low. The low sensitivity of the 
CAM-ICU in routine practice hampers early detection of delirium. 
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Abstract
Background
Suitable biomarkers associated with the development of delirium are still 
not known. Urinary proteomics has successfully been applied to identify novel 
biomarkers associated with various disease states, but its value has not been 
investigated in delirium patients.
Results
In a prospective explorative study hyperactive delirium patients after cardiac surgery 
were included for urinary proteomic analyses. Delirium patients were matched with 
nondelirium patients after cardiac surgery on age, gender, severity of illness score, 
LOS-ICU, Euro-score, C-reactive protein, renal function and aorta clamping time. 
Urine was collected within 24 hours after the onset of delirium. Matrix-assisted 
laser desorption/ionisation-time of flight mass spectrometry (MALDI-TOF MS) was 
applied to detect differences in the urinary proteome associated with delirium 
in these ICU patients. We included 10 hyperactive delirium and 10 meticulously 
matched non-delirium post-cardiac surgery patients. No relevant differences in the 
urinary excretion of proteins could be observed.
Conclusions
We conclude that MALDI-TOF MS of urine does not reveal a clear hyperactive 
delirium proteome fingerprint in ICU patients.
Clinical Trial Register number: NCT00604773
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Background
Delirium is an acute psycho-organic syndrome, that frequently occurs in hospitalized 
patients and particularly in critically ill patients. This neuropsychiatric disorder is 
associated with serious health problems, such as prolonged stay on the mechanical 
ventilator, in the intensive care unit (ICU) and hospital, and a higher mortality rates 
(1). Three subtypes of delirium; hyperactive, hypoactive and a mixed subtype, can 
be distinguished based on patients Richmond Agitation Sedation Scores (RASS) (2). 
In daily practice, nurses and physicians experience the most difficulties with the 
hyperactive delirium patients who are often aggressive or even combative and in 
whom their delirium is associated with dislocation of their endotracheal tube and 
other lifesaving materials. 
Although the pathophysiology of delirium is far from clear, several biomarkers and 
pathways, such as neuro-anatomic abnormalities, cholinergic failure, inflammatory 
responses and activation of the hypothalamic-pituitary adrenal axis, were found 
to be associated with the development of delirium (3;4). Nevertheless, suitable 
biomarkers that may facilitate the diagnosis of delirium have not been discovered. 
Proteomics is a profiling method to detect a wide range of markers simultaneously. 
This technique allows the identification of several proteins potentially involved in 
the pathophysiological mechanism of disorders (5), such as delirium. Proteomics 
can be applied for determinations in tissue (6) and in several biological fluids, i.e. 
cerebro-spinal fluid and serum (7-9). Differences in protein profiles were detected 
in brain tissue of hyperactive delirium rats (significant peak at m/z 5030 and 5179)
(10) and in the serum of delirium elderly patients with hip fracture (significant peak 
at m/z 15,900 identified as haemoglobin-β) (8). Proteomics of urine samples is of 
special interest, as urine reflects the low molecular weight protein pool of blood 
without, for mass spectrometry disturbing, abundant proteins, such as albumin (11). 
In addition, urine can be collected in a non-invasive way. Proteomics of urine has 
proven to be useful in predominantly urogenital diseases, but has recently also been 
implicated in non-urogenital diseases including cancer and coronary artery disease 
(12;13). In addition, the detection of differential protein expression in delirium 
patients may facilitate the understanding of the pathophysiology of disease.
The aim of our present study was to explore whether biomarkers associated 
with delirium could be detected in urinary protein profiles of hyperactive delirium 
compared to matched non-delirium ICU- patients.
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Methods 
Patients and delirium assessment
For this explorative study 10 hyperactive delirium post cardiac surgery patients 
were included and compared with 10 meticulously matched non-delirium patients. 
For sake of homogeneity, delirium patients after cardiac surgery were included only 
when they suffered from a hyperactive delirium (2), detected with the validated 
Dutch version of the confusion assessment method-ICU (14) by well trained ICU 
nurses (15). Patients were diagnosed, according to the Peterson criteria (2), as 
hyperactive delirium when they had only positive RASS during their delirium period. 
Patients were double checked by a delirium expert (MvdB) for the presence or 
absence of the delirium to confirm the diagnosis. To secure that only hyperactive 
delirium patients were included, follow-up took place until patients did not suffer 
from delirium anymore and only when they had positive RASS scores during their 
delirium period. In support of the homogeneity of the total group, patients were 
matched on several important risk factors for the development of delirium(16). 
Matching was performed on: gender, age, length of stay on the ICU at the time 
of urine sample collection, severity of illness score (expressed in Acute Physiology 
and Chronic Health Evaluation (APACHE)-II score), Creactive protein (CRP), Aorta 
clamping time, Euro score, serum and urine creatinine level, modification of diet 
in renal disease - glomerular filtration rate (MDRD-GFR) and type of operation. 
Patients suffering from an infection were excluded. 
The local Institutional Review Board of Arnhem-Nijmegen (study number 
2007/283) indicated that for this study no formal approval was required and no 
informed consent from patients was needed because of the observational nature of 
this study and the fact that no additional interventions were carried out. 
This study was registered on Clinical Trial Register as NCT00604773
Sample collection, preparation and measurement 
Within 24 hours after the onset of the delirium episode blood and urine were 
collected for creatinine measurement and urine for proteomics profiling under 
sterile conditions. As a control, a urine master pool was created according to 
Vanhoutte et al (13), which consisted of urine of 24 healthy volunteers (age 22-
65 years). In brief, first-morning mid-stream urine samples were collected freshly 
and a master pool reference sample of all healthy volunteers was prepared by 
mixing together 24 urine samples containing 0.2 mmol creatinine each. Protease 
inhibitors were added to the urine immediately after the collection and the samples 
were centrifuged (15 min, 2000g at 40C) and stored in small aliquots at -800C to 
minimize freeze-thaw cycles. 
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MALDI-TOF-MS analysis: preparation and measurement
To isolate proteins from the urine samples we used magnetic bead (MB) 
separation (17) with magnetic hydrophobic-interaction chromatography (MB-HIC 
C8), immobilized metal ion affinity chromatography (MB IMAC-Cu) and weak cation-
exchange chromatography (MB WCX) beads. In addition, non-magnetic weak cation-
exchange beads (CM10, Bruker Daltronics, Germany) were applied. Urine volume 
added to the beads was normalized to urine creatinine concentration. A urine 
volume of maximally 30 μL was used for MB-HIC C8 and HB IMAC-Cu; 15 μL for MB-
WCX and 150 μL for CM10 beads. To all samples an internal standard of 5 μL 0.5mM 
hepcidin 24 was added to normalize peak intensities (18). MB purifications were 
performed according to the manufacturer’s protocol for serum using the buffers 
delivered with the kit. For MB-WCX and CM10 beads other buffers were used as 
described by Kroot (19), based on Park (20). Pre-treated samples were transferred 
to a polished steel plate (Bruker Daltronics) and covered with two layers of 5 mg/mL 
α-cyano-4-hydroxy-cinnamic acid matrix (CHCA; Bruker Daltronics). A linear matrix-
associated laser desorption/ionization time-of-flight mass spectrometer (MALDI-
TOF MS Microflex, Bruker Daltronics) was used for protein profiling. 
Statistics
Since the exploratory nature of this study, a power calculation for sample size 
calculation was not performed. Group differences were tested two-tailed using the 
Mann-Whitney U-test. Mass spectra data obtained after MALDI-TOF MS profiling 
were analyzed using ClinProt Tools Software (Bruker Daltronics), including univariate 
statistical analysis and unsupervised hierarchic clustering. A two tailed p value of 
<.05 was considered statistically significant. 
Urinary protein profiling in hyperactive delirium 
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Results
The delirium and non-delirium post-cardiac surgery ICU patients were comparable 
regarding the matched variables (Table 1).
Table 1 Demographic, matched and outcome variables of delirium and non-delirium patients
Table 1. Demographic, matched and outcome variables of delirium and non‐delirium patients 
  Delirium group 
(N=10) 
Non‐delirium group 
(N=10)  p‐value 
Admission time (days)  1 [1‐1.5]  1 [1‐1]  .91 
Gender (Male)  7  6  .65 
Age (years)  75 [70‐78]  75 [68‐78]  .73 
RASS‐score (median)  0 [0 ‐ 1]  ‐0.5 [‐1 ‐ 0]  .007 
APACHE‐II score  17 [14‐19]  17 [13‐21]  .88 
C‐reactive protein  41 [35‐58]  38 [13‐48]  .28 
Aorta clamping time 
(minutes)  79 [63‐94]  106 [66‐115]  .35 
Euro score  7 [6‐9]  7 [6‐12]  .70 
Measurement Creatinine 
after operation in hours   21 [14‐43]  21 [15‐21]  .78 
Serum Creatinine µmol/L  97 [86‐114]  86 [57‐125]  .32 
Urine Creatinine µmol/L  11 [7‐16]  8 [6‐12]  .25 
MDRD‐GFR 
(ml/min/1.73m2)  69 [55‐75]  71 [52‐102]  .45 
Type of operation 
CABG                   N=4 
Valve operation N=2 
Valve/CABG        N=2 
Miscellaneous   N=2 
CABG                   N=3 
Valve operation N=1 
Valve/CABG        N=3 
Miscellaneous    N=3 
.87 
All values are median [interquartile range 25‐75%] unless other reported. 
 
The significantly higher RASS score in the delirium group is a result of the 
hyperactive delirious state of these patients compared with non delirium patients. 
All patients were mechanically ventilated at the time of ICU admission, however, 
none of the patients was ventilated during the study period. Included patients did 
not receive any sedatives and all patients were treated with morphine according to 
our postoperative protocol. All blood and urine was collected in the morning, except 
for two patients (one in each group) in whom urine was collected in the afternoon. 
Figure 1 shows representative examples of protein spectra of our master pool 
urine, which served as a control reference sample, a non-delirium patient and a 
delirium patient. 
After unsupervised hierarchic clustering, the urine protein profiles of all ICU patients 
differed from the master pool urine protein profiles, however, a clear distinction 
between delirium and non-delirium patients could not be made. Urine proteomics 
profiling did not reveal protein patterns discriminative for delirium within the ICU 
patients. However, we found two protein masses to be more abundantly expressed 
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in the non-delirium ICU patients compared to the delirium patients as assessed by 
the ClinProTools.
Figure 1 Protein spectra and hierarchical cluster after profiling with CM10 beads
A. Protein spectra of masterpool urine (upper panel), a non-delirium patient (middle panel) and 
a delirium patient (lower panel). The x-axis depicts m/z values in Dalton; the y-axis shows the 
relative peak intensity.
B. Unsupervised hierarchical clustering determines whether patient groups can be differentiated 
solely based on their urine protein profile. On the right hand side the samples are represented. 
The lengths of the horizontal lines represent the resemblance of the spectra; the shortest lines 
represent the most alikeness between samples. In this hierarchic cluster our masterpool can 
be clearly distinguished from the ICU patients, but there is no distinction between delirium and 
non-delirium patients.
Urinary protein profiling in hyperactive delirium 
and non-delirium cardiac surgery ICU patients
4
62
The clinical relevance of the 11735.7 Da (p < .044) mass and its suspected double 
charged form of 5867.12 Da (p < .044) in urine samples of non-delirium ICU patients 
is, however, questionable since these masses were found in both types of ICU 
patients and were highly variable. The mean mass intensity and standard deviation 
of 11735.7 Da in the urine of delirium ICU patients was 22.12 ± 23.47 compared to 
32.1 ± 22.1 for the non-delirium ICU patients. For the 5867.12 Da mass this was 12.3 ± 
12.3 versus 17.7 ± 10.7, respectively. Efforts to identify these protein masses were not 
undertaken because of the poor discriminative properties (viz. borderline statistical 
difference) in delirium ICU patients.
Discussion
This study shows no relevant differences in urine protein profiles between 
hyperactive delirium and matched non-delirium post cardiac surgical ICU patients. 
We could not reproduce the findings from previous studies that reported protein 
pattern specific for delirium in serum, including haemoglobin-β (8), S100-β (21;22) 
or other unidentified peaks at m/z 5030 and 5179 in rats withdrawn from cocaine 
exposure (10). This could indicate that no clear hyperactive delirium protein 
fingerprint is present in the urine of ICU patients or that associated proteins present 
in brain or serum do not pass the blood-brain-barrier or are not excreted in urine. 
Although mass spectrometry can be accurately applied to detect proteins over 
a very wide range with good sensitivity, there are some limitations to biomarker 
detection using proteomic protein profiling. In this study, beads were used to isolate 
proteins from urine and to eliminate disturbing salts for MALDI-TOF MS analysis. 
Disadvantages of this method are that proteins may be lost due to competition 
for binding to the beads and the use of beads may lead to protein selection. In 
addition, matrix based ionization is susceptible to signal suppression (23). Other 
mass spectrometry methods based on electrospray ionization, such as LC-MS/MS 
are less susceptible to signal suppression and have a higher sensitivity, but are also 
more sensitive to interfering compounds such as lipids and detergents. Moreover, 
LC-MS/MS is time consuming and not suitable for high-throughput screening. 
To identify a biomarker pattern specific for a pathological condition it is essential 
to have homogeneous patients groups. Intra-group variability and the relatively 
small sample size may have hindered to discover differences between the patient 
groups. To limit this variability, kidney function and aorta clamping time (24) were 
meticulously matched between the studied groups. Still, ICU patients have a higher 
urine protein content as compared to healthy controls (mean 0.22 ± SD 0.13 g/L 
compared to <0.100 ± 0.002g/L in masterpool control urine samples), Challenging 
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the discovery of a discriminative protein in these ICU patients a challenge. In addition, 
the sample size of our study was relatively small, therefore there is a possibility of a 
type-II error. However, we did not find any clear protein profile difference between 
delirium and non-delirium patients, which could be an indication of a specific 
delirium 10 protein in the urine. Consequently we believe that the possibility of a 
false negative finding is very low. 
Conclusion
No relevant differences in urine protein profiles between hyperactive delirium and 
matched non-delirium post cardiac surgical ICU was found. MALDI-TOF MS did not 
reveal a specific hyperactive delirium protein fingerprint in ICU patients. 
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Abstract
Background
Delirium is a serious and frequent psycho-organic disorder in critically ill patients. 
Reported incidence rates vary to a large extent and there is a paucity of data 
concerning delirium incidence rates for the different subgroups of intensive care 
unit (ICU) patients and their short-term health consequences.
Objectives
To determine the overall incidence and duration of delirium, per delirium subtype 
and per ICU admission diagnosis. Furthermore, we determined the short-term 
consequences of delirium.
Design
Prospective observational study.
Participants and setting
All adult consecutive patients admitted in one year to the ICU of a university 
medical centre.
Methods
Delirium was assessed using the Confusion Assessment Method-ICU three times 
a day. Delirium was divided in three subtypes: hyperactive, hypoactive and mixed 
subtype. As measures for short-term consequences we registered duration of 
mechanical ventilation, re-intubations, incidence of unplanned removal of tubes, 
length of (ICU) stay and in-hospital mortality.
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Results
1,613 patients were included of which 411 (26%) developed delirium. The 
incidence rate in the neurosurgical (10%) and cardiac surgery group (12%) was 
the lowest, incidence was intermediate in medical patients (40%), while patients 
with a neurological diagnosis had the highest incidence (64%). The mixed subtype 
occurred the most (53%), while the hyperactive subtype the least (10%). The median 
delirium duration was two days [IQR 1-7], but significantly longer (p < .0001) for 
the mixed subtype. More delirious patients were mechanically ventilated and for a 
longer period of time, were more likely to remove their tube and catheters, stayed 
in the ICU and hospital for a longer time, and had a six times higher chance of 
dying compared to non-delirium ICU patients, even after adjusting for their severity 
of illness score. Delirium was associated with an extended duration of mechanical 
ventilation, length of stay in the ICU and in-hospital, as well as with in-hospital 
mortality.
Conclusions
The delirium incidence in a mixed ICU population is high and differs importantly 
between ICU admission diagnoses and the subtypes of delirium. Patients with 
delirium had a significantly higher incidence of short-term health problems, 
independent from their severity of illness and this was most pronounced in the 
mixed subtype of delirium. Delirium is significantly associated with worse short-
term outcome.
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Introduction
Patients in the intensive care unit (ICU) are severely ill and need support of one 
or more organ functions. In the last decade, there is an increasing interest in brain 
dysfunctions such as delirium. Delirium is a syndrome defined as an acute onset of 
disturbances in consciousness and changes in cognition with a fluctuating course 
(1). Three subtypes of delirium can be distinguished (2). A hyperactive delirium 
subtype with symptoms of hyperalertness, agitation, delusions and hallucinations, 
a hypoactive subtype in which the patient is hypoalert, lethargic, motorically slow 
and has inappropriate speech and the alternating or mixed subtype. The latter 
subtype of delirium is characterised by alternating symptoms of hyperactive and 
hypoactive delirium. The Richmond Agitation Sedation Scale (RASS) ranging from 
+4 (heavily agitated) to -5 (coma) in combination with the delirium diagnose (3) 
is used to distinguish between the three delirium subtypes (2;4). Only positive 
RASS scores indicates a hyperactive delirium subtype. Delirious patients who only 
have RASS scores between 0 and -3 are defined as hypoactive delirious patients. 
Patients with fluctuating RASS scores, between +4 and -3 in combination with a 
positive delirium screening, are defined as mixed or alternating subtype. These 
delirium subtypes have different implications for nurses since the hyperactive 
subtype is easy to recognize but causes more nursing problems and inconvenience. 
While patients with the hypoactive subtype are, due to their lethargic state, easy to 
nurse but therefore also easily missed or misdiagnosed as sedation of depression 
(1). Meagher and Trzepactz  (5;6) suggest that the different delirium subtypes in 
hospitalized patients represent a difference in  severity of delirium. They argue 
that, since the duration of a hyperactive delirium is shorter than the duration of the 
mixed subtypes, and the length of stay in hospital is also shorter, the hyperactive 
subtype is less severe than the other subtypes. Whether this difference in severity 
of delirium is also true for ICU patients is not known.
Delirium in ICU patients is associated with short-term health consequences such 
as prolonged duration of mechanical ventilation and length of stay and higher 
mortality rates (7-9). The duration of delirium is associated with prolonged cognitive 
failure (10) and each additional day with delirium is associated with a 10% increase 
in mortality (11). 
The delirium incidence in ICU patients ranges from 11 to 89% (7;9;12-14). Despite 
the generally high delirium incidence rate accompanied and the serious health 
consequences there is lack of evidence for prevention of delirium ICU patients. 
Preventive measures consisting of a multicomponent intervention strategy (15) and 
prophylactic haloperidol (16) showed positive effects in older hospitalized patients 
with a high risk for delirium. The effects of these preventive measures are not 
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determined yet in ICU patients. 
The high incidence rate in critically ill patients is associated with the frequent 
occurrence of important risk factors for delirium (17) in ICU patients. The wide range 
of delirium incidence rates is likely related to case mix differences over studies. It is 
likely that overall delirium incidence rates and rates per subtype of delirium differ 
between (elective) surgical and medical patient groups. As these patient groups 
differ, e.g. regarding their pathophysiological disease processes, severity of illness, 
and chance of dying (18) we expect them to also differ in their chances of developing 
delirium, or chances of developing a specific subtype. 
Although the classification of the delirium subtypes according to Peterson (2) is 
commonly used in the ICU, little is known about incidence rates of the subtypes 
per ICU diagnosis group and its effects on delirium duration and short-term 
consequences. 
The aim of this study is threefold. First, to determine the delirium incidence rate 
overall, per subtype of delirium and per ICU diagnosis group. Second, to determine 
the delirium duration overall, per subtype and per ICU diagnosis group. Third, to 
determine differences in short-term consequences between delirious and non-
delirious patients, and for the delirium subtypes and to determine the contribution 
of delirium to these short-term consequences. 
Methods
The study was approved by the local Medical Ethical Committee (study number 
2007/283), which waived the need for informed consent since no interventions were 
carried out. The study was registered in the Clinical trial register as NCT00604773
Study design, sample and setting
We performed a prospective cohort study between February 2008 and February 
2009 in which all consecutive ICU patients were included and systematically screened 
for delirium. The study was carried out in the Radboud University Nijmegen Medical 
Centre, The Netherlands. This is a 960-bed university hospital that includes a level-3 
ICU (highest level) with 33 ICU-beds for adults. Annually, approximately 2000-2500 
(surgical, cardiac surgery, neurosurgical, neurological, medical, and trauma) ICU 
patients are admitted.
Delirium screening
Ideally, delirium is diagnosed by a psychiatrist, geriatrician or neurologist, as this 
is considered the ‘gold standard’. However, this is not feasible in the ICU. Therefore, 
Incidence and short-term consequences of delirium in critically ill patients: 
a prospective observational cohort study
5
74
several delirium assessment tools have been developed for daily use by ICU 
nurses. Worldwide, the validated confusion assessment method (CAM)-ICU (19;20) 
is mostly used and has the highest sensitivity and specificity (21). In the present 
study, all adult ICU patients were screened at least three times a day by trained 
ICU nurses (23) using the validated Dutch version of the CAM-ICU (22). Screening 
was performed more often if required, for example following sudden changes in 
behaviour, attention or consciousness. The implementation of the CAM-ICU in 
our daily practice is described elsewhere (23). In brief, a tailored implementation 
strategy was used and ICU nurses were trained at the bedside by a delirium expert 
nurse after they first followed one hour of group training concerning the use of the 
CAM-ICU. Furthermore, we used ‘delirium key-nurses’ for further instructions and 
support of the nurses. Importantly, the use of the CAM-ICU was fully supported by 
the medical and nursing staff. Based on the CAM-ICU result, patients were treated 
with haloperidol or not.
Patients were excluded for this study if: they were admitted to the ICU for less than 
one day; had a sustained Richmond agitation sedation score (RASS) of -4/-5 during 
complete ICU admission; had serious auditory or visual disorders; were unable 
to understand Dutch; were mentally disabled; suffered from a serious receptive 
aphasia or if the compliance rate of the delirium screening was <80% during a 
patient’s stay in the ICU.
Patients who were discharged from the ICU with delirium were followed on the 
ward until the end of the delirium episode. On the wards, patients were screened for 
delirium three times a day with the delirium observation scale. This scale is developed 
and validated by Schuurmans (24) and is commonly used in daily practice (25).
Outcome measures
Patients were diagnosed with delirium when they had at least one positive 
CAM-ICU screening during their complete ICU stay. Delirium was divided in three 
subtypes (Figure 1). The duration of delirium was measured per 8 h shift, expressed 
in days and defined as time from first positive CAM-ICU until the beginning of 
three consecutive days of negative delirium screenings (ICU patients: negative 
CAM-ICU, ward patients delirium observation scale score <3). Patients who died or 
were discharged from the hospital while delirious were discarded for the delirium 
duration calculations. 
The delirium incidence rate was calculated in all included ICU patients. In addition, 
we calculated the delirium incidence rate in patients admitted for two days or 
longer separately.
We defined short-term consequences of delirium as: days on the mechanical 
ventilator, need for re-intubation, incidence rate of unplanned removal of tubes or 
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catheters by the patient, length of stay (LOS) in the ICU and in-hospital, and in-hospital 
mortality. An extended duration of mechanical ventilation, length of stay in the ICU 
and in-hospital, and the in-hospital mortality were considered as the most important 
short-term consequences since this harms the patients directly and the most.
Patients were divided in six admission categories: cardiac surgery, neurosurgical, 
surgical, neurological, medical and trauma. This classification was set by the 
attending physician and based on main reason for ICU admission.
Variables 
Demographic variables of all included patients were collected such as age, gender, 
admission category, severity of illness expressed in Acute Physiology and Chronic 
Health Evaluation (APACHE-) II score. Furthermore, delirium outcome measures and 
short-term consequences were collected.
Quality checks during data collection
The performance of CAM-ICU screenings by the nurses was monitored to ensure 
the quality of data collection. Compliance was calculated as the percentage of 
assessments performed per day in relation to the total number of assessments 
that should have been performed. The mean compliance was 90.4%. To determine 
the quality of the CAM-ICU performance, we measured the interrater reliability. 
For this, the CAM-ICU score assessed by the attending intensive care nurse was 
compared with the CAM-ICU score assessed by an expert psychiatry nurse within a 
time-window of 1 h. One hundred-and-twenty interrater reliability measurements 
were performed at random resulting in a Cohen’s kappa of 0.90 (95%CI 0.82-0.98). 
Furthermore, medical and nursing files of all patients were screened daily for 
signs of delirium (26). When the files contained signs of delirium without a positive 
CAM-ICU screening or conversely, when files did not provide evidence of delirium 
while there was a positive CAM-ICU score, patients were additionally screened by 
a delirium expert according to the DSM-IV criteria (1) to rule out false negatives 
and positives. These signs were for instance lethargic or depressive behaviour or 
just picker or agitated behaviour which was not directly recognised or screened as 
delirium. In total 17 patients (1.1%) were additionally screened by a delirium expert. 
Finally, data-collection was randomly checked for accuracy in 15% of the patients 
by the first author. 
Statistical analyses 
Differences between delirium and non-delirium ICU patients and differences for 
the subtypes of delirium regarding the demographic characteristics and short-term 
consequences were tested non-parametrically using the Mann-Whitney U test. 
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Dichotomous variables were tested with the Chi-square test. To determine short-
term consequences of delirium covariance analyses were performed to adjust 
for severity of illness. Since the distribution of the length of stay and duration 
of mechanical ventilation were skewed, data were log transformed resulting in 
normally distributed variables where after covariance analyses was performed. 
To take differences in duration of delirium into account, incidence rates of re-
intubations, unplanned removal of catheters and the amount of removed catheters 
were calculated per 1000 delirium days. Differences in these incidence rates 
between delirium subtypes were tested using the Mann-Whitney U test. 
To determine the contribution of delirium to an extended duration of mechanical 
ventilation, length of stay in the ICU and in-hospital we used a multiple logistic 
regression analysis. The highest  quartile of the duration of mechanical ventilation, 
length of stay in the ICU and in-hospital were used as cut-off value for the definition 
of extended duration of these variables. Important variables as delirium, age, 
severity of illness score, history of respiratory diseases, re-intubation and sepsis 
were used as covariates.  
Statistical significance was defined as a p value < .05. All data were analysed using 
SPSS version 16.01 (SPSS, Chicago, IL).
Results
In total 2,116 consecutive patients were screened of which 503 were excluded 
(Figure 1). The most common reasons for exclusion were sustained coma (26.8%) 
and delirium before ICU admission (26.6%).
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Figure 1 Flowchart of patient inclusion
Delirium incidence and differences between delirious and non-delirious patients 
Out of the remaining 1,613 patients, 411 (26%) developed delirium during their ICU 
admission. When calculating the delirium incidence rate in the group of patients 
admitted to the ICU for two days or longer, the incidence rate increased to 53%.
Demographic characteristics of the patients are shown in Table 1. Patients with 
delirium were significantly older, more likely to be admitted to the ICU for urgent 
reasons, more likely to be mechanically ventilated and their severity of illness score 
was significantly higher than that of ICU patients who did not develop delirium. 
The delirium incidence rates of the cardiac surgery and neurosurgical groups was 
significantly lower compared to the other groups (all p < .0001), while the incidence 
rate in the neurology group was significantly higher than that in all other groups 
(p < .05). 
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Table 1 Demographic characteristics of non-delirium and delirium patients
Table 1. Demographic characteristics of non‐delirium and delirium patients  
  Non‐delirium 
patients  
(N=1202) 
Delirium  
patients  
(N=411) 
p value 
Age (years)  61  ±14  64  ±15  < .0001 
Gender (M)  792  (66%)  235 (57%)  .001 
Urgent admission (N)  526  (44%)  326 (79%)  < .0001 
APACHE‐II score (point)   13  ±5  18  ±6  < .0001 
Mechanically  ventilated  patients 
(N) 
903 (75%)  363 (88%)  < .0001 
Diagnosis group 
- Cardiac surgery (N=793) 
- Surgical (217) 
- Medical (N=360) 
- Trauma (N=80) 
- Neurology (N=89) 
- Neurosurgical (N=74) 
698
160
205
42
30
67
 
(88%) 
(74%) 
(60%) 
(53%) 
(34%) 
(90%) 
95 
57
155 
38
59
7 
 
(12%)* 
(26%) 
(40%) 
(47%) 
(66%)** 
(10%)* 
 
 
APACHE‐II score: Acute Physiology and Chronic Health Evaluation‐II score 
Data are expressed as mean±standard deviation or numbers of patients and percentages. 
* Significantly lower incidence rate than the other admission types 
** Significantly highest delirium incidence rate 
Delirium subtypes 
Regarding the delirium subtypes, the mixed subtype occurred most frequently, 
followed by the hypoactive delirium subtype (Table 2). The incidence of hyperactive 
delirium was significantly highest in the cardiac surgery group and the incidence of 
hypoactive delirium was significantly highest in the neurology and neurosurgical 
group, other differences between the delirium subtypes and admission categories 
are shown in Table 2.
Duration of delirium, short-term consequences and mortality
Overall the median delirium duration was 2 days [IQR 1-7, range 1-74 days] and was 
longest in the mixed subtype (p < .001). In 93 (23%) of the delirious patients it was 
not possible to determine the delirium duration mostly for reasons of discharge 
to another hospital or because the patient died. Delirious patients more likely 
needed respiratory support for a longer time and their ICU length of stay was longer 
compared to non-delirious patients (Table 3). These differences were all significant, 
even after adjusting for severity of illness at the time of ICU admission using the 
APACHE-II score. Delirious patients were significantly more likely to remove their 
tubes and catheters than non-delirious patients. Removal of their gastro-intestinal 
feeding tube occurred most frequently (51%) in patients who suffered from delirium, 
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followed by unplanned removal of the endotracheal tube (28%). The incidence 
rate of unplanned removal of tubes and catheters was significantly highest in the 
hyperactive subgroup delirium. This subgroup also more frequently removed tubes 
and catheters than the hypoactive and mixed subtype of delirium when adjusted 
for delirium duration.
Patients with a mixed subtype suffered the most from the short-term consequences 
(Table 4). Patients with the hyperactive subtype suffered the least from the short-
term consequences and the delirium duration in this subtype was the shortest 
(p < .0001).
Delirious patients were six times more likely to die as compared to non-delirious 
patients. This difference persisted following adjustment for severity of illness. 
Significantly more patients with a hypoactive and mixed subtype died compared to 
the hyperactive subtype.
The median duration of mechanical ventilation in the total group was 0.5 days [IQR 
0.3-1.0].
Table 2 Subtypes of delirium in the six different admission categories
Table 2. Subtypes of delirium in the six different admission categories 
  Hyperactive 
subtype 
Hypoactive 
subtype 
Mixed  
subtype 
Incidence rate 
 
Cardiac surgery (N=95) 
44 
 
22 
(11%) 
 
(23%)** 
148
38
(36%) 
 
(40%) 
219
35
(53%) 
 
(37%)** 
Surgical (N=57)  4  (7%)  16 (28%)  37 (65%) 
Medical (N=155)  12  (8%)  52 (34%)  91 (59%) 
Trauma (N=38)  4  (11%)  9 (24%)  25 (66%) 
Neurology (N=59)  2  (3%)*  29 (49%)*  28 (48%) 
Neurosurgical (N=7)  0  (0%)#  4 (57%)*  3 (43%) 
# not applicable 
*  p < .05    ** p < .0001 
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Table 3 Differences between non-delirium and delirium patients on short-term consequences 
Table 3. Differences between non‐delirium and delirium patients on short‐term consequences   
  Non‐delirium 
patients  
(N=1202) 
Delirium  
patients  
(N=411) 
p value* 
Days of mechanical ventilation    0.3 [0.2‐0.6]  4.6 [0.9‐10.9]  < .0001 
Re‐intubation (N)  6 (0.5)  41 (10%)  < .0001 
Accidental removal of tubes, 
catheters (N) 
7 (0.6)  49 (11.9%)  < .0001 
Total number of removals  
(N, frequency/patient) 
8 (1.1)  95 (1.9)  .35 
LOS‐ICU (days)  1  [1‐2]  6  [2‐13]  < .0001 
LOS‐Hospital (days)  7  [5‐14]  20  [10‐20]  < .0001 
Mortality rate (N)  40 (3%)  73 (18%)  < .0001 
LOS: length of stay 
Data are expressed as medians [IQRs] or numbers of patients and percentages   
* Adjusted for APACHE‐II score using analysis of covariance 
 The median length of stay in the ICU and in-hospital was 1 day [IQR 1-3] and 9 days 
[IQR 5-19], respectively. The cut-off value of extended duration of mechanical 
ventilation was defined as a duration longer than 1 day and an extended length of 
stay in the ICU, and in-hospital was defined as a stay longer than 3 days and 19 days, 
respectively. 
Adjusting for covariates delirium was after consistently and significantly associated 
to an extended duration of mechanical ventilation (odds ratio 7.0), length of stay in 
the ICU (odds ratio 8.6) and in-hospital (odds ratio 2.1), as well as with in-hospital 
mortality (odds ratio 2.1) 
Delirium in Intensive Care Patients
81
Table 4 Differences between subtypes of delirium in delirium incidence and duration 
 and on short-term consequences  
Table 4. Differences between subtypes of delirium in delirium incidence and duration and on short‐term consequences   
  Hyperactive 
subtype 
(N=44) 
P‐value 
* 
Hypoactive 
subtype 
(N=148) 
P‐value 
# 
Mixed  
subtype 
(N=219) 
p value† 
Age (years, median,[IQR])  73  [60‐77]  .20*  67 [57‐75]  .75#  66 [56‐75]  .13† 
APACHE‐II score (point)  16  [13‐19]  .10*  18 [14‐22]  .47#  18 [14‐23]  .03† 
Delirium incidence rate  44  (10.7%)    148  (36%)    219 (53.3%)   
Delirium duration (days, 
median, [IQR])  1  [1‐1]  < .001*  1 [1‐4]  < .001
#  4 [2‐13]  < .001† 
Mechanical ventilation 
(days, median, [IQR]  0.6  [0.3‐2.1]  < .001*  3 [0.8‐7.7]  < .001
#  6.9 [1.7‐13.8]  < .001† 
Re‐intubation per 1000 
delirium days  68  .02*  22  .81
#  16  .01† 
Incidence unplanned 
removal tubes, catheters 
per 1000 delirium days 
227  < .001*  35  .78#  40  < .001† 
Frequency removal of 
tubes per 1000 delirium 
days  
386  < .001*  88  .97#  86  < .001† 
LOS‐ICU  3  [1‐5]  .02*  5 [2‐9]  .001#  9 [3‐17]  < .001† 
LOS in‐hospital  10  [5‐15]  .003*  17.5 [8‐32]  .003#  24 [13‐48]  < .001† 
Deceased (N)  3  (6.8%)  .04*  28 (18.9%)  .53#  42 (19.2%)  .03† 
APACHE‐II score, Acute Physiology and Chronic Health Evaluation‐II score. LOS, length of stay 
* Difference between hyperactive and hypo active delirium subtype 
#  Difference between hypo active and mixed delirium subtype 
†   Difference between hyperactive and mixed delirium subtype
Table 5 The associationa of delirium with extendedb  mechanical ventilation, LOS-ICU 
 and in-hospital, and in-hospital mortalityTable 5. The associatio a of delirium with extendedb  mechanical ventilation, LOS‐ICU and in‐hospital, and in‐hospital  
mortality 
  Extended mechanical 
ventilation 
 
OR (95%CI) 
Extended  
LOS‐ICU 
 
OR (95%CI) 
Extended  
LOS 
in‐Hospital 
OR (95%CI) 
In‐Hospital 
mortality 
 
OR (95%CI) 
Delirium   7.0  (4.7‐10.5)  8.6 (5.8‐12.7)  2.1 (1.5‐3.0)  2.1 (1.2‐3.5) 
Age   0.99  (0.97‐1.01)  0.99 (0.98‐1.01)  0.99 (0.99‐1.01)  1.03 (1.01‐1.05) 
APACHE‐II score  1.07  (1.03‐1.11)  1.06 (1.03‐1.1)  1.08 (1.06‐1.11)  1.07 (1.03‐1.11) 
Sepsis  2.6  (1.2‐5.6)  2.6 (1.3‐5.3)  1.3 (0.8‐2.2)  2.9 (1.6‐5.1) 
Use of sedatives  2.9  (1.8‐4.6)  1.3 (0.8‐2.1)  1.0 (0.7‐1.5)  0.5 (0.3‐0.99) 
Non‐sustained coma  5.6  (3.5‐9.0)  3.4 (2.1‐5.7)  1.3 (0.9‐2.0)  1.6 (0.8‐3.2) 
Respiratory diseases  1.9  (1.3‐2.9)  2.3 (1.6‐3.4)  1.8 (1.4‐2.5)  2.4 (1.5‐3.9) 
Re‐intubation  30.1  (7.6‐119.4)  18.6 (5.4‐63.5)  5.6 (2.5‐12.7)  1.6 0.7‐3.6) 
LOS, length of stay; OR, odds ratio with 95% confidence interval; APACHE‐II score, Acute Physiology and Chronic  
Health Evaluation‐II score 
a using multiple logistic regression analysis 
b using the highest quartile of duration was used as cut‐off value 
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Discussion 
In this study we observed that the overall delirium incidence is approximately a 
quarter of all ICU patients admitted for at least one day, and half of all ICU patients 
admitted for two days or longer.  Important differences in incidence and subgroup 
distribution between patient categories exist. The incidence rate was the highest 
in the neurology group and the lowest in the cardiac- and neurosurgical group. 
The mixed delirium subtype occurred most frequently and also had the  longest 
duration. The hyperactive subtype occurred the least and the duration was the 
shortest. Furthermore we found that delirium is associated with serious short-
term health consequences, most prominently in patients with the mixed subtype. 
Additionally, delirium in ICU patients is significantly associated with an extended 
duration of mechanical ventilation, length of stay in the ICU and in-hospital, as well 
as with in-hospital mortality.
Our findings are of importance for clinical practice since this knowledge can 
contribute to taking preventive measures in patient categories with a high delirium 
incidence or to recognize patients who suffer the most from the consequences 
of delirium. To our knowledge the delirium incidence in patients admitted for 
neurological or neurosurgical reasons to the ICU has never been determined since 
these patients are mostly excluded in studies.
The high delirium incidence in ICU patients in this large prospective cohort study 
is in accordance with various studies (7;9;27;28), but was lower than some authors 
reported (8;13;29;30). Differences between these delirium incidences rates are 
likely related to differences in admission categories and in- or exclusion of patients 
with a short ICU length of stay. Indeed, we show that exclusion of patients with an 
ICU LOS of <2 days and ≥2 days importantly influences the incidence rate of delirium 
and that incidence varies greatly between diagnostic groups. Categorising the 
delirium incidence rate between ICU admission diagnosis group shows that there 
are notable differences that can be useful for others when interpreting measured 
delirium incidence rates. 
Our results concerning the short-term consequences of delirium confirm previous 
work showing that delirious patients are mechanically ventilated for a significantly 
longer time (31), have a longer ICU and in-hospital length of stay (8) and are more 
likely to die (28;32). However, none of these studies reported differences between 
the subtypes of delirium. Overall, delirious patients had significantly more short-
term health problems than non-delirious patients and these problems were most 
profound in the mixed subtype, which also had the longest duration.
Regarding these subtypes of delirium, the hyperactive subtype occurred the most 
in cardiac surgery patients, this subtype had the shortest duration and the fewest 
Delirium in Intensive Care Patients
83
short-term consequences compared with the hypoactive and mixed subtype. 
However in practice, nurses and physicians experience the most difficulties with 
patients with this easily recognizable delirium subtype. These patients are often 
agitated and consequently pull out their lines or endotracheal tube. Adjusted 
incidence rates of re-intubation and unplanned removal of catheters and tubes 
confirm these experiences of caregivers.
We found several significant differences for delirium subtypes and admission 
categories of which difference between the incidence of hyperactive delirium in the 
cardiac surgery and neurosurgical group is remarkable. There are only a few studies 
which reported incidence rates of delirium subtypes but these were only in medical 
(2) or surgical and trauma patients (4). Except for the higher incidence rate in the 
hyperactive group in our study, mainly caused by the high incidence rate in cardiac 
surgery patients, the numbers of the hypoactive and mixed subtype of delirium are 
rather comparable with these other reports. 
Some limitations of this study need to be considered. Firstly, we did not use the ‘gold 
standard’ to diagnose delirium, but the CAM-ICU, which is a delirium screening tool. 
This screening tool is however, the most frequently used tool worldwide, and has the 
highest sensitivity and specificity and a high inter-rater reliability (21;33). Moreover, 
to secure that no false negative or positive delirium assessments were used for the 
calculations in this study we also checked patients’ files and if necessary a delirium 
expert additionally screened these patients. Therefore, we believe our assessment 
is valid and our incidence rate is reliable. However, one may argue that our overall 
incidence rate is low compared to other studies on delirium in the ICU, and hence 
may not be reliable. We attribute this low incidence to the fact that we included a 
large number of cardiac surgical patients, of which most have an ICU stay of one day 
and a low incidence of delirium (34;35). When we excluded the patients with an ICU 
stay of only one day our incidence rate became comparable to that of other studies. 
Secondly, we excluded more than 20% of our screened patients. For this study we 
used similar exclusion criteria as others did when using the CAM-ICU (8;36). The 
most frequent reason for exclusion was ‘delirious before ICU admission’ which must 
be considered as a normal exclusion criteria when determining the incidence rate. 
Sustained coma was the second most frequent reason which occurred the most 
in neurological patients. This patient category is mostly excluded in other studies. 
Despite we included also patients admitted to the ICU for a neurological disease, 
we excluded a similar amount of patients  when compared with other studies which 
ranges up to 43% (7;9;32;37).
Thirdly, in this prospective cohort study we determined that delirium is associated 
with several short-term consequences which does not necessarily indicate there 
is a causal relationship between delirium and the outcome parameter. Our study 
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design is too limited to draw these strong conclusions. Despite this limitation it 
is important to recognize that delirium is a serious disorder with serious short-
term consequences and our results corroborates findings of other smaller studies 
(8;11;32).
Lastly, in our study a notable number of patients died or were discharged to other 
hospitals before the end of the delirium episode and like others (38) we did not 
include the residual duration of their delirium period. One may argue that this 
resulted in an underestimation of the delirium duration and unplanned removal 
of tubes and catheters. Although this could have influenced the delirium duration, 
this calculation method will not influence the incidence of unplanned removal of 
tubes and catheters as all these patients were already discharged from the ICU to 
the ward and therefore had less indwelling tubes and catheters. 
Conclusion
Over a quarter of our ICU population with a length of stay >1 day and half of the 
ICU patients with a length of stay of ≥2 days developed delirium during their ICU 
stay. There is an important difference between admission categories concerning the 
delirium incidence rates and the occurrence of subtypes of delirium. Patients who 
developed delirium were significantly more likely to suffer from short-term health 
problems and had a six times higher chance of dying compared to ICU patients who 
did not develop delirium, independently of their severity of illness. The problems 
were most pronounced in patients with a mixed subtype of delirium. 
In summary, the high delirium incidence rate and serious short term health related 
problems for patients must be sufficient to convince health care professionals to 
screen patients for delirium and should encourage nurses to take preventive 
measures such as cognitive stimulation (15), music therapy (39), prophylactic 
haloperidol (16;40) or early mobilization (41) of which the latter is the only measure 
which was examined in ICU patients.
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ABSTRACT
Introduction
Predictive models, such as acute physiology and chronic health evaluation II 
(APACHE-II), are widely used in intensive care units (ICUs) to estimate mortality. 
Although the presence of delirium is associated with a higher mortality in ICU 
patients, delirium is not part of the APACHE-II model. The aim of the current study 
was to evaluate whether delirium, present within 24 hours after ICU admission, 
improves the predictive value of the APACHE-II score.
Methods
In a prospective cohort study 2116 adult patients admitted between February 
2008 and February 2009 were screened for delirium with the confusion 
assessment method-ICU (CAM-ICU). Exclusion criteria were sustained coma and 
unable to understand Dutch. Logistic regression analysis was used to estimate the 
predicted probabilities in the model with and without delirium. Calibration plots 
and the Hosmer-Lemeshow test (HL-test) were used to assess calibration. The 
discriminatory power of the models was analyzed by the area under the receiver 
operating characteristics curve (AUC) and AUCs were compared using the Z-test.
Results
1740 patients met the inclusion criteria, of which 332 (19%) were delirious at the time 
of ICU admission or within 24 hours after admission. Delirium was associated with 
in-hospital mortality in unadjusted models, odds ratio (OR): 3.22 (95% confidence 
interval [CI]: 2.23 - 4.66). The OR between the APACHE-II and in-hospital mortality 
was 1.15 (95% CI 1.12 - 1.19) per point. The predictive accuracy of the APACHE-II did 
not improve after adding delirium, both in the total group as well as in the subgroup 
without cardiac surgery patients. The AUC of the APACHE model without delirium 
was 0.77 (0.73 - 0.81) and 0.78 (0.74 - 0.82) when delirium was added to the model. 
The z-value was 0.92 indicating no improvement in discriminative power, and the 
HL-test and calibration plots indicated no improvement in calibration.
Conclusions
Although delirium is a significant predictor of mortality in ICU patients, adding 
delirium as an additional variable to the APACHE-II model does not result in an 
improvement in its predictive estimates.
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INTRODUCTION
Predictive models are widely used in ICUs to estimate the disease severity and 
estimate the risk of death or to identify patients at high risk of dying (1). Predictive 
estimates are important from both a clinical and administrative perspective. These 
estimates can be used to inform patients and their families about likely outcomes 
(1;2), to monitor response to treatment, to guide physicians in making clinical 
decisions (2), and to monitor or compare the performance of different ICUs (3). A 
commonly used prediction model in the ICU is the Acute Physiology and Chronic 
Health Evaluation (APACHE)-II (4), which is measured within 24 hours of ICU 
admission. Importantly, although the APACHE-II score was developed in the early 
1980s, it still represents the most widely used predictive model to estimate in-
hospital mortality and it remains a valid measure of severity of illness. The APACHE-
II is able to correctly differentiate between patients who are and who are not at risk 
of dying in 62% to 88% of patients (5). The Glasgow Coma Scale is the only variable 
referring to brain (dys)function in the APACHE-II score (4). Delirium, another brain 
disorder, is not included in the APACHE-II model, despite its high incidence rate in 
ICU patients and the growing evidence of its association with poor outcomes such 
as increased morbidity and mortality rates, and prolonged length of hospital stay 
(6;7). 
Delirium, defined as a disturbance of consciousness and cognition that develops 
over a short period of time and fluctuates over time, is induced by an underlying 
physical cause such as the development of severe medical illness, co-morbidities and 
changes in drug use (8;9). One-third of patients are delirious on initial assessment, 
and the majority who develop delirium do so within 48 hours of admission (8). 
Consequently, adding delirium to the existing APACHE-II model could improve the 
predictive estimates. However, despite the strong association between delirium 
and mortality, such an association does not necessarily imply clinical relevance or 
better prediction. 
The aim of our study was to evaluate whether delirium, if present within 24 hours 
after ICU admission, improves the predictive accuracy of the APACHE-II score of in-
hospital mortality of critically ill patients. 
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Material and methods
This prospective cohort study was carried out in the Radboud University Nijmegen 
Medical Centre, the Netherlands. This is a 960 bed university hospital with 33 
ICU beds for adults where annually 2,000 to 2,500 (cardiothoracic surgery, 
neurosurgical, medical, surgical and trauma) ICU patients are admitted. The study 
was approved by the local Medical Ethical Committee, which waived the need for 
informed consent because no interventions were carried out. 
Consecutive adult patients admitted to the ICU between February 2008 and 
February 2009 were included. Patients were excluded when they had a sustained 
Richmond agitation sedation score (RASS) of -4/-5, length of stay on the ICU for 12 
hours or less, had serious auditory or visual disorders, were unable to understand 
Dutch, were severely mentally disabled or suffered from receptive aphasia. 
To detect delirium, all patients were screened with the validated Dutch version of 
the Confusion Assessment Method-ICU (CAM-ICU) (10). The assessment with the 
CAM-ICU was performed three times per day by well trained ICU nurses during the 
patient’s entire ICU stay (11). For this study patients were diagnosed with delirium 
when they had a minimum of one positive CAM-ICU screening assessment. As for 
the other parameters used in the APACHE-II score, we used delirium that occurred 
within 24 hours after ICU admission. Demographic, laboratory, clinical data, and 
hospital mortality were collected. Naturally, various risk factors for the development 
of delirium may differ between patients, but these were not registered because the 
aim of the present study was merely to investigate if the predictive value of the 
APACHE-II score improved when delirium, irrespective of its cause, was added.
As the APACHE-II was originally not validated for cardiac surgery patients, a 
subgroup analysis was also performed without cardiac surgery patients.
Statistical analysis 
Patient characteristics at baseline and the incidence of delirium within 24 hours, 
and in-hospital mortality were evaluated. Normally distributed data were tested 
parametrically using the Student’s T-test, and not normally distributed data 
were tested non-parametrically using the Mann-Whitney U test. The correlation 
between delirium and the APACHE-II score was tested using the Spearman’s rho. 
The association between delirium and in-hospital mortality was evaluated in a 
univariate and multivariate logistic regression model. The first model consisted of 
patient’s overall score on all variables of the APACHE-II score as the only predictive 
variable. The second model, based on the data of the same patients, consisted 
the variables of the APACHE-II score with delirium added as a new predictor. 
Differences in model performance between the APACHE-II model with and without 
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delirium were estimated on discrimination (area under the receiver-operating-
characteristic (AUC) curve). The two AUCs were compared using the z-statistic for 
comparing AUCs derived from the same cases as described by Hanley and McNeil 
(12). A z-value between -1.96 and +1.96 was considered as there being no significant 
differences between the two AUCs and with the most common used features on 
calibration (Hosmer-Lemeshow’s goodness-of-fit and calibration plots). A two-sided 
significance level of 5% and 95% confidence intervals (CI) were used for statistical 
inference. Statistical analysis was performed using SPSS 16.01 and MedCalc® version 
11.3.1.0 (MedCalc Software, Mariakerke, Belgium).
Results 
During the study period, 2,116 patients were admitted to the ICU of whom 376 
patients were excluded, leaving 1,740 patients for outcome analysis. The main 
reason for exclusion was persistent coma (36%) that made the detection of delirium 
impossible. Baseline characteristics of the included patients, with and without 
delirium within 24 hours, are shown in Table 1, and baseline characteristics of the 
patients, with and without cardiac surgery patients, are shown in Table 2. 
Table 1 Baseline characteristics and differences of delirious (within 24 hours 
 after ICU admission) and non-delirious patients*Table 1. Baseline characteristics and differences of delirious (within 24 hours after ICU 
admission) and non‐delirious patients* 
  Non‐delirium     
<24 hours 
Delirium       
<24 hours 
p value 
Age in years  61 ± 15  66 ± 14  .11 
Male, N (%)  134 (21.1)  198 (17.9)  .08 
APACHE‐II score  14 ± 6  17 ± 6  .18 
Length of stay‐ICU in days (median‐IQR)  1 (1‐3)  3 (1‐9)  < .0001 
Length of stay‐hospital in days (median‐IQR)  8 (5‐16)  15 (8‐33)  < .0001 
Urgent admission, N (%)  708 (50.3)  253 (76.2)  < .0001 
ICU admission type (%): 
- Surgical 
- Medical 
- Trauma 
- Neurology/neurosurgical 
 
910 (87.7) 
302 (70.1) 
66 (78.6) 
130 (69.1) 
 
127 (12.2) 
129 (29.9) 
18 (21.4) 
58 (30.9) 
 
 Died, N (%)   80 (5.7)  54 (16.2)  < .0001 
APACHE, Acute Physiology and Chronic Health Evaluation‐II; IQR, interquartile range. 
* Data are presented as mean ± standard deviation, unless otherwise mentioned. 
A total of 332 patients (19%) were delirious, 132 at the time of admission and 200 
within 24 hours after admission. The overall in-hospital mortality rate was 7.7%. In 
the non-delirious group 80 of 1,408 patients (5.7%) died, and in the delirious group 
this was 54 of 332 patients (16.2%).
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Table 2 Baseline characteristics of the patients in the total group and the subgroup 
 without cardiac surgery patients *Table 2. Baseline characteristics of the patients in the total group and the subgroup without 
cardiac surgery patients * 
 
Total 
group 
N = 1740 
Non‐cardiac 
surgery patients 
N = 881 
Age in years  62 ± 14  58 ± 16 
Gender M/F, N  1109/631  506/375 
APACHE‐II score  15±5  16±6.6 
Length of stay‐ICU in days (median‐IQR) 
- non delirious (within 24 hours after admission) 
- delirious  
 
1 (1‐3) 
3 (1‐9) 
 
2 (1‐7) 
3 (2‐10) 
Length of stay‐hospital in days (median‐IQR) 
- non delirious (within 24 hours after admission) 
- delirious 
 
8 (5‐16) 
15 (8‐33) 
 
14 (8‐27) 
19 (10‐36) 
Urgent admission, N (%)  961 (55.2)  703 (82.8) 
ICU admission type (%): 
- Surgical 
- Medical 
- Trauma 
- Neurology/neurosurgical 
 
59.6 
24.8 
4.8 
10.8 
 
23.4 
45.9 
9.4 
21.3 
Delirium, N (%) 
- before admission 
- within 24 hours after admission 
332/1740 (19.1) 
132 (7.6) 
200 (11.5) 
223/881 (25.3) 
106 (12.0) 
117 (13.2) 
 Died, N (%) 
- non delirious (within 24 hours after admission) 
- delirious  
 
80 (5.7) 
54 (16.2) 
 
71 (10.8) 
36 (16.1) 
APACHE,  Acute  Physiology  and  Chronic  Health  Evaluation‐II;  F,  female;  IQR,  interquartile 
range; M, male.  
* Data are presented as mean ± standard deviation, unless otherwise mentioned. 
The crude odds ratio (OR) of the presence of delirium within 24 hours of ICU 
admission and in-hospital mortality was 3.22 (95% CI: 2.23 to 4.66), and between 
the APACHE-II score and in-hospital mortality was 1.15 (95% CI: 1.12 to 1.19) per 
APACHE-point. The AUC of the APACHE-II model without delirium was 0.77 (95% 
CI: 0.73 to 0.81, standard error 0.19) and 0.78 (95% CI: 0.74 to 0.82, standard error 
0.19) when delirium was added. Comparison of the two AUCs with the Hanley and 
McNeil test resulted in a z-value of 0.92 (p = .36) indicating that both AUCs were not 
significant different and that addition of delirium to the APACHE-II score does not 
result in an improvement in discriminative power (Figure 1).
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Figure 1 Receiver-operating-characteristic and the area under the curve 
 of different prediction models with and without delirium. 
 APACHE-II, Acute Physiology and Chronic Health Evaluation-II.
Calibration plots (Figure 2) and the Hosmer-Lemeshow test (HL-test) showed a 
decrease of calibration after adding delirium to the APACHE-II score (HL-test chi-
square 12.38 and after adding delirium to the APACHE-II chi-square 17.93). The 
Spearman’s rho correlation between delirium and the APACHE-II score was 0.22 
(p < .0001). The subgroup, in which cardiac surgery patients were excluded, 
consisted of 881 patients. The crude OR for delirium present within 24 hours after 
ICU admission and in-hospital mortality in this subgroup was 1.59 (95% CI: 1.03 to 
2.46) and for APACHE-II and in-hospital mortality was 1.11 (95% CI: 1.08 to 1.15) per 
point. 
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Figure 2 Calibration plots of the APACHE-II model and of the APACHE-II model 
 with delirium. APACHE-II, Acute Physiology and Chronic Health Evaluation-II
Discussion
The main finding of the present study is that, although delirium present within 
24 hours after ICU admission, is associated with increased in-hospital mortality, 
adding delirium to the APACHE-II score does not improve its accuracy in predicting 
in-hospital mortality. Similar results were obtained in a subgroup analysis of non-
cardiac surgery patients.
The availability of an easy to use instrument that needs a limited amount of 
variables to predict the outcome of ICU patients is of great importance for clinical 
ICU practice. The APACHE-II score represents such an instrument with a moderate 
predictive value for in-hospital mortality. Comparable with previous reports (5) 
we found an AUC of the APACHE-II of 0.77. Theoretically, adding a prevalent and 
relevant variable to the APACHE-II score could improve its predictive value. Delirium 
could represent such a variable, because it is a frequent and serious disorder on the 
ICU associated with poor patient outcome. Although our study confirms previous 
reports (13), showing that the presence of delirium is an independent risk factor 
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for mortality, we demonstrate that the addition of delirium does not improve the 
predictive value of the APACHE-II score. There are several reasons why adding a new 
predictive variable may not result in a better accuracy of a predictive model including 
a low prevalence of the variable, the absence of predictive value of this variable, and 
the presence of a correlation between the predictive variable and the variable(s) 
originally included in the predictive model (i.e. APACHE-II). We showed that 
prevalence and predictive value of the presence of delirium are adequate. However, 
although the occurrence of delirium in critically ill patients is an independent risk 
factor for mortality (14), we found that the APACHE-II score correlated significantly 
with the occurrence of delirium within 24 hours. As a consequence, delirium has no 
additive effect in the predictive value of the APACHE-II score. 
Importantly, our data do not exclude a possible additive effect of incorporating 
delirium in models that are not focused on the first 24 hours of ICU stay, such 
as the sequential organ failure assessment (SOFA) score. Although there is a 
statistically significant association between delirium present within 24 hours after 
ICU admission and APACHE-II score, an association of 0.22 is rather low. Probably 
residual confounding plays an important role. The effect of adding delirium to 
dynamic predictive models such as the SOFA score, warrants further investigations 
because in a substantial part of the patients delirium is detected after the first 24 
hours after ICU admission as a result of worsening of their clinical situation.
Conclusion
An independent association was found between delirium present within 24 
hours after ICU admission and in-hospital mortality. However, adding delirium as a 
predictive variable to the APACHE-II score did not improve its predictive value. 
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Abstract
Objective
To examine the impact of delirium during their ICU stay on long-term health-
related quality of life and cognitive function in intensive care survivors.
Design
Prospective 18-month follow-up study.
Setting
Four intensive care units of a university hospital.
Patients
A median of 18 months after intensive care discharge, questionnaires were sent 
to 1292 intensive care survivors with (n=272) and without (n=1020) delirium during 
their intensive care stay.
Measurements and Main Results
The short form-36v1, checklist individual strength-fatigue and cognitive failure 
questionnaire were used. Covariance analysis was performed to adjust for relevant 
covariates. Of the 915 responders, 171 patients were delirious during their intensive 
care stay (median age 65 [interquartile range 58-85], Acute Physiology and Chronic 
Health Evaluation-II score 17 [interquartile 14-20]), and 745 patients were not (median 
age 65 [interquartile 57-72], Acute Physiology and Chronic Health Evaluation-II score 
13 [interquartile 10-16]). After adjusting for covariates, no differences were found 
between delirium and nondelirium survivors on the short form-36 and checklist 
individual strength-fatigue. However, survivors who had suffered from delirium 
reported that they made significantly more social blunders and their total cognitive 
failure questionnaire score was significantly higher compared to survivors who 
had not been delirious. Survivors of a hypoactive delirium subtype performed 
significantly better on the domain mental health than mixed and hyperactive 
delirium patients. Duration of delirium was significantly correlated to problems 
with memory and names.
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Conclusions
Intensive care unit survivors with delirium during their intensive care unit stay 
had a similar adjusted health-related quality of life evaluation, but significantly 
more cognitive problems than those who did not suffer from delirium, even after 
adjusting for relevant covariates. In addition, the duration of delirium is related to 
long-term cognitive problems.
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Introduction
Delirium is a disorder that frequently occurs in intensive care unit (ICU) patients 
(1-3) and is recognized as acute brain dysfunction with changes in consciousness 
and cognition which fluctuate during the day (4). This disorder is associated with 
serious health problems and long-term cognitive impairment (5;6). Generally, 
without distinguishing between delirium and nondelirium patients, 25 to 78% of 
ICU patients experience cognitive impairments after discharge from the ICU (7) 
emphasizing the need for more attention in the period following critical illness. 
There is a growing interest in Health Related Quality of Life (HRQoL) after ICU 
discharge (8-13). HRQoL questionnaires are usually subdivided into dimensions 
relating to physical, mental and social functioning. It is recognized that the value 
of measurements of cognitive functioning with a general HRQoL questionnaire is 
limited in this setting and specific surveys measuring patients cognitive functioning, 
such as the validated self-reporting cognitive failure questionnaire (CFQ) (14), have 
been developed.
Only two studies have examined the impact of delirium on HRQoL in ICU survivors 
(6;13). These studies were rather small, relatively short with a maximum follow-up 
of 3 and 12 months, and no analyses of the delirium subtypes were performed (6;13). 
A significant difference between delirium and nondelirium patients in role-physical 
function, which mostly reflects functioning in daily activities, was reported (13), 
however no correction for disease severity was performed (13). This implies that 
these findings could be the result of an epiphenomenon. The duration of delirium 
during patients’ ICU stay was associated with their observed impaired cognitive 
performance (6). Little is known about the long-term (>1 yr) effects of delirium on 
aspects of the HRQoL in this specific group of patients. In addition, it is unknown if 
there are differences in HRQoL (including cognitive function) for subtypes of delirium 
(3) and if there is a correlation between the duration of delirium and HRQoL.
Therefore, the aim of this study was to compare the HRQoL, including selfreported 
cognitive functioning, in ICU survivors with delirium during their ICU stay with those 
that did not suffer from delirium, after a median of 18 months after ICU discharge. 
Furthermore, we examined the correlations between duration of delirium and 
HRQoL, and if subtypes of delirium exerted different effects on HRQoL. 
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Material and methods
Subjects 
All consecutive patients admitted to the intensive care unit of the Radboud 
University Nijmegen Medical Centre between February 2008 and February 2009 
were screened for delirium three times a day with the confusion assessment method 
(CAM)-ICU (1;15) by well trained ICU nurses (16). In February 2010, after a median 
duration of 18 months after ICU discharge, we evaluated the health related quality 
of life of the surviving patients. The regional Medical Ethical Committee approved 
the study (study number 2010/008) and waived the need for informed consent, 
since the objective of this study was to evaluate regular patient care.
Procedures 
All ICU patients were included in this study except those: admitted for < 1 day; were 
suffering from sustained coma on the ICU; had serious auditory or visual disorders; 
were unable to understand Dutch; were severely mentally disabled; were suffering 
from a serious receptive aphasia; or whose delirium screening was not complete 
during their ICU stay. Patients were diagnosed with delirium when they had at 
least one positive CAM-ICU screening during their complete ICU stay, as previously 
described (17;18). To secure the quality of the delirium diagnosis medical and nursing 
files of all patients were also screened daily for signs of delirium (19). When the files 
contained signs of delirium without a positive CAM-ICU screening, patients were 
additionally screened by a delirium expert according to the DSM-IV criteria (4) to 
rule out false negatives and positives. In total, 17 patients (1.1%) were additionally 
screened this way by a delirium expert. Patients with delirium were divided in three 
subtypes (3): hyperactive delirium subtype with symptoms of hyper alertness and 
agitation (Richmond Agitation Sedation Scale +1/+4), hypoactive subtype in which 
the patient is hypoalert, lethargic (Richmond Agitation Sedation Scale 0/-3), and the 
alternating or mixed subtype (Richmond Agitation Sedation Scale +4/-3). This last 
subtype of delirium is characterised by alternating symptoms of hyperactive and 
hypoactive delirium. 
Demographic variables as well as data of severity of illness, delirium duration and 
delirium subtype of these patients were collected.
At median 18 months after ICU discharge, an HRQoL survey was sent out to the 
cohort of ICU survivors. Four weeks after this a reminder letter was sent to the 
nonresponders. We used three different validated instruments to measure the 
HRQoL. We will refer to these three tests as the HRQoL. Although there is no specific 
HRQoL instrument for ICU-patients, recommended instruments for ICU patients 
are the short form-36 (SF-36) and the EuroQoL-5D (20). We used the validated 
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Dutch version of the short form-36 (SF-36) version 1 (21) containing eight multi-
item dimensions: physical functioning, role-physical, bodily pain, general health, 
vitality, social functioning, role-emotional and mental health. Aggregated summary 
scores were calculated for physical and mental functioning expressed in physical 
component score and mental component score, respectively. To calculate the 
physical component score and mental component score, we used the standardized 
Dutch population scores (22). In line with the SF-36 Health Survey Manual (23) 
missing values were imputed, data were recoded and subsequently scored (range 
0 to 100). A higher score indicates a higher level of functioning. Additionally, the 
shortlist of the Dutch validated checklist individual strength-fatigue (CIS)-fatigue, 
consisting of 8 questions scoring on a 7 point Likert scale (24), was used. The range 
of the CIS-fatigue is 8 to 56, a higher score indicating more pronounced fatigue. The 
third instrument was the validated Dutch translation (25) of the cognitive failure 
questionnaire (CFQ) which is a self-reported cognitive functioning questionnaire. 
This questionnaire consists of 25 questions (14). The self-reported CFQ measures 
consist of four dimensions (26) of cognition: memory, distractibility, social blunders, 
and names. Each question of the CFQ was scored on a 5-point Likert scale. The total 
score on the CFQ ranges from 0 to 100, a higher score indicates more self-reported 
cognitive dysfunction. Thus, our self-reported HRQoL survey consisted of a total of 
69 questions which took an estimated 45-60 mins to answer. 
To guarantee the patient’s privacy, the survey was sent out anonymously and 
numbered. This allowed the primary and supervising investigator to match the 
returned survey with the patient’s registry number in a separate confidential 
database.
Statistical analyses 
The differences between those who suffered from delirium and nondelirium 
ICU survivors were tested nonparametrically using the Mann-Whitney U test. 
Dichotomous variables were tested with the chi-square test. Since the results of 
our HRQoL were non-normally distributed, log transformation of all HRQoL data 
was carried out successfully and the duration of delirium was divided into quartiles, 
resulting in normally distributed outcome measurements. The correlation between 
duration of delirium divided into quartiles and the log transformed HRQoL was 
tested using Pearson’s correlation coefficient. Significant differences in demographic 
variables between nondelirium and delirium patients and differences between the 
delirium subtypes were considered as covariates and a multivariate analysis of 
covariance was performed. Since there was no difference in age between delirium 
and nondelirium responders in our population, adjusting for age was unnecessary. 
In view of the explorative nature of this study, and to increase its sensitivity, no 
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correction for multiple testing was performed. 
Statistical significance was defined as a p value < .05. All data were analyzed using 
SPSS version 16.01 (SPSS, Chicago, IL).
Results
At the median of 18 months prior to this HRQoL survey, a total of 1,613 consecutive 
patients who fulfilled the inclusion criteria were admitted (Figure 1). In this group 
1,202 patients had no delirium and 411 were delirious during their ICU stay. Overall 
183 patients died, of whom 58 (5%) had not been delirious and 80 (19%) had. The 
hypoactive delirium subgroup had a similar number of survivors as compared to the 
mixed subgroup, while survival was significantly higher (p = .02) in the hyperactive 
subgroup (Figure 1), a median 18 months after ICU discharge. In total, 55 patients 
were admitted to the ICU more than once and 14 patients were lost to follow-up. 
In total, there were 1,292 ICU survivors (Figure 1) of whom 272 patients (21%) 
suffered from delirium during their ICU stay and 1,020 patients did not. In the 
delirious group seven  patients (3%) with a hyperactive subtype of delirium had one 
positive CAM-ICU screening, and 264 patients had at least two positive CAM-ICUs 
during their ICU stay.
Median 18 months (interquartile range 15-21) after ICU discharge a total of 915 out 
of the 1,292 eligible patients (71%) returned the questionnaire. Of these responders 
171 out of 272 (63%) patients suffered from delirium during their ICU stay and 744 
out of 1,020 (73%) did not.
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Figure 1 Flowchart of included patients for the Health Related Quality of Life survey
Seven hundred eighty-eight survivors completed all questionnaires, 91% completed 
the SF-36, 98% completed the CIS-fatigue and 97% answered all the questions of 
the CFQ. The demographic data and illness-related characteristics of the responders 
and nonresponders are illustrated in Table 1. 
Responders with delirium during their ICU stay were significantly more likely to 
be admitted for urgent reasons and for sepsis, were more likely to be female than 
male, had a higher Acute Physiology and Chronic Health Evaluation-II score and 
their ICU and hospital length of stay was significantly longer compared to patients 
that did not develop delirium during their ICU stay (Table 2).
Differences between delirium and nondelirium patients on HRQoL: SF-36
Eighteen months (median 18, interquartile range 15-21) after ICU discharge, patients 
with delirium during their ICU stay rated their quality of life lower on all dimensions 
of the SF-36 and the physical and mental component scores compared to patients 
who did not have delirium (Table 3). However, when adjusted for the covariates 
Acute Physiology and Chronic Health Evaluation-II score, sepsis, ICU length of stay, 
gender and urgent admission, no statistically significant differences between groups 
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remained. The results of our ICU survivors were worse on several domains of the 
SF-36 compared with an age-adjusted general Dutch population (Table 3) and are in 
line with those of others (10).
Table 1 Demographic characteristics of responders and non-responders
Table 1. Demographic characteristics of responders and non‐responders 
  Responders 
(n=915) 
Non‐responders 
(n=377)  p 
Age  65 [57‐72]  60 [47‐71]  < .0001 
Delirium (n=272) 
- Hypo active (n=94) 
- Hyperactive (n=32) 
- Mixed (n=146) 
171 (19%) 
63 (7%) 
19 (2%) 
89 (10%) 
101 (27%) 
31 (8%) 
13 (3%) 
57 (15%) 
.001 
Gender (male)  609 (67%)  231 (61%)  .005 
Sepsis (n)  28 (3%)  11 (3%)  .53 
Urgent admission (n)  389 (43%)  204 (54%)  < .0001 
Acute  Physiology  and  Chronic 
Health Evaluation‐II score  14 [11‐17]  13 [10‐17] 
.06 
LOS‐ICU (days)  1  [1‐2]  1 [1‐3]  .03 
LOS‐Hospital (days)  7 [5‐14]  9 [6‐18]  .001 
Admission type 
- Surgical 
- Medical 
- Trauma 
- Neurology/Neurosurgical 
 
666 (73%) 
131 (14%) 
41 (5%) 
77 (8%) 
 
225 (59%) 
74  (20%) 
32  (9%) 
46  (12%) 
< .05 
 
Data are expressed as median with IQR unless other reported   
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Table 2 Demographic characteristics of responders 
Table 2. Demographic characteristics of responders  
  Nondelirium     
Patients   
(n=744) 
Delirium 
Patients 
(n=171) 
p 
Age  65  [57‐72]  65  [58‐75]  .13 
Gender (male)  508  (68%)  101  (60%)  .01 
Acute Physiology and Chronic 
Health Evaluation‐II score  13  [10‐16]  17  [14‐20]  < .0001 
Urgent admission (n)  261  (35%)  128  (75%)  < .0001 
Length of stay‐intensive care unit 
(days)  1  [1‐1]  5  [2‐11]  < .0001 
Length of stay‐hospital (days)  7  [5‐11]  16  [9‐37]  < .0001 
Sepsis (n)  12  (2%)  16  (9%)  < .0001 
Admission type 
- Surgical 
- Medical 
- Trauma 
- Neurology/Neurosurgical 
589 
 77  
24 
54 
 
(79%) 
(10%) 
(3%) 
(7%) 
77 
54  
17 
23 
 
(45%) 
(32%) 
(10%) 
(14%) 
< .01 
 
 
 
 
Data are expressed as median with IQR unless other reported   
 
Differences between delirium and nondelirium patients on HRQoL: CIS-fatigue
Patients who suffered from delirium experienced more problems with physical 
exertions expressed in a higher total CIS score, compared to the nondelirium 
patients (Table 3). Again, after adjusting for covariates, no significant differences in 
the CIS scores between the two groups remained.
Differences between delirium and nondelirium patients on HRQoL: CFQ
The delirium survivors reported more pronounced cognitive failure on all measured 
cognitive dimensions compared to patients who did not suffer from delirium. Even 
after adjusting for covariates this difference between the groups persisted. Adjusted 
for covariates, patients who had previously had delirium tended to experience more 
problems with their memory (p = .08). Overall, their total self-reported cognitive 
function was significantly impaired. In addition, patients with delirium reported 
significantly more long-term problems with memory and concentration after ICU 
discharge than before when compared with nondelirium patients (Table 3). 
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Table 3 Results of Short Form-36, Checklist Individual Strength-fatigue, 
 and the Cognitive Failure Questionnaire measurements 18 months 
 after ICU discharge adjusted for covariates Table 3. Results of Short Form‐36, Checklist Individual Strength‐fatigue, and the Cognitive 
Failure Questionnaire  measurements 18 months after ICU discharge adjusted for covariates  
 
Nondelirium 
Patients 
(n=744) 
     Delirium 
Patients 
(n=171)  P
a 
General 
Population 
Subgroup Age  
55‐64y (21) 
Short‐Form‐36     
Physical Functioning  75 [50‐90]  55 [25‐80]  .18  72±26 
67±41 
71±25 
62±20 
82±23 
68±20 
81±35 
77±18 
50±9 
52±10 
Role‐Physical  50 [0‐100]  25 [0‐75]  .20 
Bodily Pain  78 [57‐100]  78 [55‐100]  .26 
General Health  60 [40‐75]  55 [35‐70]  .90 
Social Functioning    88 [63‐100]  75 [50‐88]  .65 
Vitality  60 [45‐75]  55 [40‐75]  .94 
Role‐Emotional  100 [33‐100]  100 [22‐100]  .64 
Mental Health  80 [64‐92]  72 [60‐88]  .26 
Physical Component 
Score  44 [35‐52]  38 31‐48]  .66 
Mental Component 
Score  53 [43‐58]  50 [38‐57]  .61 
Checklist individual 
strength‐total   28 [17‐39]  32 [22‐44]  .13 
 
Cognitive Failure 
Questionnaire     
 
Memory  7.0 [4‐10]  8.0 [5‐12]  .08 
Distractibility  11.0 [6‐15]  11.0 [7‐16]  .19 
Social blunders  6.0 [4‐9]  8.0 [4‐10]  .04* 
Names   3.0 [2‐4]  3.0 [2‐4]  .22  
CFQ‐total  26 [17‐35]  28 [19‐39]  .03* 
Data are expressed as median with interquartile range or mean with SD (±) 
a Adjusted for gender, urgent admission, Acute Physiology and Chronic Health Evaluation‐II 
score, sepsis and length of stay‐intensive care unit using log transformed data (not shown); b 
< .05  
 
Duration of delirium and HRQoL
The median duration of delirium was 2 days (interquartile range 1-7, range 1-69 
days). The delirium duration was significantly correlated with the dimensions 
‘memory’ (r = .21; p = .01) and ‘names’ (r = .18; p = .04) of the CFQ. This indicates that 
a longer duration of delirium is related to more pronounced problems in memory 
and remembering names. No other statistically significant correlations between 
duration of delirium and the dimensions of the SF-36 and CIS-fatigue were found.
Differences in HRQoL between subtypes of delirium
There were no differences between the subgroups of delirium concerning age, 
Acute Physiology and Chronic Health Evaluation-II score, gender and sepsis. 
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However, there were significant differences between the delirium subtypes on 
admission type, admission to the ICU for urgent reasons, ICU and in-hospital length 
of stay (Table 4). These variables were considered as covariates. In the unadjusted 
database, survivors of a hypoactive delirium subtype evaluated their HRQoL on 
several dimensions higher compared with hyperactive and mixed delirium survivors. 
After adjusting for the covariates patients who had a hypoactive delirium evaluated 
their mental health significantly better than those who suffered from a mixed or 
hyperactive  delirium subtype (p = .01 and p = .04, respectively).
We found no other significant differences in the SF-36, CIS-fatigue and CFQ tests 
between the subtypes of delirium. Taken together, the three subgroups of delirium 
suffered more extensive cognitive impairment compared to the patients without 
delirium during their ICU stay. 
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Table 4 Differences between subtypes of delirium on Health Related Quality of Life scores 
Table 4. Differences between subtypes of delirium on Health Related Quality of Life scores  
  Hypoactive 
subtype 
(n=63) 
Hyperactive 
subtype 
(n=19) 
Mixed subtype 
(n=89) 
Age  68 [59‐75]  64 [57‐75]  64  [57‐75] 
Gender (male)  36 (57%)  10  (53%)  55  (62%) 
Acute Physiology and Chronic 
Health Evaluation‐II score  16 [14‐21]  14 [13‐18]  17  [15‐21] 
Urgent admission (N)  43 (68%)  9 (47%)  76  (85%) a,b 
Length of stay‐intensive care unit 
(days)  4 [2‐7]  3 [1‐6]  8  [3‐16]
a,b 
Length of stay‐hospital (days)  15 [7‐29]  10 [5‐20]  24  [12‐24]a,b 
Sepsis (n)  3 (5%)  1 (5%)  12  (14%) 
Admission type 
- Surgical 
- Medical 
- Trauma 
- Neurology/Neurosurgical 
29
21
4
9
 
(46%) 
(33%) 
(6%) 
(14%) 
14
3
2
0
 
(74%)a 
(16%)a 
(11%)a 
(0%) a 
 
 
30 
11 
14 
 
(38%)a,b 
(34%)b 
(12%) 
(16%)b 
Short Form‐36d         
Physical Functioning  66 [35‐85]   32 [15‐71]  50  [30‐75] 
Role‐Physical  50 [0‐100]  38 [0‐100]  25  [0‐63] 
Bodily Pain  78 [67‐100]  57 [32‐100]  78  [55‐100] 
General Health  56 [38‐70]  48 [19‐65]  50  [35‐65] 
Social Functioning    75 [63‐100]  63 [34‐90]  69  [50‐88] 
Vitality  58 [45‐76]  50 [35‐60]  55  [40‐70] 
Role‐Emotional  100 [33‐100]  83 [17‐100]  100  [0‐100] 
Mental Health  80 [65‐92]a‐c  64 [56‐84]  72  [52‐84] 
Physical Component Score  37 [22‐48]  41 [33‐49]  36  [29‐45] 
Mental Component Score  48 [33‐56]  52 [41‐59]  49  [37‐57] 
Checklist individual strength d 
 ‐total  30
 
[16‐44]  33
 
[26‐48] 
 
33 
 
[23‐44] 
Cognitive Failure Questionnaire d     
Memory   9 [5‐12]  8 [5‐13]  8  [5‐12] 
Distractibility  11 [7‐16]  11 [6‐16]  11  [7‐16] 
Social blunders  8 [4‐9]  5 [2‐11]  8  [5‐11] 
Names   3 [2‐4]  4 [3‐5]  3  [2‐4] 
CFQ‐total  29 [20‐37]  25 [17‐39]  29  [19‐42] 
a Significant difference between hypoactive and hyperactive subtype; b Significant difference 
between hypoactive and mixed type subtype; c Significant difference between hyperactive 
and mixed type subtype; d adjusted for urgent, length of stay‐ICU and in‐hospital, and 
admission type using log transformed data (data not shown) 
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Discussion and conclusion
We demonstrated that median 18 months after ICU discharge there was no 
difference between patients with delirium and nondelirium patients on all domains 
of the SF-36 and the CIS-fatigue, adjusted for relevant covariates. However, patients 
who suffered from delirium during their ICU stay experienced significantly more 
cognitive problems than those who did not, even after adjusting for covariates. 
Furthermore, delirium duration was significantly correlated to problems with 
memory and names. Interestingly, after adjusting for relevant covariates, survivors 
with a hyperactive or mixed subtype of delirium qualified their mental health on the 
SF-36 as significantly worse than the hypoactive delirium patients. 
Delirium is recognized as a frequent disorder with serious short-term health 
related problems and is associated with longer hospital length of stay and increased 
mortality rates (5;27-30). Furthermore, in long-term studies it is recognized that 
hospitalized, non-ICU, patients with delirium suffer from persistent cognitive 
impairment (31;32). Also, ICU patients suffer from persistent cognitive impairment 
during long-term follow-up (7;33;34), but in these studies no distinction between 
delirious and nondelirious patients was made. A long-term ICU study that 
distinguished between delirious and non-delirious patients showed that, in addition 
to role functioning, there was no statistically significant difference between either 
group (13) while in another long-term study it was observed that duration of delirium 
was independently associated with more pronounced cognitive impairment (6). 
Definite conclusions cannot be drawn from these relatively small studies, because 
they used a more restricted HRQoL survey (13), their maximum follow-up duration 
was 12 months (6;13), they mainly focused upon cognitive impairment (6) and made 
no adjustments for relevant covariates (13). This last point is of particular concern 
as more severely ill patients have a higher incidence of delirium and long-term 
impairments which may not be related to each other (27).
The strength of the present study is that we used a set of validated questionnaires, 
such as the SF-36, which is the preferred choice for the post-ICU setting (20). In 
addition, because of the large sample size we were able to correct for covariates 
and the longer follow-up emphasizes the clinical relevance of the observations.
Overall and consistently, each group of delirium subtype evaluated their cognitive 
functioning lower than the patients who did not suffer from delirium during their 
ICU stay. In our study we found that patients who suffered from a hypoactive 
delirium evaluated their HRQoL on several domains of the SF-36 as less affected 
than the hyperactive or mixed subtype delirium patients. After adjusting for relevant 
covariates the domain mental health remained significantly better in hypoactive 
delirium survivors. The hypoactive subtype is associated with a higher mortality 
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rate (35;36), a finding that we confirmed in our study and this may have biased the 
results to some extent. 
Our findings of prolonged cognitive impairment in ICU survivors who suffered 
from delirium corroborate the results of a recent meta-analysis that showed that 
hospitalized (non-ICU) patients with delirium have a significantly increased risk of 
developing dementia (37). Our results that duration of delirium correlates with 
prolonged cognitive problems further extends the reported effects in 77 patients 
12 months after their ICU stay (6) and illustrates its clinical importance. This may 
indicate that interventions aimed at reducing delirium incidence and/or shortening 
its duration may produce long-term beneficial effects. This has not been studied yet.
We wish to acknowledge several study limitations. Firstly, it is intrinsic to long-term 
research in this patient group that the most severely ill may not be alive 18 months 
after their ICU discharge. As the occurrence and duration of delirium is related to 
increased mortality (27;29;38) and the cognitive impairments recover in time (6) this 
may result in an underestimation of the effects of delirium on cognitive impairment 
in a long-term study such as ours. This implies that the correlation between duration 
of delirium and HRQoL and cognitive impairment could be underestimated in our 
population. Secondly, we diagnosed delirium on minimal one positive CAM-ICU 
screening during patients’ ICU stay. One could argue that it is better to use at least 
two consecutive positive CAM-ICU screenings to diagnose delirium. However, in 
all guidelines and delirium protocols we are aware of, patients are treated when 
they meet the criteria of delirium. This is the case following one positive CAM-ICU 
screening. According to our intensive care delirium protocol patients are treated with 
haloperidol when a patient has at least one positive CAM-ICU screening. This early 
treatment with haloperidol may result in negative following CAM-ICU’s. Therefore, 
to include patients with two or more positive CAM-ICU scores may underestimate 
the presence of delirium in successfully treated patients (with haloperidol). To not 
recognize these patients as delirium patients is, in our opinion, not correct and not 
in line with daily practice. In addition, in total only seven out of the 171 responding 
patients with a delirium had only one positive CAM-ICU screening and they were 
all treated with haloperidol following the first positive CAM-ICU. These were all 
patients with a hyperactive delirium subtype. The results of our study would not be 
influenced if these seven patients would not be included. Thirdly, we adjusted for 
significant differences in demographic variables between nondelirium and delirium 
patients. As delirium is an independent predictor of longer ICU length of stay (27), 
presumably independent of severity of illness, then adjustment for ICU length of 
stay in the analyses relating delirium to long-term outcomes may underestimate 
the long-term effects of delirium. Furthermore, we measured patients’ long-term 
evaluation on HRQoL after ICU discharge once only. This can be considered as a 
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limitation as we do not know how patients’ QoL developed during these 18 months. 
It appears plausible that the results would have been different when we would have 
also measured them in an earlier stage after discharge. Khouli et al (39) showed 
that a higher proportion of older patients died within 6 months after ICU discharge 
and the HRQoL worsened after 6 months in the oldest group but improved in the 
younger group. However, taking into account the fact that cognitive impairment 
improved in delirium patients between 3 and 12 months after ICU discharge (6), 
differences between the delirium and nondelirium ICU survivors in our group was 
probably more pronounced earlier in the course of recovery. Since the aim of our 
study was to examine the long-term effects of delirium, we decided not to conduct 
repeated measures of the HRQoL status in a smaller group of patients, instead we 
chose to measure one point in time, after 18 months, in a large group of patients. 
This allowed adjustment for relevant covariates. 
In conclusion, in this large and long-term follow-up study we demonstrated that 
ICU survivors with delirium during their ICU stay had a similar adjusted health related 
quality of life evaluation, but experienced significantly more cognitive problems in 
comparison to those who did not suffer from delirium. Furthermore, the duration 
of delirium is related to long-term cognitive problems. 
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Abstract
Objectives
While delirium is a serious and frequent disorder in intensive care patients, a 
prediction model is currently not available. We developed and validated a delirium 
prediction model for adult intensive care patients and determined its additional 
value compared to the prediction of the caregivers.
Design
Observational multicenter study.
Setting
Five intensive care units in the Netherlands (two University hospitals and three 
University-affiliated teaching hospitals).
Participants
3,056 intensive care patients aged ≥18 years.
Main outcome measures
The main outcome was the development of delirium during patient stay in the 
intensive care. Delirium was defined as minimal one positive delirium screening 
during patients’ intensive care stay.
Methods
Two independent cohort studies were performed in one hospital to develop and 
temporally validate the model. All admitted adult ICU patients were screened for 
delirium and 25 potentially important risk factors were collected within 24 hours 
after intensive care admission. Data of four other hospitals were used for external 
validation. In a subgroup, caregivers were asked to predict whether or not the 
patient would develop delirium during their intensive care stay.
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Results
We included 1,613 and 549 consecutive intensive care patients to develop and 
temporally validate the model. For external validation data of 894 patients were 
collected. The prediction (PRE-DELIRIC) model contains 10 risk factors; i.e. age, 
APACHE-II, admission group, coma, infection, metabolic acidosis, use of sedatives 
and morphine, urea level and urgent admission.  The model had an area under 
the receiver-operating-characteristic (AUROC) of 0.87 (95%CI 0.85 to 0.89) and 
0.86 after bootstrapping. Temporal validation and external validation resulted in 
AUROC’s of 0.89 (95%CI 0.86 to 0.92) and 0.84 (95%CI 0.82 to 0.87), respectively. 
The pooled AUROC (N=3056) was 0.85 (95%CI 0.84 to 0.87). The AUROC of nurses’ 
and physicians’ prediction (N=124) was significantly lower, both 0.59 (95%CI 0.49 
to 0.70).
Conclusion
The PRE-DELIRIC model for intensive care patients consists of 10 risk factors that 
are readily available within 24 hours after intensive care admission and has a 
high predictive value. The clinical prediction of nurses and physicians performed 
significantly worse. The model allows for early delirium prediction and the initiation 
of preventive measures.
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INTRODUCTION
Delirium, characterized by an acute onset of fluctuating changes in mental status 
and changed levels of consciousness and inattentiveness,(1) has a high incidence 
rate in critically ill patients (2-4). It is a serious disorder associated with a prolonged 
intensive care unit and in-hospital stay, higher costs and increased morbidity and 
mortality rates (2;3;5).
There are several delirium assessment tools for intensive care patients of which 
the confusion assessment method–intensive care unit (CAM-ICU) has the highest 
sensitivity and specificity (6;7). It is important that intensive care patients are 
screened (8-10) in order to provide timely treatment. However, preventive measures 
for delirium may also reduce its incidence, severity and duration as determined 
in other patient groups (11;12). General preventive measures in all intensive care 
patients is time consuming and may expose a substantial number of patients to 
unnecessary risks, for example the side-effects of pharmacological prophylaxis. 
Whilst several predictive models for non-intensive care patients exist (13;14) and 
one for the older medical intensive care patient (15), currently no evidence-based 
prediction model for general intensive care patients is available. In addition, we 
wished to determine whether or not the model had additional value compared to 
the prediction of the caregivers. 
Objective
The aim of our study was to develop and validate a delirium prediction model for 
intensive care patients and to determine its value compared to the prediction of the 
attending nurses and physicians.
Methods 
Study design
Observational multicenter study in which first the PREdiction of DELIRium for 
Intensive Care patients (PRE-DELIRIC) model was developed and on a second 
prospective cohort the model was temporally validated in the same hospital. The 
model was then validated externally in four other Dutch hospitals.
Development and temporal validation of the model
To develop the prediction model a prospective cohort study was carried out in 
the Radboud University Nijmegen Medical Centre, the Netherlands. This study was 
conducted between February 1, 2008 and February 1, 2009. 
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A second prospective cohort study was carried out in the same hospital for 
temporal validation (16) of the model and was conducted between May 1, and 
September 1, 2009. 
External validation
After development and temporal validation the delirium prediction model was 
externally validated with data of intensive care patients admitted to four other 
Dutch hospitals between January 1 and September 1, 2009. 
Table 1 Characteristics of participating hospitals 
Table1.Characteristicsofparticipatinghospitals
Participating
Hospitals
ICUͲbeds
foradults
(annually
admissions)
TypeofICUͲ
population
Implementation
CAMͲICU
CAMͲICU 
screening
Radboud
University
NijmegenMedical
Centre,Nijmegen1
33beds
(2000Ͳ2500)
Medicine,surgery,
neurocriticalcareand
cardiothoracicsurgery
Ͳ year:2007
Ͳtypeoftraining:
groupand
individualtraining
Ͳ3/daily
ͲCompliance
rate90.4%
ͲIRR>0.8
UniversityMedical
CentreUtrecht,
Utrecht1
32beds
(2000Ͳ2500)
Medicine,surgery,
neurocriticalcareand
cardiothoracicsurgery
Ͳ year:2007
Ͳtypeoftraining:
groupand
individualtraining
Ͳ2/daily
ͲCompliance
andIRR:NM
MedicalCentre
Leeuwarden,
Leeuwarden2
16beds
(1400Ͳ1500)
Medicine,surgeryand
cardiothoracicsurgery
Ͳ year:2008
Ͳtypeoftraining:
groupand
individualtraining
Ͳ3/daily
ͲCompliance
rate90%
ͲIRR:NM
GelreHospital,
Apeldoorn2
10beds
(600)
MedicineandSurgery Ͳ year:2004
Ͳtypeoftraining:
groupand
individualtraining
Ͳ3/daily
ͲCompliance
rate90%
ͲIRR:NM
OnzeLieveVrouwe
Gasthuis,
Amsterdam2
18beds
(1500Ͳ1800)
Medicine,surgeryand
cardiothoracicsurgery
Ͳ year:2006
Ͳtypeoftraining:
groupand
individualtraining
Ͳ3/daily
ͲCompliance
rate96.2%
ͲIRR:NM
1Universityhospital,2UniversityͲaffiliatedteachinghospital
IRR:InterraterreliabilityexpressedinCohen’skappa,NM:notmeasured

One of these hospitals was a university hospital and three were university-affiliated 
teaching hospitals, all with mixed intensive care populations (Table 1). In these 
hospitals, the CAM-ICU was performed at least twice daily by trained intensive care 
nurses. 
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Delirium prediction of caregivers
To compare the predictive value of the model with that of the caregivers, within 
24 hours after intensive care admission, intensive care nurses and physicians caring 
for the patient independently were asked to predict if the patient would develop a 
delirious period during their complete intensive care stay. 
Study population for the development and validation studies 
After the successful implementation of the validated Dutch version of the CAM-
ICU,(17) the interrater reliability of the delirium screenings of the intensive care 
nurses was above 0.80 Cohen’s kappa, with a compliance rate of over 90%, as 
described in more detail previously (10). During the development and temporal 
validation studies all adult patients admitted to the intensive care were included. In 
order to detect delirium, all consecutive adult intensive care patients were screened 
by the intensive care nurses at least three times daily, and more often if required, 
for example following sudden changes in behaviour, attention or consciousness. 
This screening frequency was in accordance with screening in daily practice. 
Patients were excluded if: they were delirious within 24 hours after intensive care 
admission; had a sustained Richmond agitation sedation score (RASS) of -4/-5 
during complete intensive care admission; stayed on the intensive care for less than 
one day; had serious auditory or visual disorders; were unable to understand Dutch; 
were severely mentally disabled; suffered from a serious receptive aphasia or if the 
compliance rate of the delirium screening was <80% during a patients’ stay in the 
intensive care.
In order to meet the same inclusion and exclusion criteria during the external 
validation study consecutive patients with complete CAM-ICU screenings, defined 
as CAM-ICU compliance rate >80% per patient, were used. Patients were diagnosed 
as having a delirium when they had at least one positive CAM-ICU screening during 
their intensive care stay or were treated with haloperidol, since in these hospitals 
haloperidol is only used for delirium treatment. To examine the predictive value 
of the PRE-DELIRIC model in daily practice in these hospitals, no compliance and 
interrater reliability measurements were performed and only data of CAM-ICU 
screenings as performed in normal daily practice were used.
Potential predictors
Demographic variables and information on potential risk factors identified by 
a recent systematic review (18) were collected electronically within 24 hours of 
intensive care admission (see appendix A, electronic supplement). In addition, we 
included variables from the Dutch National Intensive Care Evaluation database 
(19) as potential risk factors when the delirium incidence rate associated with that 
Delirium in Intensive Care Patients
129
variable was >50% higher than the incidence rate of the total group (see appendix 
B, electronic supplement). Wherever possible, the risk factors were collected as 
continuous variables (categorical or dichotomized when otherwise).
Outcome definition
In view of the study aim to develop and validate a delirium prediction model 
the main outcome measure was delirium development during patient stay in 
the intensive care. Delirium was defined as a minimum of one positive CAM-ICU 
screening during each patient’s intensive care stay. In addition, medical and nursing 
files of patients were screened daily for signs of delirium (20). If the files provided 
signs of delirium without a positive CAM-ICU screening or conversely, if the files did 
not provide evidence of delirium and there was a positive CAM-ICU result, patients 
were additionally screened by a delirium expert according to the DSM-IV criteria (1) 
to rule out false negatives and false positives. 
Data management and quality checks for the development and temporal validation 
studies
The performance of CAM-ICU screenings was monitored to ensure the quality 
of data collection. Compliance was calculated as the percentage of assessments 
performed per day in relation to the total number of assessments that should have 
been performed. The mean compliance during the development and temporal 
validation studies was 90.4%. The quality of the CAM-ICU performance was 
measured as the interrater reliability. For this, the CAM-ICU screening assessed by 
the attending intensive care nurse was compared with the CAM-ICU score assessed 
by an expert psychiatry nurse within a time-window of one hour. 120 interrater 
reliability measurements were randomly performed resulting in a Cohen’s kappa of 
0.90 (95%CI 0.82 to 0.98). The data of 15% of all patients included were randomly 
double checked by the first author for completeness and accuracy. 
The regional Medical Ethical Committee approved the study and waived the need 
for informed consent, since no additional interventions were carried out and data 
collection was not burdensome to patients. 
The development and validation studies were registered in the Clinical trial register 
as NCT00604773 and NCT00961389, respectively.
Statistical analysis 
The sample size needed for the development of the model was calculated based on 
the need of 10-15 delirious patients per risk factor plus 10% drop-outs. Missing data 
concerning the risk factors were imputed. Missing values during the development 
study were urea (0.7%), liver enzymes (3.0%), bilirubin (18.0%), calcium (4.5%), 
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sodium (0.3%), hematocrit (0.4%), metabolic acidosis (1.0%), Acute Physiology and 
Chronic Health Evaluation (APACHE)-II scores 0.7%. Data for all other variables were 
complete. All data of the temporal validation study were complete. We decided that 
if a laboratory measurement was not determined, there was no reason to assume 
that the missing variable had an abnormal value, and imputed the mean normal 
value. To calculate the normal value we first select all patients with a normal value 
and then the mean value was calculated of these group of patients and used for 
imputation. When the APACHE-II score was missing we imputed the mean value of 
the variable of the delirium or non-delirium group, depending on the results of the 
CAM-ICU. In the external validation data set 6.3% of the urea values were missing 
and imputed. Concerning the APACHE-II, 0.6% of the scores were missing and a 
mean APACHE-II score of the group was imputed in the external validation set.
Univariate logistic regression was used to develop the prediction model by assessing 
the association between each potential prognostic determinant and the presence 
and absence of delirium. Determinants with a p value > .15 in univariate analysis 
or with a prevalence rate <10%, were excluded. With the remaining risk factors, 
multivariate logistic regression analysis with backward elimination (excluding risk 
factors with p values > .10) was used to evaluate the independent associations with 
the occurrence of delirium. The final model therefore contains independent risk 
factors for delirium. The prognostic ability to discriminate between patients with 
and without delirium was estimated using the area under the receiver operating 
characteristic curve (AUROC). Bootstrapping techniques were used to adjust for 
overfitting, i.e. for overly optimistic estimates of the regression coefficients of the 
risk factors in the final model. Two hundred random bootstrap samples resulted in 
shrunken regression coefficients of the risk factors and area under the curve(21) of 
the developed model.
In both validation studies shrunken regression coefficients of each risk factor were 
multiplied by the observed patients’ value. The outcome is a calculated predicted 
probability on which a new AUROC was built. Finally, to examine how well the model 
was calibrated, linear predictor values were calculated for each patient of every 
one cohort using the coefficients from the final development model. These linear 
predictors were used in a logistic regression model to test whether the prediction 
rule was well calibrated resulting in a calibration slope and an intercept. A calibration 
slope of ‘1’ and an intercept of ‘0’ demonstrates a perfect calibration.  Calibration 
plots of each cohort are available in the electronical supplement Appendix D. 
Statistical analysis were performed using Statistical Package for Social Sciences 
(SPSS®) 16.01, R statistics version 2.10.1(22) using the rms package.(23)
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Results
Development of prediction model
In total 2,116 consecutive patients were screened of which 503 were excluded 
(Figure 1). Out of the remaining 1,613 patients, 411 (25.5%) developed delirium. 
Patient characteristics are shown in Table 2 and prevalence rates and delirium 
incidence rates for the separate risk factors are shown in the electronical supplement 
Appendix B and Appendix C. Of the 25 potential risk factors we excluded alcohol 
abuse (7.8%), dementia (1.7%), use of an epidural catheter (2.2%), hyperamylasemie 
(3.9%), hyponatriemia (5.8%), use of dopamine (0.2%) and use of lorazepam (0.7%) 
because of a prevalence rate below 10%. Hypertension was excluded because of 
P-value >0.15 in univariate logistic regression analysis. After multivariate logistic 
regression analysis with the remaining risk factors, we constructed the PRE-DELIRIC 
model which consisted of ten risk factors (Table 3). The AUROC was 0.87 (95%CI 
0.85 to 0.89) and 0.86 after bootstrapping. Calibration of the model resulted in an 
calibration slope of 1.08 and an intercept of -0.06. 
Temporal validation of prediction model 
In the prospective validation study, 748 consecutive patients were screened of 
which 199 patients were excluded (Figure 1). Out of the remaining 549 patients, 171 
(31.1%) patients developed delirium (Table 2). The temporal validation resulted in an 
AUROC of 0.89 (95%CI 0.86 to 0.92). The calibration slope of the temporal model 
was 1.2 and the intercept 0.22.
External validation of the prediction model
Data of 894 non-selected intensive care patients (Table 2) were used for external 
validation resulting in an AUROC of 0.84 (95%CI 0.82 to 0.87) with a calibration 
slope of 0.76 and an intercept of -0.59. The AUROCs of the four different hospitals 
did not differ from each other (data not shown).
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Table 2 Patient characteristics of the cohort studies
Table 2. Patient characteristics of the cohort studies. 
Variable 
Developmen
t study 
(N=1613) 
Temporal 
validation 
study 
(N=549) 
External 
validation 
study 
(N=894) 
All included 
patients 
(N=3056) 
Age mean in y  
median [IQR, range] 
64 [54‐72, 76]  64 [54‐73, 72]  67 [58‐75, 78]  65 [55‐73, 78] 
Male (%)  1027 (63.7) 353 (64.3) 557 (62.3)  1937 (63.4)
APACHE‐II score  
median [IQR, range] 
14 [11‐18, 41]  15 [11‐18, 47]  16 [13‐21, 44]  15 [12‐19, 48] 
Delirium (%)  411 (25.5) 171 (31.1) 329 (36.8)  911 (29.8)
Days till onset delirium in 
days median[IQR, range]  
2 [2‐5, 53]  2 [2‐5, 44]  N.A.  N.A. 
Urgent admission (%) 852 (52.8) 232 (42.3) 495 (55.4)  1579 (51.7)
Mechanically ventilated (%)  78.5% 87.1% 89.6%  83.7%
Sedation (%)  386 (23.9) 184 (33.5) 543 (60.7)  1113 (36.4%)
LOS‐ICU, in days 
median [IQR, range] 
2 [2‐4, 118]  2 [2‐4, 69]  4 [2‐8, 100]  3 [2‐7, 118] 
LOS‐in hospital in days
median [IQR, range] 
9 [5‐19, 247]  9 [5‐15, 98]  10 [6‐20, 88]  10 [5‐19, 249] 
Admission category (%) 
1. Surgery 
2. Medical 
3. Trauma 
4. Neurology/ 
neurosurgery 
1010 (62.6) 
360 (22.3) 
80 (5) 
163 (10.1) 
 
340 (61.9) 
123 (22.4) 
18  (3.3) 
68  (12.4) 
 
 
507 (57.0) 
297 (33.2) 
30 (3.4) 
60 (6.7) 
 
1857 (60.8) 
780 (25.5) 
128 (4.2) 
291 (9.5) 
 
Data are presented as mean (SD, with range), unless mentioned otherwise 
 
As there were no differences in prediction between the three studies we pooled 
the data (N=3056) resulting in an AUROC of 0.85 (95%CI 0.84 to 0.87) (Figure 2). 
The pooled data resulted in an overall calibration slope of 0.93 with an intercept of 
-0.29 indicating a good calibration. 
We divided the complete group in four different risk groups; low, moderate, high 
and very high risk group with a cut of value 20%, 40%, 60% and >60%, respectively. 
Sensitivity, specificity and likelihood ratios per risk group are expressed in Figure 2. 
The calibration plot of the pooled data is depicted in Figure 3.
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Figure 1 Study flow chart of the development and temporal validation study
Delirium prediction of caregivers
In a convenience sample of 124 patients, attending intensive care nurses and 
physicians were asked to predict delirium independently of each other, similar to 
the prediction model 24 hours within intensive care admission. The AUROC of the 
prediction of the nurses (AUROC 0.59; 95%CI 0.49 to 0.70) and physicians (AUROC 
0.59; 95%CI 0.49 to 0.70) was inferior compared with the predictive value of the 
PRE-DELIRIC (AUROC 0.87; 95%CI 0.81 to 0.93) in this specific subgroup of 124 
patients. There were no significant differences between the prediction made by 
intensive care nurses (75%) and student intensive care nurses (25%) and between 
predictions made by intensivists (36%), fellow-intensivists (40%) and residents 
(24%) predictions (data not shown).
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Table 3 Variables of the PRE-DELIRIC model and regression coefficients
Table 3. Variables of the PRE‐DELIRIC model and regression coefficients. 
Variable 
Regression 
coefficient 
Odds ratio 
(95%‐CI) 
Shrunken 
regression 
coefficient  
1. Age (y)  0.04 
1.04 (1.03 to 
1.06) 
0.04 
2. APACHE‐II score (per point)  0.06 1.06 (1.03 to 2.0) 0.06 
3. Coma  
1. Medication induced 
2. Miscellaneous  
3. Combination  
0.59 
2.92 
3.06 
1.8 (1.1 to 3.1) 
18.5 (4.6 to 73.8) 
21.3 (5.9 to 77.1) 
 
0.55 
2.70 
2.84 
4. Admission category 
1. Surgery 
2. Medical 
3. Trauma 
4. Neurology/ 
neurosurgery 
 
RC 
0.33 
1.22 
1.49 
 
RC 
1.4 (0.9 to 2.2) 
3.4 (1.7 to 6.8) 
4.5 (2.6 to 7.5) 
 
RC 
0.31 
1.13 
1.38 
5. Infection (yes)  1.14 3.1 (2.0 to 4.8) 1.05 
6. Metabolic acidosis (yes)  0.32 1.4 (1.0 to 2.0) 0.29 
7. Morphine use  
1. 0.01‐7.1mg/day 
2. 7.2‐18.6mg/day 
3. >18.6mg/day 
0.44 
0.14 
0.55 
1.6 (0.8 to 3.1) 
1.2 (0.8 to 1.8) 
1.8 (1.1 to 2.7) 
 
0.41 
0.13 
0.51 
8. Sedation (yes)  1.51 4.5 (2.8 to 7.4) 1.39 
9. Urea (mmol/L)  0.03 1.03 (1.0 to 1.1) 0.03 
10. Urgent admission (%)  0.43 1.5 (1.1 to 2.3) 0.40 
Intercept   ‐6.76 ‐6.31 
RC= reference category. Shrunken regression coefficients are a result of the used 
bootstrapping technique to correct for over optimistic estimation of the model. 
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The formula of the PRE-DELIRIC model is: 
 Risk of delirium = 1/(1+exp- (-6.31 
+0.04 x age  
+ 0.06 x APACHE-II score 
+ 0 for non coma or 0.55 for medication induced coma or 2.70 for miscellaneous 
coma or 2.84 for combination coma 
+ 0 for surgical patients or 0.31 medical patients or 1.13 for trauma patients or 
1.38 for neurology/neurosurgical patients 
+ 1.05 for infection 
+ 0.29 for metabolic acidosis 
+ 0 for non morphine use or 0.41 for 0.01-7.1mg/24hours morphine use 
or 0.13 for 7.2-18.6mg/24hours morphine use or 0.51 for >18.6mg/24hours 
morphine use 
+ 1.39 for use of sedatives 
+ 0.03 x urea level (mmol/L) 
+ 0.40 for urgent admission))
The scoring system’s intercept is expressed as -6.31 represents, the other numbers 
represent the shrunken regression coefficients (weight) of each risk factor.
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Figure 2 Area under the receiver-operating-characteristic of pooled data of the development 
 (AUROC 0.86), the temporal validation (AUROC 0.89) and external validation 
 (AUROC 0.84) resulting in an AUROC of 0.85. The AUROC of the prediction 
 of the nurses was 0.59 (95%CI 0.49 to 0.70) and physicians 0.59 (95%CI 0.49 to 0.70)
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Figure 3 Calibration plot of the pooled data with a calibration slope of 0.93 
 and an intercept of -0.29.
Discussion
Principal findings
In this multicenter study we developed and validated a delirium prediction 
model for intensive care patients. To our knowledge, our study is the first delirium 
prediction study for general intensive care patients and represents by far the 
largest delirium-related study in intensive care patients to date. Our PRE-DELIRIC 
model reliably predicted the development of delirium for the complete length of 
ICU stay, based on ten readily available risk factors within 24 hours of intensive 
care admission. In addition, the AUROC of the PRE-DELIRIC model was significantly 
higher than the delirium prediction capacity of attending caregivers. These findings 
confirm that the model has additional value in daily practice. Importantly, dementia 
and alcohol abuse are not in the model since these patients need to be considered 
as high risk patients, irrespectively the presence of other risk factors.
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Clinical relevance
The early prediction of delirium development in intensive care patients with the 
PRE-DELIRIC model  facilitates the use of non-pharmacological preventive measures 
in high risk patients, such as improvement of orientation, cognitive stimulation, 
early mobilization(11) and music listening(24). In addition, it also facilitates 
pharmacological interventions in high risk patients such as the administration 
of prophylactic haloperidol (12). These interventions aim to improve patients’ 
cognition or have a systemic effect, although the evidence of beneficial preventive 
measures of drugs (25) and nursing interventions in critically ill patients is limited 
at this moment. Non-pharmacological preventive measures were successful in 
reducing the incidence and duration of delirium in a non-critically ill hospital 
population with an intermediate to high risk for the development of delirium(11), 
while pharmacological prevention with haloperidol resulted reduced severity of 
delirium and delirium days, and a shorter hospital length of stay (12). Importantly, no 
data from ICU patients is available. Interestingly, early mobilization of mechanically 
ventilated intensive care patients results, besides other significant effects, resulted 
in a reduced duration of delirium (26).
The use of the PRE-DELIRIC model to identify and consequently preventively treat 
high risk patients could offer an important contribution to intensive care practice and 
efficient use of research resources to study only in high-risk patients. In addition, the 
modifiable risk factors of the model may facilitate the use of preventive measures. 
Currently, the PRE-DELIRIC model is used in clinical daily practice in the hospital that 
developed the model and intensive care patients with a high risk for delirium, ≥50% 
PRE-DELIRIC score, and patients with dementia or alcohol abuse, receive delirium 
preventive measures. Importantly, the optimal cut-off point of the PRE-DELIRIC-
model and the most effective delirium preventive interventions for intensive care 
patients need to be studied in the near future. 
Limitations of the study
Several limitations of our study should be addressed. First, although the CAM-ICU 
has a high sensitivity and specificity when used by dedicated research nurses,(27;28) 
recently the performance in daily practice used by bedside nurses proved to be 
lower (29). In this performance study, the CAM-ICU was measured at one point on 
one day, while our delirium diagnosis was based on all CAM-ICU screenings during 
patients’ complete ICU stay, increasing the sensitivity of the test. In addition we 
also used haloperidol as  a proxy for the delirium diagnose since in all participating 
centres haloperidol was only used to treat delirium and the hospitals with the 
highest CAM-ICU performance participated in the present delirium prediction study. 
In view of the fluctuating nature of delirium, all patients were screened three times 
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daily and more often if needed. When delirium was not detected with the CAM-
ICU, but delirium was suspected based on medical and nursing reports, patients 
were additionally screened by a delirium expert according to the DSM-IV criteria (1). 
In addition, during the development and temporal validation study, we performed 
quality checks that demonstrated a high compliance rate and interrater reliability. 
We therefore presume that few patients were misdiagnosed. 
Second, we used data of four other hospitals collected in the same study period. 
These centres implemented and clinically used the CAM-ICU combined with a delirium 
treatment protocol prior to the conduct of the present study. Regarding the external 
validation study, we only included patients with complete CAM-ICU screenings and 
patients who were treated with haloperidol for delirium. The case-mix of these 
patients showed a higher APACHE-II score, more sedated patients and more patients 
were admitted for medical reasons compared to the hospital were the primary 
development and validation studies were performed. These differences may explain 
the higher incidence rate of delirium in these hospitals. Because of logistic reasons 
and the fact we wanted to examine the predictive value of the PRE-DELIRIC model 
in daily intensive care practice, we did not perform quality checks such as interrater 
reliability measurements in these other hospitals. Despite these limitations, the PRE-
DELERIC model showed a good predictive value in daily intensive care practice. 
Third, as recommended (21), the risk factors used in our study were primarily based 
on a systematic review (18). Additional variables were included following the results 
of our first cohort. We added the ‘diagnosis group’, and ‘urgent admission’ as new risk 
factors because of a high delirium incidence rate associated with these items. While 
these variables were not found in the systematic review (18), some studies show that 
urgent admission to the intensive care and neurological conditions are risk factors 
for delirium (30;31). Our results of the development study demonstrate that these 
risk factors are of importance to predict delirium in intensive care patients. Because 
of a low prevalence rate, relevant risk factors such as hyponatraemia, alcohol abuse 
and dementia were excluded from the multivariate logistic regression analysis. The 
additional value of hyponatraemia for the model would be expected low since also 
the delirium incidence rate in patients with a hyponatraemia in the first 24 hours 
after intensive care admission is low. The importance of, e.g., dementia and alcohol 
abuse is recognized in several studies (4;32), and also in the present study their 
delirium incidence rate was high. In many institutes all these patients will receive 
preventive measures and therefore, physicians do not need a delirium prediction 
model in these specific subgroups. Moreover, adding these covariates to the model 
would decrease its sensitivity to the other covariates. For these reasons we did not 
include alcohol abuse and dementia in the PRE-DELERIC model.
Fourth, the negative likelihood ratio for patients with a predicted low chance to 
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develop delirium is relatively rather moderate. This indicates that in this group 
patients will develop delirium while they were classified as having a low risk. On 
the other hand, preventive measures are advised to be taken in patients with a 
high risk, and the higher the delirium risk the better the performance of the model. 
Nevertheless, it is important to realize that a predicted low risk does not exclude 
the possibility to develop delirium.
Finally, the PRE-DELIRIC model is a static model that yields a calculated probability 
for delirium 24 hours after ICU admission. Since the health status of a patient can 
improve or deteriorate during ICU stay, the probability of the development of 
delirium may also change. The present model does not take into account changes 
in health status. Despite this limitation of the PRE-DELIRIC model, the AUROC of the 
model is high. Still, it would be interesting to develop a dynamic prediction model 
using dynamic parameters, such as the sequential organ failure assessment (SOFA)-
score, in order to improve its predictive value during the patients’ stay on the ICU 
which may possibly also result in a better performance in the low risk group.
Conclusions and policy implications
In summary, using the PRE-DELIRIC model can predict delirium for the complete 
stay in the intensive care within 24 hours of admission. It is now possible to identify 
patients who have a high risk for developing delirium during their intensive care 
stay. This will facilitate identification of high risk patients and targeted initiation 
of preventive measures. Our study demonstrates that the use of the PRE-DELIRIC 
model is significantly better than the predictions of the attending caregivers and 
should therefore be used daily in intensive care practice.
An automatic version of the PRE-DELIRIC model (Excel and web based) can be 
downloaded at: http://www.umcn.nl/Research/Departments/intensive%20care/
Pages/vandenBoogaard.aspx (English and Dutch version available) 
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Collected delirium predictors within 24 hours after intensive care admission 
Variable  Category  Description  
Age (years)*  C  Continuous variable 
Alcohol abuse*  D  Known medical history of alcohol abuse 
Anaemia (L/L)*  C  Continuous variable of hematocrit, lowest value  
APACHE‐II score (per point)*  C  Calculated 24 hours after ICU admission 
Coma*   
Cat 
No coma: RASS‐4/‐5 maximum 8 hours 
RASS‐4/‐5 for longer than 8 hours: 
1. With use of medication 
2. Other (i.e. intra cerebral bleeding, post‐
resuscitation) 
3. Combination (1+2) 
Dementia*  D  Known medical history  of dementia 
Admission category#  Cat  
1. Surgical 
2. Medical  
3. Trauma  
y/neurosurgical 4. Neurolog
Dopamine use*  D  Any use of dopamine  
Elevated hepatic enzymes 
C 
ransferase (ALAT) and 
solute 
(ASAT and ALAT in U/L)* 
Level of alanine aminot
aspartate aminotransferase (ASAT), highest ab
value  
Epidural catheter*  D   of an epidural catheter  Any use
Fever (in C0)*  C  Continuous variable, highest absolute value 
Hyperamylasemia (U/L) *  C  Continuous variable, highest absolute value 
Hyperbilirubinemia 
(umol/L)*   C  Continuous variable, highest absolute value 
Hypertension*  B  Medical history of hypertension 
Hypocalcaemia (mmol/L)*   lute value  C  Continuous variable, lowest abso
Hyponatraemia (mmol/L )*  C  Continuous variable, lowest absolute value  
Hypotension*  B  Symptomatic, resulting in treatment, or systolic blood 
pressure < 80 mmHg 
Infection*  D  icion of infection for which Proven or strong susp
antibiotics were started 
Lorazepam use*   or parenteral) D  Any use of lorazepam (oral
Metabolic acidosis*   B  pH <7.35 with bicarbonate <24mmol/L 
Morphine use*  Cat 
e: 
g 
No morphine: no use of any morphine 
Cumulative use of any form of morphin
1. 0.01‐7.1mg 
2. 7.2‐18.6mg 
3. 18.7‐331.6m
Respiratory disease*   D 
 pulmonary disease, cor 
horax 
Chronic obstructive
pulmonale, pneumothorax, hematothorax, t
trauma 
Sedative use*  D  of propofol, midazolam, lorazepam or Any use 
combination 
Urgent admission#  ensive care admission  D  Unplanned int
Urea (mmol/L )*  C  Continuous variable, highest value in blood 
C= continuously   B=binary   dicho
 on   revi sk  m Dutch 
 D= tomized   Cat.=categorical 
Risk factors based systematic ew* or potential ri factors derived fro
National Intensive Care Evaluation database # 
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  Prevalence rate of risk factors and delirium incidence rates in these group 
Dichotomized variables 
Percentage patients 
in development 
cohort  
(N=1613) 
Delirium incidence 
rate in the specific 
group 
Alcohol abuse  3.3%  (53)  60.4%  (32/53)** 
Coma 
1. Medication 
2. Miscellaneous  
3. Combination  
20% (323) 
78.6% (253/323) 
6.5% (21/323) 
15.2% (49/323) 
69% (223/323)** 
62.8% (159/253) 
85.7% (18/21) 
93.9% (46/49) 
Dementia  0.5% (8)  87.5% (7/8)** 
Admission category: 
1. Surgical 
2. Medical 
3. Trauma 
4. Neurology/neurosurgic
al 
 
62.6% (1010) 
22.3% (360) 
5% (80) 
10.1% (163)  
 
15% (152/1010) 
43.1% (155/360)** 
47.5% (38/80)** 
40% (66/163)** 
Dopamine use  0.2% (3)  0% (0/3) 
Epidural catheter  5.1% (83)  0.6% (9/83) 
Hypertension  30.6% (494)  26.3% (130/494) 
Infection  14.9% (241)  58.1% (140/241)** 
Lorazepam use  0.6% (9)  33.3% (3/9) 
Metabolic acidosis  18.2% (294)  58.8% (173/294)** 
Morphine use: 
1. 0.01‐7.1mg/24hrs 
2. 7.2‐18.6mg/24hrs 
3. 18.7‐331.6mg/24hrs 
54.8% (884) 
8.5% (75) 
63.1% (558)  
28.4% (251) 
19.7% (174/884) 
1.6% (14/884) 
8.1% (72/884) 
10% (88/884) 
Respiratory disease  31.5% (508)  37.8% (192/508) 
Sedative use  23.9% (386)  62.4% (241/386)** 
Urgent admission  52.8% (852)  38.3% (326/852)** 
** Delirium incidence rate for the variable was >50% higher than the incidence rate of the  
total group (=25.5%) 
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  Prevalence rate of risk factors and delirium incidence rates in these group 
Dichotomized variables 
Percentage patients 
in development 
cohort  
(N=1613) 
D lirium incid nce 
rate in the specific 
group 
Alcohol abuse  3.3%  (53)  60.4%  (32/53)** 
Coma 
1. Medication 
2. Miscellaneous  
3. Combination  
20% (323) 
78.6% (253/323) 
6.5% (21/323) 
15.2% (49/323) 
69% (223/323)** 
62.8% (159/253) 
85.7% (18/21) 
93.9% (46/49) 
Dementia  0.5% (8)  87.5% (7/8)** 
Admission category: 
1. Surgical 
2. Medical 
3. Trauma 
4. Neurology/neurosurgic
al 
 
62.6% (1010) 
22.3% (360) 
5% (80) 
10.1% (163)  
 
15% (152/10 0) 
43.1% (155/360)** 
47.5% (38/80)** 
40% (66/163)** 
Dopamine use  0.2% (3)  0% (0/3) 
Epidural catheter  5.1% (83)  0.6% (9/83) 
Hypertension  30.6% (494)  26.3% (130/494) 
Infection  14.9% (241)  58.1% (140/241)** 
Lorazepam use  0.6% (9)  33.3% (3/9) 
Metabolic acidosis  18.2% (294)  58.8% (173/294)** 
Morphine use: 
1. 0.01‐7.1mg/24hrs 
2. 7.2‐18.6mg/24hrs 
3. 18.7‐331.6mg/24hrs 
54.8% (884) 
8.5% (75) 
63.1% (558)  
28.4% (251) 
19.7% (174/884) 
1.6% (14/884) 
8.1% (72/884) 
10% (88/884) 
Respiratory disease  31.5% (508)  37.8% (192/508) 
Sedative use  23.9% (386)  62.4% (241/386)** 
Urgent admission  52.8% (852)  38.3% (326/852)** 
** Delirium incidence rate for the variable was >50% higher than the incidence rate of the  
total group (=25.5%) 
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  Pr valence rate of risk factors and delirium incidenc  rates in these group 
Dichotomized variables 
Perc ta e patients 
in development 
co ort  
(N=1613) 
Delirium incidence 
rate in the specific 
group 
Alcohol abuse  3.3%  (53)  60.4%  (32/53)** 
Coma 
1. Medication 
2. Miscellaneous  
3. Combination  
20% (323) 
78.6% ( 53/3 3) 
6.5  (21/323) 
15.2% (49/3
69% (223/323)** 
62.8% (159/253) 
85.7% (18/21) 
3.9% (46/49) 
Dementia  0.5% (8)  87.5% (7/8)** 
Admission category:
1. Surgical 
2. Medical 
3. Trauma 
4. Neurology/neurosurgic
al 
 
62.6% (1010) 
22.3% (36 ) 
5% (80) 
10.1% (163)  
 
15% (152/1010) 
43.1% (155/360)** 
47.5% (38/80)** 
40% (66/163)** 
Dopamine use  0.2% (3)  0% (0/3) 
Epidural catheter  5.1% (8 0.6% (9/83) 
Hypertension  30.6  (494)  26.3% (130/494) 
Infection  14.9% (241)  58. % (140/241)** 
Lorazepam use  0.6% (9)  33.3% (3/9) 
Metabolic acidosis  18.2% (294)  58.8% (173/294)** 
Morphine use: 
1. 0.01‐7.1mg/24hrs
2. 7.2‐18.6mg/24hrs 
3. 18.7‐331.6mg/24hrs 
54.8% (884) 
8.5% (75) 
63.1% (55 )  
28.4% (251) 
19.7% (174/884) 
1.6% (14/884) 
8.1% (72/884) 
10% (88/884) 
Respiratory disease 31.5% (50 )  37.8% (192/508) 
Sedative use  23.9% (386)  62.4% (241/386)** 
Urgent admission  52.8% (852)  38.3% (326/852)** 
** Delirium incidence r te for the variable was >50% higher tha  the incidence rate of the  
total group (=25.5%) 
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Prevalence of the PRE‐DELIRIC risk factors in each cohort 
Risk variable 
Development 
study 
(N=1613) 
Temporal 
validation 
study 
(N=549) 
External 
validation 
study 
(N=894) 
Age mean in y (SD)  62 (±15) 62 (±15) 65 (±14) 
APACHE‐II score (SD)  15 (±6) 15 (±6) 18 (±7) 
Coma (%) 
1. Medication induced 
2. Miscellaneous  
3. Combination 
253 (15.7) 
21 (1.3) 
49 (3.0) 
82 (14.9) 
7 (1.3) 
40 (7.3) 
 
273 (30.5) 
8 (0.9) 
58 (6.5) 
Admission category (%) 
1. Surgery 
2. Medical 
3. Trauma 
4. Neurology/ 
neurosurgery 
1010 (62.6) 
360 (22.3) 
80 (5) 
163 (10.1) 
 
340 (61.9) 
123 (22.4) 
18  (3.3) 
68  (12.4) 
 
 
507 (57.0) 
297 (33.2) 
30 (3.4) 
60 (6.7) 
 
Infection (%)  241 (14.9) 70 (12.8) 245 (27.4) 
Metabolic acidosis (%) 294 (18.2) 84 (15.3) 220 (24.6) 
Morphine use  
1. 0.01‐7.1mg/day 
2. 7.2‐18.6mg/day 
3. >18.6mg/day 
75 (4.6) 
558 (34.6) 
251 (15.6) 
143 (26.0) 
147 (26.8) 
11 (2.0) 
 
44 (4.9) 
24 (2.7) 
291 (32.6) 
Sedation (%)  386 (23.9) 184 (33.5) 543 (60.7) 
Urea (mmol/L) median [IQR]  7.0 [5.0‐9.0] 7.6 [5.7‐10.2] 7.5 [5.5‐11.2] 
Urgent admission (%) 852 (52.8) 232 (42.3) 495 (55.4) 
Data are presented as mean (SD), unless mentioned otherwise 
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Figure A Calibration plot of the development model
Figure B Calibration plot of the temporal validation model 
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Figure C Calibration plot of the external validation model
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Abstract
Purpose
Delirium is a serious and frequent disorder but the effects of delirium prevention 
in intensive care (ICU) patients are unknown. We aimed to evaluate the effects of 
haloperidol prophylaxis in ICU patients with a high risk for delirium.
Methods
A prospective case-control study in 535 ICU patients with a predicted risk for 
delirium of ≥50%. Patients received haloperidol a 1mg/q/8 hours. Primary outcome 
were delirium incidence, delirium free days without coma and 28-day mortality. 
Results of prophylactic treatment were compared with a historical control group 
and a contemporary group that did not receive haloperidol prophylaxis.
Results
In 12 months 177 patients received haloperidol prophylaxis. Except for sepsis, 
patient characteristics were comparable between the prevention and the historical 
(n=299) group. Haloperidol prophylaxis resulted in a lower delirium incidence 
(65% vs. 75%, p=0.01), and more delirium-free-days (median 20 days [IQR 8-27] 
vs. median 13 days [3-27], p=0.003). Cox-regression analysis adjusted for sepsis 
showed an odds ratio of 0.80 (95%CI 0.66-0.98) for 28-day mortality. Furthermore, 
haloperidol prophylaxis resulted in less ICU re-admissions (18% vs. 11%, p = .03) and 
unplanned removal of tubes/lines (19% vs. 12%, p = .02). Haloperidol was stopped 
in 12 patients due to QTc-time prolongation (n=9), renal failure (n=1) or suspected 
neurological side-effects (n=2). No other side-effects were reported. Patients who 
were not treated during the intervention period (n=59) showed similar results 
compared to the untreated control group.
Conclusion
Haloperidol prophylaxis in patients with a high risk for delirium reduces delirium 
incidence, increases the number of delirium-free-days and reduces mortality rate. 
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Introduction
Delirium is a neuropsychiatric disorder characterized by an acute onset of 
confusion and consciousness alterations that fluctuate during the day (1). The 
incidence of delirium in intensive care (ICU) patients is high (2-5) and its presence 
is associated with prolonged duration of mechanical ventilation, increased ICU- and 
hospital length of stay (3;5), unplanned removal of tubes and catheters (5) and 
an increased mortality (5;6). Therefore, preventive treatment may be beneficial. 
In non-ICU patients beneficial effects of prophylactic haloperidol in older (7) and 
surgical patients (8)  have been reported. A retrospective cohort study showed 
that ICU patients treated with haloperidol appear to have a lower mortality rate 
compared to non-treated ICU patients (9). 
Preventive treatment of all ICU patients may attenuate the potential beneficial 
effects of haloperidol and would expose a substantial number of patients to 
unnecessary risks, for example the side-effects of haloperidol administration. With 
the use of a recently developed and validated delirium prediction model for ICU 
patients (10), patients with a high risk to develop delirium can be identified. 
The aim of our present study was to evaluate the effects of prophylactic treatment 
with haloperidol in critically ill patients with a high risk for delirium. 
Methods
Design and setting
A prospective case-control study carried out on the 33-beds intensive care unit 
(ICU) of the Radboud University Nijmegen Medical Centre, the Netherlands. 
Delirium prevention
In August 2010 the delirium prevention policy was implemented in daily practice. 
Patients with an estimated risk of 50% or more determined with the delirium 
prediction model PRE-DELIRIC (10), and patients with a history of dementia or alcohol 
abuse were considered high risk. These high-risk patients received haloperidol 1 
mg/8 hours or a lower dose of 0.5 mg/8 hours when they were ≥80years, had a body 
weight <50 kg, had a serum creatinine level >150 µmol/L or had serum bilirubin level 
>50 μmol/L. Prevention was not started when haloperidol was contra-indicated 
in case of Parkinson’s disease, hypokinetic rigid syndrome, Lewis body dementia, 
prolonged QTc-time, pregnancy or in patients who were treated with other anti-
psychotics. Patients who developed delirium were treated with therapeutic doses 
of haloperidol according to the department’s protocol.
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It was decided on beforehand to evaluate the effects of prophylactic use of 
haloperidol after 1 year and this evaluation study was registered in the Clinical trial 
register (NCT01187667).
Delirium assessment
All patients were screened by well-trained ICU nurses (11) using Dutch version of 
the CAM-ICU(12) at least three times daily, and more often if required. Patients 
were excluded in case of coma during complete ICU stay defined as sustained 
Richmond agitation sedation score (RASS) (13) of -4/-5, serious auditory or visual 
disorders, were unable to understand Dutch, severely mentally disabled or suffered 
from a receptive aphasia. Patients with delirium were divided in three subtypes 
(14): hyperactive (RASS +1/+4), hypoactive (RASS 0/-3), and mixed (RASS +4/-3). This 
last subtype of delirium is characterised by alternating symptoms of hyperactive 
and hypoactive delirium. 
Patients were diagnosed with delirium when they had at least one positive CAM-
ICU screening during their complete ICU stay. A delirium-and-coma-free day was 
defined as a negative CAM-ICU screening without RASS -4/-5 during a complete day. 
Follow-up of all patients was conducted prospectively.
Patients 
Consecutive patients with a high risk for delirium admitted to our intensive care 
unit between August 1, 2010 and August 1, 2011 received haloperidol prophylaxis. To 
evaluate the effects of this prevention policy results were compared with a control 
group of high risk patients admitted between February 1, 2008 and February 1, 
2009 and with a contemporary group of patients who did not receive prophylactic 
treatment for various reasons (Figure 1) during the prevention period. 
Outcome measures
Primary outcome was; delirium incidence, number of delirium-free and coma-
free days in 28 days, and 28-day mortality. Secondary outcomes were: duration of 
mechanical ventilation, incidence of re-intubation and re-admissions, incidence of 
unplanned removal of tubes/catheters and ICU- and hospital length of stay.
Statistical analyses 
Demographic characteristics of patients who received haloperidol prophylaxis 
were compared with non-treated patients. Differences were tested depending on its 
distribution with Students T-test, Mann-Whitney U test or with the Chi-square test. 
Survival analyses with Kaplan-Meier curves as graphical presentation were used. To 
determine the effect of haloperidol on 28-day mortality adjusted for covariates we 
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used Cox-regression analysis with mortality as the dependent variable and baseline 
characteristics with a p-value <0.05 between groups as possible covariates. To 
examine which patients were most likely to benefit, we equally divided the total 
group in three risk groups (predicted risk up to 71%, between 71-89% and >89%). We 
also studied outcome in four different admission categories i.e. surgical, medical, 
trauma and neurological or neurosurgical patients. 
Statistical significance was defined as a p value < .05. All data were analyzed using 
SPSS version 18.0 (SPSS, Chicago, IL).
Results
During the intervention period (2010-2011) 320 patients fulfilled the inclusion 
criteria and the control group (2008-2009) consisted of 432 patients. During the 
intervention period in total 143 patients were excluded for several reasons and in the 
control group 133 patients (Figure 1). Overall, 177 patients in the intervention group 
and 299 patients in the control group were evaluated. Patient and demographic 
characteristics are shown in Table 1. In the intervention group significantly more 
patients were admitted with sepsis compared with the control group. Twenty-two 
(12%) patients in the intervention and 46 (15%) patients in the control group were 
enrolled because of alcohol abuse or dementia. 
Primary outcomes
The predicted chance to develop delirium in the intervention and control group 
was 75±19% and 73±22%, respectively. The actual delirium incidence was 65% in the 
intervention group, compared with 75% in the control group (Table 2).
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Table 1 Demographic and patients characteristics
Table 1. Demographic and patients characteristics 
  Control 
group 
(N=299) 
Intervention 
group  
(N=177) 
Differences 
(p value) 
Gender (M/%)  181 (61%)  115 (65%)  .20 
Age   64±14  63±14  .64 
APACHE‐score   20±7  19±6  .06 
Urgent admission (%)  261 (87%)  152 (86%)  .52 
Sepsis (N/%)  64 (21%)  53 (30%)  .02 
Admission specialism (N/%): 
- Surgical 
- Medical 
- Trauma 
- Neurology/neurosurgical  
 
75 (25%) 
143 (48%) 
32 (11%) 
49 (16%) 
 
33 (19%) 
106 (60%) 
18 (10%) 
20 (11%) 
 
.99 
PRE‐DELIRIC score   73±22  75±19  .50 
Other risk  
- Alcohol abuse 
- Dementia  
 
41 (14%) 
5 (2%) 
 
20 (11%) 
2 (1%) 
 
.37 
Data are presented as mean±standard deviation unless mentioned otherwise 
 
The number of delirium free days was significantly higher in the intervention 
group (median 20 days [interquartile range 8-27] versus median 13 days [3-27]. 
Cox regression analysis was performed with sepsis as a covariate. Prophylactic 
treatment with haloperidol resulted in a relative 28-day mortality reduction of 20% 
(Exp(B) 0.80; 95%CI 0.66-0.98).
Figure 1 Flowchart of inclusion of patients
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Figure 2 shows the 28-day Kaplan-Meijer survival curve of both groups. Although 
the APACHE-II score did not significantly differ between the two groups, when 
including this variable in the Cox-regression analysis together with sepsis the 
reduction is 16% (Exp(B) 0.84; 95%CI 0.69-1.02). 
Figure 2 Kaplan-Meijer survival plot of 28-day survival
Secondary outcomes
No significant differences were found between groups in duration of mechanical 
ventilation, ICU- and hospital length of stay, and incidence of re-intubation. Patients 
who received prophylaxis were less likely to remove their tubes and catheters and 
were less likely to be re-admitted to the ICU (Table 2).
Risk groups and admission categories
To examine which patients benefit most from the prophylactic therapy with 
haloperidol the total group was equally divided in three groups based on their 
predicted risk. Patients with the highest risk appear to benefit most from the 
prophylactic treatment with haloperidol (Table 3). 
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Table 2 Differences between control group and complete intervention group
Table 2. Differences between control group and complete intervention group 
  Control 
group  
(N=299) 
Intervention 
group  
(N=177) 
Differences 
(p value) 
Predicted delirium chance   73±22  75±19   
Observed delirium incidence  225 (75%)  115 (65%)  .01 
Non‐delirum: 
Delirium subtype: 
- Hyperactive 
- Hypoactive 
- Mixed  
74 (25%) 
 
20 (7%) 
81 (27%) 
124 (41%) 
62 (35%) 
 
6 (3%) 
33 (19%) 
76 (43%) 
.38 
 
Number of delirium free days without 
coma in 28 days  
13 [3‐27]  20 [8‐27]  .003 
Re‐intubation (%)  25 (8%)  15 (9%)  .51 
Duration mechanical ventilation in hrs.   118 [39‐250]  90 [36‐229]  .24 
Unplanned removal tubes/lines (%) 
- Tube 
- Gastric tube 
- CVC/arterial line 
- Other  
58 (19%) 
8 (3%) 
26 (9%) 
24 (8%) 
0 (0%) 
21 (12%) 
4 (2%) 
14 (8%) 
1 (<1%) 
2 (1%) 
.02 
Re‐admission   55 (18%)  20 (11%)  .03 
LOS‐ICU   7 [3‐13]  6 [3‐12]  .65 
LOS‐in hospital   21 [12‐41]  20 [11‐31]  .16 
28‐day mortality  36 (12%)  13 (7•3%)  .03* 
Data are presented as median, interquartile range [IQR], unless mentioned otherwise 
* Cox regression analyses adjusted for sepsis and cohort (Exp(B) 0.80; 95%CI 0.66‐0.98 
 
Results of prophylactic haloperidol treatment for the different admission categories 
are shown in Appendix A. The beneficial effects of prophylactic treatment were 
comparable between patient groups. Medical patients appeared to benefit most 
from prophylactic haloperidol treatment.
Non-treated patients during the implementation period
During the implementation period a total of 59 patients did not receive prophylaxis 
with haloperidol, mostly due to non-compliance to the new protocol. There were 
no demographic differences between the control group and the non-treated group 
(Appendix B, supplementary Table available online). The incidence of delirium, 
unplanned removal of tubes and re-admission rate was significantly higher and 
the number of delirium free days was significantly lower in the untreated group 
compared with the treated intervention group. In addition, the delirium incidence 
in the non-treated intervention group was also significantly higher compared with 
the treated intervention group (Appendix B, supplementary Table available online).
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Haloperidol treatment
In 14 out of 177 (8%) patients adjustments in dosage were made because of possible 
side effects, with drowsiness as the most frequently mentioned reason (71%). 
Haloperidol was stopped in 12 (7%) patients because of prolonged QTc-time (n=9, 
all in patients treated with mild hypothermia), signs of Parkinsonism (n=1), renal 
failure (n=1) and in one patient malignant neuroleptic syndrome was suspected, but 
later not confirmed. Patients in whom the dosage of haloperidol was adjusted or 
stopped were allocated to the treated intervention group in the analyses.
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Table 3 Differences between control group and complete intervention group divided 
 in 3 delirium risk groups
Table 3. Differences between control group and complete intervention group divided in 3 delirium risk groups 
Predicted chance <71%  Control group (N=110) 
Intervention 
group (N=69) 
Differences 
(p value) 
Predicted chance  50±19 55±16  .08
Age  63±13 63±14  .88
APACHE‐II score  17±5 16±5  .12
Sepsis (%)  11 (10%) 18 (26%)  .005
Observed delirium incidence  55(50%) 30 (44%)  .27
28 days delirium free without coma  26 [10‐28] 26 [13‐28]  .17
28‐day mortality  13 (12%) 6 (9%)  .34*
Re‐intubation (%)  5 (5%) 6 (9%)  .25
Duration mechanical ventilation in hrs.   42 [14‐150] 63 [15‐168]  .43
Unplanned removal tubes/lines (%) 
- Tube 
- Gastric tube 
- CVC/arterial line 
- Other  
14 (13%)
1 (1%) 
2 (2%) 
11(10%) 
0 (0%) 
7 (10%) 
1 (2%) 
4 (6%) 
1 (2%) 
1 (<1%) 
.41
Re‐admission   18 (16%) 4 (6%)  .03
LOS‐ICU   3 [2‐8] 4 [2‐8]  .32
LOS‐in hospital   17 [9‐31] 16 [8‐27]  .48
Predicted chance 71‐89%  (N=111) (N=60)  Differences 
Predicted chance  81±5 80±5  .66
Age  64±14 61±15  .14
APACHE‐II score  20±6 20±7  .94
Sepsis (%)  31 (28%) 24 (40%)  .08
Observed delirium incidence  94 (85%) 44 (73%)  .06
28 days delirium free without coma  11 [3‐22] 20 [7‐27]  .02
28‐day mortality  13 (12%) 5 (8%)  .93
Re‐intubation (%)  11 (11%) 6 (10%)  .56
Duration mechanical ventilation in hrs.   124 [55‐278] 133 [50‐281]  .76
Unplanned removal tubes/lines (%) 
- Tube 
- Gastric tube 
- CVC/arterial line 
22 (20%)
4 (4%) 
12 (11%) 
6 (5%) 
8 (13%) 
      2 (3%) 
6 (10%) 
      0 (0%) 
.20
Re‐admission   27 (24%) 12 (20%)  .33
LOS‐ICU   8 [3‐15] 8 [4‐17]  .57
LOS‐in hospital   23 [13‐43] 26 [16‐41]  .99
Predicted chance>89%    (N=78) (N=48)  Differences 
Predicted chance  95±3 95±3  .95
Age  62±16 65±12  .34
APACHE‐II score  24±8 21±6  .05
Sepsis (%)  22 (28%) 11(23%)  .33
Observed delirium incidence  76 (97%) 41 (85%)  .06
28 days delirium free without coma  4 [0‐14] 13 [6‐21]  .002
28‐day mortality  10 (13%) 2 (4%)  .07†
Re‐intubation (%)  9 (12%) 3 (6%)  .25
Duration mechanical ventilation in hrs.   185 [112‐353] 94 [62‐266]  .02
Unplanned removal tubes/lines (%) 
- Tube 
- Gastric tube 
- CVC/arterial line 
- Other  
22 (28%)
3 (4%) 
12 (15%) 
7 (9%) 
0 (0%) 
6 (13%) 
1 (2%) 
3 (6%) 
0 (0%) 
2 (4%) 
.04
Re‐admission   10 (13%) 4 (8%)  .32
LOS‐ICU   11 [7‐18] 6 [4‐15]  .03
LOS‐in hospital  30 [14‐56] 20 [15‐31]  .07
Data are presented as median, interquartile range [IQR], unless mentioned otherwise 
* Cox regression analysis with sepsis as covariate  
† Cox regression analysis with APACHE‐II score as covariate  
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Discussion
We report that prophylactic treatment with haloperidol in ICU patients with 
a high risk for delirium results in a lower delirium incidence, associated with 
more delirium free days and a reduction in mortality compared to patients who 
did not receive prophylactic haloperidol. Importantly, only few side-effects of 
low dose haloperidol were reported of which none were severe. Our study may 
have important implications for daily practice in the ICU concerning prevention of 
delirium. Although prophylactic treatment with haloperidol was successfully used 
in elderly (7) and surgery patients (8), this is the first study in ICU patients that 
confirms these previous findings. In addition, our study shows that patients that 
received prophylactic haloperidol were less likely to remove their tubes or catheters 
or to be readmitted to the ICU, also illustrating the beneficial effects of prophylactic 
therapy with haloperidol. 
While prophylactic therapy for delirium is sparsely studied in critically ill 
patients, more data is available concerning treatment of delirium. Haloperidol is 
recommended as first choice drug for delirium treatment (1;15;16). Several studies 
showed that use of other anti-psychotics than haloperidol (17-19) or use of other 
anti-psychotics in combination with haloperidol (20) does not further improve 
patient outcome, but could be even worsen it (21). These randomized trials 
demonstrated less severe or shorter duration of delirium, but were underpowered 
to detect an effect on length of stay or mortality (17-19). In an observational study 
a lower mortality rate in ICU patients was observed in ICU patients treated with 
haloperidol compared to those that were not treated (9). In addition, observational 
data also suggest that early treatment of delirium results in a lower mortality rate 
compared with delayed treatment (22). These data indicate that the effectiveness 
of early treatment, or possibly even better prophylaxis, may be superior compared 
to treatment of delirium. Importantly, prophylactic treatment of all ICU patients 
results in an unnecessary number of patients who are exposed to the side-effects 
of haloperidol. Therefore, there is a need for a delirium prediction model for ICU 
patients that identifies the patients with a high risk to develop delirium. In the 
present study we used our delirium prediction model with a high predictive value 
(10). Importantly, the higher the predicted risk, the more effective prophylaxis with 
haloperidol was. 
Several limitations need to be addressed. Most importantly, we performed a case 
control study instead of a more powerful and controlled design such as a randomized 
controlled trial. Nevertheless, the fact that a better outcome was observed in 
patients that received prophylactic haloperidol also compared to case controls 
during the intervention period indicates that the results were not confounded by 
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a time-dependent bias. In addition, we chose relevant end-points known to be 
related to delirium. In view of the congruent effects of prophylactic treatment with 
haloperidol, this further supports the plausibility of our findings.
Second, potential side-effects of haloperidol were only obtained when 
spontaneously reported and mild extrapyramidal side-effects may have been 
missed, although a thorough physical examination of all patients is usual care in our 
ICU. Regarding QTc-time, this was measured daily and in 9 patients haloperidol was 
stopped for reason of prolonged QTc-time. This was probably due to the immediate 
start of haloperidol in the post-cardiopulmonary resuscitation phase after ICU 
admission combined with mild therapeutic hypothermia (23) in all 9 patients. 
Importantly, none of these patients developed ventricular arrhythmia as reported 
in some case reports (24-27). Furthermore, in several patients, haloperidol dose 
was adjusted for reasons of drowsiness or a possible sedative effect. Importantly, all 
these patients were delirious and these effects may also represent manifestations 
of delirium (1;14). The low incidence of side effects is in accordance with previous 
studies (7;8;28;29). 
Third, the choice of the haloperidol dose likely influences the treatment effect. 
Our dosage was lower than the 5 mg/day that was used in surgery patients (8) 
which also resulted in a reduction of the delirium incidence. Similar to a study in 
elderly patients (7), we chose a lower dose in critically ill patients as they are also 
more likely to be vulnerable to the side-effects of haloperidol. In view of the few 
reported side-effects of haloperidol in our study and the still relatively high delirium 
incidence rate in ICU patients that received prophylactic treatment, a higher 
prophylactic dosage should be considered in future research.
In conclusion, prophylactic treatment with low dose haloperidol in critically ill 
patients with a high risk for delirium exerts several beneficial effects. With the 
encouraging results of the present study, we feel that a randomized prospective 
intervention study in ICU patients with a high risk for delirium using prophylactic 
haloperidol should be conducted. It should be considered, given the few side-effects 
of a low dose haloperidol, to also investigate the effect of a higher prophylactic 
dosage of haloperidol.
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Appendix A
Results of the prophylactic haloperidol treatment in the different admission categories
Appendix A. Supplementary Table online available 
 
Results of the prophylactic haloperidol treatment in the different admission categories 
Surgical patients 
Control group 
(N=75) 
Intervention 
group  
 (N=33) 
Differences 
(p value) 
Predicted chance (mean, SD)  62±25  62±24  .68 
Observed delirium incidence  47 (63%)  18 (55%)  .28 
28 days delirium free without coma  13 [3‐28]  22 [10‐28]  .05 
28‐day mortality  6 (8%)  1 (3%)  .31 
Re‐intubation (%)  7 (9%)  3 (9%)  .64 
Duration mechanical ventilation in hrs.   57 [16‐181]  20 [6‐170]  .21 
Unplanned removal tubes/lines (%)  12 (16%)  5 (15%)  .58 
Re‐admission   15 (20%)  7 (21%)  .54 
LOS‐ICU   8 [4‐15]  3 [2‐9]  .55 
LOS‐in hospital   23 [12‐45]  20 [11‐37]  .92 
Medical patients    (N=143)  (N=106)  Differences 
Predicted chance (mean, SD)  75±20  77±17  .97 
Observed delirium incidence  116 (81%)  69 (65%)  .003 
28 days delirium free without coma  11 [3‐22]  20 [7‐27]  .04 
28‐day mortality  20 (14%)  9 (9%)  .13 
Re‐intubation (%)  11 (11%)  9 (9%)  .56 
Duration mechanical ventilation in hrs.   153 [72‐330]  120 [63‐260]  .17 
Unplanned removal tubes/lines (%)  26 (18%)  9 (9%)  .02 
Re‐admission   30 (21%)  11 (10%)  .02 
LOS‐ICU   8 [3‐15]  7 [4‐14]  .36 
LOS‐in hospital   23 [13‐43]  20 [11‐34]  .06 
Trauma patients      (N=32)  (N=18)  Differences 
Predicted chance (mean, SD)  76±16  71±18  .35 
Observed delirium incidence  22 (69%)  12 (67%)  .56 
28 days delirium free without coma  14 [0‐27]  20 [11‐27]  .59 
28‐day mortality  1 (3%)  0 (0%)  .64 
Re‐intubation (%)  3 (9%)  2 (11%)  .61 
Duration mechanical ventilation in hrs.   80 [17‐284]  62 [19‐261]  .02 
Unplanned removal tubes/lines (%)  9 (28%)  5 (28%)  .62 
Re‐admission   1 (3%)  0 (0%)  .64 
LOS‐ICU   8 [3‐14]  5 [4‐16]  .86 
LOS‐in hospital   22 [14‐40]  23 [15‐28]  .77 
Neurology/neurosurgical  patients      (N=49)  (N=20)  Differences 
Predicted chance (mean, SD)  82±18  87±16  .26 
Observed delirium incidence  40 (82%)  16 (80%)  .56 
28 days delirium free without coma  14 [4‐26]  18 [15‐27]  .14 
28‐day mortality  9 (19%)  3 (15%)  .52 
Re‐intubation (%)  7 (14%)  1 (5%)  .28 
Duration mechanical ventilation in hrs.   112 [36‐220]  71 [36‐175]  .43 
Unplanned removal tubes/lines (%)  11 (22%)  2 (10%)  .22 
Re‐admission   9 (18%)  2 (10%)  .32 
LOS‐ICU   6 [3‐14]  6 [4‐10]  .89 
LOS‐in hospital   20 [9‐37]  19 [15‐25]  .70 
Data are presented as median, interquartile range [IQR], unless mentioned otherwise 
Supplementary table online available
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Appendix B
Non-treated patients in the intervention group compared with treated and control group
 
Appendix B. Supplementary Table online available 
 
Non‐treated patients in the intervention group compared with treated and control group  
  Control  
group 
 
(N=299) 
Intervention 
group  
non‐treated  
(N=59) 
Intervention 
group  
treated  
(N=177) 
PRE‐DELIRIC score (mean±sd)  73±22  77±17  75±19 
Other risk  
- Alcohol abuse 
- Dementia  
 
41 (14%) 
5 (2%) 
 
4 (7%) 
0 
 
20 (11%) 
2 (1%) 
Age (mean±)  64±14  62±15  63±14 
Urgent admission (%)  261 (87%)  52 (88%)  152 (86%) 
APACHE‐II score  20±7  20±6  19±6 
Sepsis (%)  64 (21%) b  16 (28%)   53 (30%) 
Gender (M/%)  181 (61%)  35 (59%)  115 (65%) 
Admission specialism (N/%): 
- Surgical 
- Medical 
- Trauma 
- Neurology/neurosurgical  
 
75 (25%) 
143 (48%) 
32 (11%) 
49 (16%) 
 
11 (19%) 
30 (51%) 
5 (9%) 
13 (22%) 
 
33 (19%) 
106 (60%) 
18 (10%) 
20 (11%) 
Delirium incidence  225 (75%) b  53 (90%) a‐b  115 (65%) 
28 days delirium free without coma  13 [3‐27] b  14 [1‐22] b  20 [8‐27] 
28‐day mortality  36 (12%) b  7 (12%)   13 (7%) 
Re‐intubation (%)  25 (8%)  8 (14%)  15 (9%) 
Duration mechanical ventilation in 
hrs.  
118 [39‐250]  103 [54‐251]  90 [36‐229] 
Unplanned removal tubes/lines (%)  58 (19%) b  13 (22%) b  21 (12%) 
Re‐admission   55 (18%) b  13 (22%) b  20 (11%) 
LOS‐ICU   7 [3‐13]  7 [4‐14]  6 [3‐12] 
LOS‐in hospital  21 [12‐41]  27 [13‐48] b  20 [11‐31] 
Data are presented as median, interquartile range [IQR], unless mentioned otherwise 
a statistically significantly different (p < .05) compared with control group  
b statistically significantly different (p < .05) compared with treated intervention group  
 
Supplementary table online available
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Abstract
Introduction
Effects of systemic inflammation on cerebral function are not clear, as both 
inflammation-induced encephalopathy as well as stress-hormone mediated 
alertness have been described.
Methods
Experimental endotoxemia (2 ng/kg Escherichia coli lipopolysaccharide [LPS]) was 
induced in 15 subjects, whereas 10 served as controls. Cytokines (TNF-α, IL-6, IL1-RA 
and IL-10), cortisol, brain specific proteins (BSP), electroencephalography (EEG) and 
cognitive function tests (CFTs) were determined.
Results
Following LPS infusion, circulating pro- and anti-inflammatory cytokines, and 
cortisol increased (p < .0001). BSP changes stayed within the normal range, in 
which neuron specific enolase (NSE) and S100-β changed significantly. Except in 
one subject with a mild encephalopathic episode, without cognitive dysfunction, 
endotoxemia induced no clinically relevant EEG changes. Quantitative EEG analysis 
showed a higher state of alertness detected by changes in the central region, and 
peak frequency in the occipital region. Improved CFTs during endotoxemia was 
found to be due to a practice effect as CFTs improved to the same extent in the 
reference group. Cortisol significantly correlated with a higher state of alertness 
detected on the EEG. Increased IL-10 and the decreased NSE both correlated with 
improvement of working memory and with psychomotor speed capacity. No other 
significant correlations between cytokines, cortisol, EEG, CFT and BSP were found.
Conclusions
Short-term systemic inflammation does not provoke or explain the occurrence of 
septic encephalopathy, but primarily results in an inflammation-mediated increase 
in cortisol and alertness.
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Introduction
With recorded prevalence rates of up to 70% (1), most patients with sepsis develop 
reversible brain dysfunction called sepsis-associated delirium or septic encephalopathy 
(2). In patients suffering from septic encephalopathy, electroencephalographic 
(EEG) abnormalities have been observed (2), although there are conflicting results 
concerning elevated levels of serum brain specific proteins (BSP) in septic patients 
(3;4). The mechanisms for brain dysfunction in septic patients are far from clear. 
Accumulating data suggest that circulating cytokines are associated with a neurotoxic 
effect in humans (1;2;5;6), either through a direct effect (7) or mediated via oxidative 
stress (8;9). In addition, genetic variation in the IL-1β-converting enzyme resulting 
in chronically higher levels of IL-1β is associated with memory and learning deficits 
(10). Moreover, there is evidence that increased levels of TNF-α and IL1-β further 
exacerbate ischemic and excitotoxic brain damage in humans (11;12).
On the other hand systemic inflammation induces a stress hormone response. This 
may lead to improvement of alertness, as throughout daytime temporal coupling 
between endogenous cortisol release and central alertness has been demonstrated 
in humans (13). Also, elevated cortisol concentrations and cortisol administration 
(13-19) were shown to improve cognitive functions (CF). Intravenous administration 
of Escherichia coli lipopolysaccharide (LPS) to young healthy volunteers induces 
an acute systemic inflammatory response mediated by high levels of cytokines, 
resulting in oxidative stress (9;20;21) and increased levels of cortisol (22). These 
effects are dose-dependent (23), and currently the administration of 2 or 4 ng/
kg of LPS is mostly used in cases of experimental human endotoxemia. Human 
experimental endotoxemia can be used as a model to study the pathophysiological 
changes observed in septic patients, resulting in for example cardiac (24), vascular 
and endothelial dysfunction (21;25), coagulation abnormalities (26;27) and 
other subclinical end-organ dysfunction (28). However, up to now the effects of 
experimental human endotoxemia on brain function has not been adequately 
investigated. Although high-dose LPS infusion in mice results in encephalopathy 
(29), experiments in humans demonstrated conflicting results. Experimental 
endotoxemia resulted in no change (30), deterioration (31) or improvement and 
deterioration of different cognitive function tests (CFTs) (22). Endotoxemia-induced 
effects on EEG and BSP have not been investigated.
The aim of our present study was to investigate the effects of endotoxemia-
induced inflammation on the brain. We addressed the question of whether LPS 
infusion induces changes in EEG, cortisol, BSPs, and CFs. Furthermore we wanted 
to examine if there is a correlation between the LPS-induced increased level of 
cytokines, cortisol, changes in EEG signals, BSPs and various CFs. 
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Material and methods
Study design of human endotoxemia experiments 
This study is registered at the Clinical Trial Register under the number NCT00513110. 
After approval of our ethics committee, 15 healthy male volunteers gave written 
informed consent to participate in the LPS study. Screening before the experiment 
revealed no abnormalities in medical history or physical examination. Routine 
laboratory tests and electrocardiogram (ECG) were normal and the volunteers had no 
reported brain dysfunction or psychiatric disorders. Ten healthy male volunteers were 
recruited for only cognitive measurements after they gave informed written consent.
During the experiment all 15 volunteers were monitored for heart rate (ECG), blood 
pressure (intra-arterially), body temperature (infrared tympanic thermometer; 
Sherwood Medical, ‘s-Hertogenbosch, the Netherlands) and EEG activity (Nicolet 
One system, Viasys Healthcare, Houten, The Netherlands), from about two hours 
before the administration of LPS and continued until the end of the experiment 
(about eight hours after the LPS administration). A cannula was inserted in a deep 
forearm vein for prehydration (1.5 L of 2.5% glucose/0.45 saline solution in the hour 
before LPS administration). During the first six hours after the LPS administration all 
subjects received 150 mL/h, and after that period until the end of the experiment 75 
mL/h of 2.5% glucose/0.45 saline solution to ensure an optimal hydration status (32).
In one minute E. coli LPS 2 ng/kg was injected at t = 0 hours. The course of 
symptoms (headache, nausea, shivering, muscle pain and back pain) were scored 
on a six-point Likert scale; 0 = no symptoms, 5 = very severe symptoms, resulting in 
a total score of 0 to 25. 
Laboratory tests (cytokines, cortisol and brain specific proteins)
Analysis of cytokines and cortisol 
All blood was allowed to clot and after centrifugation serum was stored at -80°C 
until analysis.
To determine the time course and peak values per individual, serial blood samples 
were taken. Cytokines concentrations of TNF-α, IL-6, IL-1-receptor antagonist, and 
IL-10 were measured in samples taken at baseline (t = 0) and at one, two, four and 
eight hours after LPS administration and batchwise analysed using Luminex assay. 
Cortisol levels were determined with luminometric immunoassay on a random 
access analyzer (Architect® i System, Abbott,  Illinois, USA) at baseline (t = 0) and at 
2-4-8 hours after LPS administration.
Delirium in Intensive Care Patients
173
Analysis of brain specific proteins: S100-β, NSE, and GFAP 
Proteins S100 calcium binding protein-β (S100-β) and neurospecific enolase (NSE) 
were analyzed using a commercially available monoclonal two-site luminometric 
assay (Sangtec Medical, Dietzenbach, Germany) according to the manufacturer’s 
instructions using a Liaison automated analyzer (Byk Sangtec, Dietzenbach, 
Germany). The lower detection limit for S100-β is 0.02 µg/L. The upper reference 
range (95%) of S100-β serum concentrations in healthy subjects is 0.12 µg/L. The 
lower detection limit for NSE is 0.04 µg/L, and the upper reference range (95%) of 
NSE in serum from healthy subjects is 12.5 µg/L. The glial fibrillary acidic protein 
(GFAP) assay is a two-site luminometric assay. The serum sample is pipetted 
into coated wells of a microtitre strip containing the tracer antibody labelled 
with an isoluminol derivative. After incubation, the strips are washed and the 
chemiluminescent signal is measured in a luminometer. All steps of the assay are 
performed at room temperature. The lower detection limit for GFAP is 0.02 µg/L, 
and the upper limit (95%) of GFAP in serum in 75 healthy subjects was 0.49 µg/L.
Electroencephalography 
Subjects were monitored continuously with EEG, using a standard 21-lead 
recording with surface Ag/AgCl cup electrodes that were attached with Elefix EEG 
paste (Nihon Koden Inc., Foothill Ranch, California, USA) and placed according to 
the international 10-20 system. Recordings were made from electrode positions 
Fp1, Fp2, Fz, F3, F4, F7, F8, Cz, C3, C4, Pz, P3, P4, T3, T4, T5, T6, A1, A2, O1, and O2. 
Additional electrodes were placed for the recording of ocular movements and the 
ECG. Electrode impedance was kept below 5 KOhm, and the signals were filtered 
with a 1 Hz (high-pass) and 70 Hz (low-pass) filter. EEG signals were digitally sampled 
with a frequency of 256 Hz and stored on a computer hard disk. The full-length 
recordings were analyzed visually by an experienced clinical neurophysiologist 
(NvA) blinded to the LPS protocol. Raw EEGs were scored using a five category 
classification system for septic encephalopathies (33). At least once per hour a 
one-minute artefact-free raw EEG sample (10-second epoch) of the subject lying 
awake with his eyes closed was selected for further quantitative analysis. In each 
subject, the power spectrum of samples was calculated for the standard frequency 
bands (delta <4 Hz; theta 4 to <8 Hz; alpha 8 to <13 Hz, beta >13Hz) using Fourier 
transformation. The peak frequency in the occipital regions (P3 to O1 and P4 to O2 
bipolar montages) was assessed for each time point. To detect changes in central 
alertness alpha and beta activity changes in the relative band power and absolute 
band power of the occipital and central electrodes (P4O2, P3O1 and F4C4, F3C3, 
respectively) were used, and also changes in peak frequency in the occipital region 
(13). Changes in activity were expressed as percentage of change of the individual 
baseline level of activity before the LPS administration.
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Cognitive function tests 
The anxiety level of each individual was measured at baseline after arrival at our 
research unit, with the Dutch State-Trait Anxiety Inventory (STAI) scale (34). Higher 
scores (range 0 to 80) indicate higher levels of psychological distress. The time the 
participants required to finish the Grooved Pegboard test with the dominant hand 
served as an indication of fine motor control (35). Working memory was assessed 
with the digit span forward and backward subtests of the Dutch translations of 
the Wechsler Adult Intelligence Scale (WAIS) III (36). The total number of correct 
responses on the two-second stimulus interval condition of the Paced Auditory 
Serial Addition Test (PASAT) served as a measure for divided attention under time 
pressure (37). The total number of correct responses on the Digit Symbol Test 
(SDT) of the WAIS III was chosen as an indication of psychomotor speed capacity 
as well as the information processing ability (36). Reading speed, colour naming 
speed and distractibility were measured with the Stroop colour-word naming test 
(38) (Pearson Assessment and Information B.V., Amsterdam, The Netherlands). To 
measure a possible practice effect as a result of test-retesting of the CFTs, the same 
CFTs under the same conditions and time intervals were performed in a reference 
group of 10 healthy male volunteers that did not receive LPS.
Data analysis and statistics 
All data were analyzed using SPSS version 16.01 (SPSS, Chicago, Illinois, USA). Results 
are expressed by means ± standard error of the mean or median (interquartile 
range (IQR)) depending on their distribution. LPS-induced effects were tested for 
significance with Friedman’s analysis of variance (non-parametric test). To detect 
practice effect we compared the experimental group and the reference group with 
the repeated measurement-analysis of variance. Correlation analysis was performed 
with the Spearman’s correlation coefficient. Because of the exploratory nature of 
this study, a correction for multiple testing was not included. Statistical significance 
was defined as a p value less than .05.
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Results
Baseline characteristics 
Baseline characteristics of the 15 healthy male volunteers are shown in Table 1. All 
participants had a mean age of 23 ± 2 years, and had a high (college or university) 
educational level. 
Table 1 Baseline demographic characteristics of the study group Table 1. Baseline demographic characteristics of the study group  
 
Characteristic (n = 15)
Age (years)  23 ± 2 
Height (cm)  186 ± 7 
Weight (kg)  77.1 ± 9.0 
Body mass index (kg/m2)  22.3 ± 2.0 
Systolic blood pressure (mmHg)  130 ± 6 
Diastolic blood pressure (mmHg)  65 ± 9 
Heart rate (bpm)  61 ± 8 
Temperature (ºC)  35.7 ± 0.3 
Symptom score (median)  0 (IQR 0‐1) 
All values are means ± standard deviation unless other reported 
LPS‐induced changes in clinical and inflammatory parameters and cortisol levels  
 
LPS administration induced the expected transient flu-like symptoms. Body 
temperature increased by 1.4 ± 0.1ºC (p < .0001) and heart rate by 27 ± 2 bpm 
(p < .0001). Cumulative symptom scores increased from a median score of 0 
(IQR 0 to 1) to 4 (IQR 2 to 7) at 70 minutes after LPS administration, after which 
there was a decrease to a median of 2 (IQR 1 to 5) and 1 (IQR 0 to 2) at two and four 
hours, respectively (p < 0.0001). Relevant to the present study, LPS administration 
induced an increase in headache score from 0 score to a maximum of 2 (IQR 1 to 3) 
at 90 minutes after endotoxin administration (p < .0001). 
All plasma cytokine concentrations increased significantly (all p < .0001) after the 
administration of LPS (Figure 1). Cortisol levels increased significantly from 0.31 
± 0.07 to 0.60 ± 0.07 µmol/l (p < .0001) two hours after LPS administration and 
dropped to baseline levels eight hours after LPS administration (Figure 1).
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LPS-induced changes in brain specific proteins 
As illustrated in Figure 1, NSE levels showed a small, but statistically significant 
decrease from 11.1 ± 0.47 to 7.7 ± 0.39 µg/L after the administration of LPS (p < .0001). 
S100-β showed a significant biphasic change (from 0.049 ± 0.002 up to 0.055 ± 
0.004 and down to 0.047 ± 0.002 µg/L, p = .04), whereas GFAP levels did not 
change significantly (p = .41). 
LPS-induced changes in EEG
Visual analysis
For each subject, at least eight hours of raw EEG were available for visual analysis. 
All EEGs before LPS infusion were within the normal range. One hour after LPS 
infusion mild transient encephalopathic EEG changes in the theta range were 
present in one subject for 15 minutes, without associated cognitive impairment. 
Of note, this subject had a very low cytokine response during endotoxemia (TNF-α 
level of 169 pg/ml compared with the group mean of 814 ± 133 pg/ml, and IL-6 
level of 508 pg/ml compared with the group mean of 1,111 ± 142 pg/ml) and an 
average cortisol response (0.29 to 0.67 µmol/l). The EEGs from the other 14 subjects 
remained within the normal range after LPS infusion, and no focal or epileptiform 
abnormalities were found. 
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Figure 1 LPS-induced changes in cytokine plasma concentrations, cortisol 
 and brain specific proteins. 
Time -0- reflects baseline concentrations. Administration of lipopolysaccharide (LPS) resulted in a 
marked increase in TNF-α, IL-6, IL-10, IL-1Ra and cortisol concentrations. All changes in cytokine and 
the cortisol concentrations were significant (p < .001). Concentrations of neuron specific enolase 
(NSE) decreased after administration of LPS (p < .001) and S100-β showed a significant biphasic 
change (p = 0.038). All data are expressed as mean ± standard error of the mean (n = 15). GFAP, glial 
fibrillary acidic protein; S100β, S100 Calcium Binding Protein B. * p < .05. ** p < .001.
Endotoxemia-induced inflammation and the effect on the human brain
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Table 2 Neuropsychological test outcomes (mean ± SD) at 0 (baseline), 
 2 and 8 hours after LPS administrationTable 2: Neuropsychological test outcomes (mean ± SD) at 0 (baseline), 2 and 8 hours after LPS administration  
 
LPS group (n = 15)  Reference group (n = 10) 
p‐value 
(between 
group) 
Age  22.8 ± 2.2  25.5 ± 2.5  .87* 
(Dutch) STAI total  32.7 ± 1.5  29.1 ± 3.7  .13* 
 
Neuropsychologic
al test 
t = 0  t = 2  t = 8 
p‐value 
(within 
group) 
t = 0  t = 2  t = 8 
P value
(within 
group) 
 
Stroop A (in seconds) 1   39 ± 2  35 ± 2    35 ± 2  .0001  37 ± 5  34 ± 4  34 ± 4  .001  .49 
Stroop B (in seconds) 1  51 ± 3  45 ± 3  43 ± 2  .0001  48 ± 7  44 ± 7  43 ± 7  .001  .45 
Stroop C (in seconds) 1  75 ± 6  65 ± 4  64 ± 4  .003  67 ± 10 62 ± 12  61 ± 11  .004  .23 
Pasat 2  49 ± 2  50 ± 2  56 ± 2  .001  50 ± 7  54 ± 4  54 ± 5  .031  .07 
Digits forward 2  11 ± 1  12 ± 1  11 ± 1  .115  10 ± 2  11 ± 1  11 ± 2  .235  .81 
Digits backward 2  8 ± 1  9 ± 1  9 ± 1  .30  9 ± 2  9 ± 1  9 ± 2  .454  .65 
Digits total 2  19 ± 1  20 ± 1  20 ± 1  .066  19 ± 4  20 ± 3  21 ± 4  .203  .63 
Pegboard 1  64 ± 2  59 ± 2  61 ± 2  .037  58 ± 5  56 ± 6  56 ± 7  .362  .35 
Symbol substitution task2  87 ± 3  99 ± 4  101 ± 3  .0001  98 ± 14 108 ± 17  112 ± 19  .0001  .53 
All values are means ± SD unless other reported. * Unpaired T‐test. 
1 Decrease indicates an improvement of the test. 2 Increase indicates an improvement of the test. 
Reading speed was measured by Stroop A‐B‐C word naming test. 
Attention under time pressure was measured by the paced auditory serial addition test (PASAT). 
Working memory was tested in numbers with the Digits forward and backward test . 
The fine motor control was tested with the Grooved Pegboard test. 
Psychomotor speed capacity was measured by the symbol substitution task. 
LPS, lipopolysaccharide; SD, standard deviation; STAI, Dutch State‐Trait Anxiety Inventory scale. 
Quantitative analysis 
LPS induced a significant increase of the peak frequency and absolute band power 
of alpha and beta activity in the occipital region, P4O2 and P3O1 (all p < .0001). The 
absolute power of the alpha activity in the central region, F4C4 and F3C3, increased 
significantly (both p < .0001). The relative band power of the beta activity in P4O2 
increased significantly (p = .017), indicating a higher state of alertness. No other 
relevant EEG changes were found (Figure 2).
LPS-induced changes in cognitive function 
Baseline STAI in the LPS group was 32.7 ± 1.5, indicating a low level of anxiety that 
did not differ from the reference group 29.1 ± 3.7 (p = 0.13). During endotoxemia all 
measured CFs significantly improved. These improvements were not significantly 
different from those observed in the reference group who did not receive LPS 
(Table 2), indicating that the improvement of the CFT in the LPS group was due to a 
practice effect. 
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Correlation analyses 
Cytokines, cortisol, BSP, EEG, and CF 
To analyse the effects between the measured cytokine levels, cortisol, BSP levels, 
EEG parameters and cognitive performances, data were correlated. 
In the LPS group the elevated levels of the anti-inflammatory cytokine IL-10 
significantly correlated with the improvement of the working memory (r = 0.71, 
p = .003) and the psychomotor speed capacity (r = 0.71, p = .003). The increased 
cortisol levels significantly correlated with the increased peak frequency in the 
occipital electrodes P4O2 (r = 0.61, p = .016) and P3O1 (r = 0.69, p = .005). In the 
LPS group, the decreased level of NSE significantly correlated with the improvement 
of the working memory and psychomotor speed capacity (r = -0.53, p = .048 and 
r = -0.67, p = .006, respectively). The increased alpha activity in F3C3 central region 
correlated significantly with the improvement of the working memory (r = 0.66, 
p = .007). No other correlations between cytokines, cortisol, BSP, EEG and CF were 
found. 
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Figure 2 Increase of the EEG occipital peak frequencies, relative alpha band power 
 and absolute alpha and beta band power two to three hours after LPS infusion. 
Data of peak frequency are absolute numbers, data of absolute and relative band power are 
expressed as percentage changes. Time -0- reflects baseline measurements. (standard error of the 
means were omitted for reasons of clarity). * p < .05. ** p < .001. (a) Peak frequency in occipital 
region. Friedman analysis of variance revealed changes in P4O2 and P3O1 (both p < .001). (b) 
Percentage change compared to baseline in absolute band power (ABP) of alpha activity in occipital 
and central region. Friedman analysis of variance revealed changes for alpha activity in P4O, P3O1 
and F4C4, F3C3 all p < .001. (c) Percentage change compared with baseline in absolute band power 
(ABP) and relative band power (RBP) of beta activity in occipital region. Friedman analysis of variance 
revealed changes of RBP for beta activity in P4O2 (p = .017), P3O1 (p = .575) and ABP for beta activity 
in P4O and P3O1 (both p < .001). 
Delirium in Intensive Care Patients
181
Discussion
The main result of the present study is that, despite very high cytokine 
concentrations during experimental endotoxemia, no indications were found that 
acute systemic inflammation results in increased levels of BSPs and deterioration of 
CFs in humans in vivo. In addition, a group level quantitative EEG analysis showed a 
higher state of alertness that correlated with cortisol concentrations. Nevertheless, 
the concomitant improvement in CFTs turned out to represent a practice effect as 
a similar improvement was observed in subjects who did not receive LPS. Although 
the increased alpha activity in the central region of the brain correlated with the 
improvement of working memory in the LPS group, it appears conceivable that this 
correlation may also be present in the control group during the repeated CFTs, but 
this finding needs to be confirmed. Interestingly, the one subject with a transient 
mild encephalopathic episode on EEG, that is category 2 following the score used 
by Young and colleagues (33), showed that this was not associated with objective 
cognitive dysfunction. In addition, this subject had one of the lowest LPS-induced 
proinflammatory cytokine responses of the whole group, arguing against a cytokine-
mediated effect.
Although experimental endotoxemia in young humans without any co-morbidity 
mimics the pathophysiological changes in septic patients in many ways, important 
differences also exist. For example, TNF-α concentrations found during experimental 
endotoxemia are much higher than in septic patients, whereas other cytokines 
are released to a lesser extent and some inflammatory mediators found in septic 
patients are not induced during experimental endotoxemia (39). It appears likely 
that the relatively mild insult and short duration of elevated cytokine levels during 
experimental endotoxemia does account for the increase in cortisol concentration 
and observed stimulating effects on the brain, but may not reflect the neurotoxic 
effects of inflammatory mediators present in septic patients. In addition, age and 
the pre-existing neurological situation is likely to be important. Healthy elderly 
people show a more pronounced inflammatory response during experimental 
endotoxemia (40) and pre-existing micro-glial inflammation primes the brain for 
development of cognitive impairment in non-infectious and infectious central 
nervous system dysfunction (41). Therefore, although our study shows that a short 
duration of very high cytokine levels is not associated with brain dysfunction it does 
not exclude the possible effects of cytokines on neurons in older ICU patients with 
co-morbidities. 
Cortisol secretion is related to electroencephalographic alertness (13). We showed 
a significant correlation between the elevated levels of cortisol and the change in 
occipital peak frequency. It is likely that this higher state of alertness was due to the 
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LPS-induced inflammation with feelings of sickness resulting in a stress hormone-
driven ‘flight-fight’ response (42), which is also associated with increased cortisol. 
This appears to be a short-lived effect, because chronically elevated levels of 
glucocorticoids result in a deterioration of CF (43). As a result of this, it is possible 
that in the septic patient the stimulating effect of stress hormones on the brain is 
overshadowed by the neurotoxic effect of persistently elevated level of cytokines 
and other mediators. In septic patients, levels of some proinflammatory cytokines 
are not as high as in the LPS model, but the duration of the elevated cytokine 
level is much longer (44). If these cytokines play a role in the sepsis-associated 
encephalopathy, it is apparently not the absolute peak concentration of the 
proinflammatory cytokine that is of importance. Presumably, sustained elevated 
levels of cytokines are more important in the development of organ failure and brain 
dysfunction in sepsis. In accordance, chronic small increases in proinflammatory 
cytokine levels due to polymorphisms were found to be associated with decreased 
brain function (10). Naturally, other not yet identified mediators of inflammation 
that may be increased in septic patients but not during experimental endotoxemia 
may also account for brain dysfunction observed in septic patients. 
In previous studies with much lower doses of LPS (0.2 to 0.8 ng/kg), with 
little systemic inflammatory response, conflicting effects on CFs were reported 
(22;30;31). Compared with experiments with 0.2 ng/kg, improvement of working 
memory was shown in a study with 10 healthy volunteers with a dose of 0.8 ng/kg 
LPS (22). In these studies, cortisol level and cytokines increased slightly, compared 
with our results (22;30;31), which is associated with dysfunction of other organs 
(24;28;45). Furthermore, a potential problem in the studies with low doses of LPS 
was that no correction for practice effect was performed while practice effects 
during CFT are common, especially in situations with short test-retest intervals. Our 
study demonstrates that the observed improvement in CFs after LPS infusion in all 
domains was due to a practice effect. Without the use of a control group and the 
measurement of practice effect results are bound to be misinterpreted. Our results 
suggest that a short-term inflammation does not influence practice effect or lead to 
a significant deterioration or improvement of CFs. 
The observed relations between EEG changes and inflammatory markers indicate 
a higher state of inflammation-induced alertness. Higher dosages of LPS result in 
higher levels of cytokines (23) and more elevated levels of cortisol result in a higher 
state of alertness (13). The higher state of alertness during endotoxemia is possibly a 
so-called fight and flight response, rather than being due to the increased cytokine 
concentrations. 
Although it is tempting to speculate, due to the observational nature of the 
present study we cannot conclude whether or not the anti-inflammatory innate 
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immune response, measured by IL-10, exerts a protective effect on the brain, and 
this correlation needs further study. In addition, the pathophysiological mechanism 
by which systemic inflammation results in the observed decrease of NSE is not clear. 
Increased levels of NSE are associated with deterioration of CF after cardiac surgery 
(46). Also, increased NSE levels are associated with brain injury in septic patients, 
but an association between NSE and CFs in septic patients has not been examined. 
Conclusions
Administration of LPS to humans results in systemic inflammation with high levels 
of cytokines and increased cortisol levels. In young healthy volunteers this can 
sporadically lead to a transient mild deterioration of brain function without clinical 
correlation. Overall, LPS infusion results in a higher state of alertness determined 
on the EEG, while the practice effects in CFTs are not significantly influenced. Short-
term systemic inflammation does not provoke or explain the occurrence of a septic 
encephalopathy. 
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ABSTRACT
Introduction
Delirium occurs frequently in critically ill patients and is associated with disease 
severity and infection. Although several pathways for delirium have been described, 
biomarkers associated with delirium in intensive care unit (ICU) patients is not well 
studied. We examined plasma biomarkers in delirious and nondelirious patients 
and the role of these biomarkers on long-term cognitive function.
Methods
In an exploratory observational study, we included 100 ICU patients with or 
without delirium and with (“inflamed”) and without (“noninflamed”) infection/
systemic inflammatory response syndrome (SIRS). Delirium was diagnosed by 
using the confusion-assessment method-ICU (CAM-ICU). Within 24 hours after 
the onset of delirium, blood was obtained for biomarker analysis. No differences 
in patient characteristics were found between delirious and nondelirious patients. 
To determine associations between biomarkers and delirium, univariate and 
multivariate logistic regression analyses were performed. Eighteen months after 
ICU discharge, a cognitive-failure questionnaire was distributed to the ICU survivors.
Results
In total, 50 delirious and 50 nondelirious patients were included. We found that 
IL-8, MCP-1, procalcitonin (PCT), cortisol, and S100-β were significantly associated 
with delirium in inflamed patients (n = 46). In the noninflamed group of patients 
(n = 54), IL-8, IL-1ra, IL-10 ratio Aβ1-42/40, and ratio AβN-42/40 were significantly 
associated with delirium. In multivariate regression analysis, IL-8 was independently 
associated (odds ratio, 9.0; 95% confidence interval (CI), 1.8 to 44.0) with delirium 
in inflamed patients and IL-10 (OR 2.6; 95% CI 1.1 to 5.9), and Aβ1-42/40 (OR, 0.03; 
95% CI, 0.002 to 0.50) with delirium in noninflamed patients. Furthermore, levels of 
several amyloid-β forms, but not human Tau or S100-β, were significantly correlated 
with self-reported cognitive impairment 18 months after ICU discharge, whereas 
inflammatory markers were not correlated to impaired long-term cognitive function.
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Conclusions
In inflamed patients, the proinflammatory cytokine IL-8 was associated with 
delirium, whereas in noninflamed patients, antiinflammatory cytokine IL-10 
and Aβ1-42/40 were associated with delirium. This suggests that the underlying 
mechanism governing the development of delirium in inflamed patients differs 
from that in noninflamed patients. Finally, elevated levels of amyloid-β correlated 
with long-term subjective cognitive-impairment delirium may represent the first 
sign of a (subclinical) dementia process. Future studies must confirm these results.
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Introduction
Delirium is a serious and frequently occurring disorder in critically ill patients 
associated with both physical and cognitive impaired outcome (1-4). Because the 
pathogenesis of delirium is probably multifactorial, biomarker analysis may provide 
valuable information regarding the underlying mechanisms (5-7).
Several previous investigations in non-ICU patients established an association 
between inflammation and delirium, as correlations between proinflammatory 
cytokine levels and delirium have been found (6;8-10). Furthermore, in elderly 
delirious patients with hip fractures, increased concentrations of IL-6, IL-8 and 
cortisol were correlated with elevated levels of the brain specific protein (BSP) 
S100-β (a marker for astrocyte damage) (11). Interestingly, sepsis is also associated 
with elevated levels of BSP (12;13). Furthermore, it has been hypothesized that 
serious illness such as sepsis, as well as the use of sedatives and analgesic, could 
result in apoptosis and long-term cognitive impairment (14). mice, tumor-necrosis 
factor (TNF)-α is a mediator of apoptotic cellular death in the brain (15), and may 
therefore be causally associated with the development of delirium in patients with 
severe inflammation.
In the long-term delirium is associated with an over 12-fold increased risk for 
developing dementia (16), resulting in permanent impairment of cognitive function 
that is associated with altered levels of amyloid-β (17;18). The association between 
biomarkers in delirious patients and long-term cognitive function are unknown.
With regard to its multifactorial nature, it is likely that the underlying mechanisms 
of delirium may differ between inflamed and noninflamed patients. In the present 
study, we explored which biomarkers were associated with delirium in inflamed 
patients and which were associated with delirium in noninflamed patients, thereby 
using these biomarkers to explore whether different underlying mechanisms are 
involved. We included biomarkers that are directly linked to delirium, as determined 
in previous studies, and biomarkers that are linked with the onset of delirium. 
Apart from well-established pro- and antiinflammatory cytokines, we determined, 
for example, procalcitonin (19), macrophage migration inhibitory factor (20) and 
human neutrophil peptide-1 (21) that play a role in inflammation, directly associated 
to delirium (22). Finally, we searched for correlations between mediators that were 
related to delirium and brain-specific proteins and cognitive functions 18 months 
after ICU discharge to establish whether the different pathways exert different long-
term cognitive effects.
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Material and methods
Patients and definitions
A convenience sample was taken of all medical and surgical patients older than 
18 years admitted to our Intensive Care Department (tertiary referral hospital in 
Nijmegen, the Netherlands) between February and July 2008. These patients 
were screened for delirium using the confusion assessment method-ICU (CAM-
ICU) (23;24). Patients were excluded when delirium screening during patients’ 
complete ICU stay could not be performed (for example, because of persistent 
coma). Patients who were admitted to the ICU for trauma, postcardiac arrest, or 
neurologic reasons were also excluded. Finally, patients were excluded when they 
had a history of serious cognitive impairment, defined as reported in their medical 
history, or had from any form of dementia, delirium, or obvious signs of cognitive 
impairment reported by their relatives. If doubt existed concerning preexistent 
cognitive function, patients were not included in this study.
In delirious patients, blood was drawn within 24 hours after the onset of delirium. 
For the nondelirious group, because no point in time exists to relate to, we draw 
blood after a similar ICU length of stay compared with that of the group of delirious 
patients. A total of 5 ml blood was drawn for all measurements.
In delirious patients, blood was drawn within 24 hours after the onset of delirium. 
For the nondelirious group, there is no point in time to relate to. Therefore we draw 
blood after a similar ICU length of stay compared to the group of delirious patients. 
A total of 5 ml blood was drawn for all measurements. Delirium and nondelirium 
patients were furthermore divided into inflamed and noninflamed patients. This 
distinction was made because inflamed patients are suspected to have high levels 
of inflammatory mediators, and from a group of noninflamed patients, it is expected 
that they have low levels of inflammatory mediators. Inflamed was defined as a 
positive culture, regardless the origin from which specimens were taken, for which 
the patient was treated with antibiotics. Although systemic inflammatory response 
syndrome (SIRS) criteria lack specificity, the study was designed to differentiate 
between inflamed patients and noninflamed patients, and therefore, we used the 
presence of more than two SIRS criteria as a marker of inflammation (25). Absence 
of inflammation was defined as the absence of proven or suspected infection and 
the presence of no more than of one SIRS criterion. 
The regional Medical Ethics Committee of Arnhem-Nijmegen approved the study 
and waived the need for informed consent because a single blood withdrawal is not 
considered a burden for the patient, and the results of this study did not influence 
the standard care for that patient. The study was registered in the Clinical Trial 
Register (NCT00604773). 
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Procedures
Demographic variables as well as illness related characteristics were collected. The 
validated CAM-ICU method was used to detect whether patients were delirious. 
All patients were screened at least 3 times per day by using the CAM-ICU with a 
high interrater reliability of 0.90 (95%CI 0.82-0.98) Cohen’s kappa by well trained 
ICU-nurses (26). Patients were diagnosed with delirium when they had at least 
one positive CAM-ICU screening. Patients without any positive CAM-ICU screening 
during the complete ICU stay were classified as nondelirious. In case of doubt 
regarding the delirium diagnosis, patients were not included in this study. 
Blood for the determination of biomarkers was drawn between 6 and 10 a.m. and 
within 24 hours of the first positive CAM-ICU screening from an indwelling arterial 
line. Blood was centrifuged at 2,000 g for 15 minutes, and plasma was stored at 
-80 °C until analysis. Proinflammatory cytokines (tumor necrosis factor (TNF)-α, 
interleukin (IL)-1β, IL-6, IL-8, IL-17, IL-18 and macrophage migration inhibitory 
factor (MIF), antiinflammatory cytokines (IL-1RA and IL-10), and the chemotactic 
cytokine MCP-1 were determined using a simultaneous Luminex assay (Milliplex, 
Millipore, Billerica, MA, USA). Plasma defensin (human neutrophil peptide-1 (HNP-
1) was measured using mouse anti-human HNP-1-3 monoclonal antibody (HyCult 
Biotechnology, Uden, The Netherlands) and the wells were then incubated with 
rabbit anti-human HNP-1-3 polyclonal antibody (Host Defence Research Centre, 
Toronto, Canada), followed by incubation with peroxidase-conjugated goat-anti-
rabbit IgG (Jackson ImmunoResearch). C-reactive protein (CRP) concentrations 
were measured using immunological detection (turbidimetric method, Aeroset, 
Abbott Laboratories, Abbott Park, IL, USA) and procalcitonin (PCT) levels were 
determined using an immunometric assay with time-resolved amplified cryptate 
emission technology (PCT sensitive Kryptor kit; Brahms, Germany). The stress 
hormone cortisol was measured with luminometric immunoassay on a random 
access analyzer  (Architect® i System, Abbott, Il, USA).
The brain specific proteins full length amyloidβ1-42 and 1-40 (Aβ1-42 and Aβ1-40) 
and truncated Aβ-42 and -40 (AβN-42 and AβN-40) were determined in plasma 
using a simultaneous Luminex assay (INNO-BIA plasma Aβ forms, Innogenetics, 
Ghent, Belgium) which has been shown to be a reliable assay with a low variability 
(27). Plasma levels of S100 calcium binding protein-β (S100-β) and total human 
Tau were analyzed using two commercially available ELISA kits (Cosmo Bio Co. 
Ltd; Tokyo, Japan and Cusabio biotech Co Ltd, Donghu; China, respectively). All 
biomarkers were determined according to the manufacturer’s instructions. 
Subjective long-term cognitive functioning 
All included patients received the validated Dutch translation (28) of the cognitive 
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failure questionnaire (CFQ) 18 months (median) after discharge from the ICU (29). The 
self reported CFQ measures four dimensions of cognition: memory, distractibility, 
social blunders, and names (30). Each question was scored on a 5-point Likert scale. 
The total score on the CFQ ranges from 0-100, a higher score indicates more severe 
cognitive dysfunctioning. The subjective CFQ shows good correlation with more 
quantitative mental health tests (29). An extensive description concerning the use 
of the CFQ in critically ill patients was recently published (31).
Statistical analysis 
Differences in baseline characteristics between delirious and nondelirious patients 
were tested by using χ2 tests and the Mann-Whitney U or Student t tests, depending 
on its measure and distribution. Biomarkers and CFQ data were successfully log 
transformed to obtain normally distributed data. To determine the association 
between biomarkers and delirium in the inflamed and the noninflamed group of 
patients, univariate logistic regression analysis was performed. To examine the 
associations between the biomarkers and delirium, a multivariate logistic regression 
analysis method backward conditional was performed, including biomarkers with 
the 10 best-associated biomarkers in the univariate analysis. Correlations between 
biomarkers and CFQ outcomes, measured 18 months after ICU discharge, were 
determined by using Pearson’s correlation coefficients. 
Because of the exploratory nature of this study, no correction for multiple testing 
was performed to increase sensitivity. Statistical significance was defined as a 
p value < 0.05. 
All data were analyzed by using SPSS version 16.01 (SPSS, Chicago, IL, USA). 
Results
In total, 105 patients were screened for this study, of which 5 patients were 
excluded for reasons of doubt concerning the delirium diagnosis or history of 
cognitive dysfunction of the patients. In three patients it was not possible to 
retrieve information of the relatives and in two patients there was some doubt 
concerning the delirium diagnosis (in both cases the CAM-ICU was negative). In 
total, 100 patients were included for this study, of whom 50 patients were delirious 
during the ICU stay and 50 patients were not delirious during the ICU stay. No 
statistically significant differences in demographic variables and several clinical 
covariates related to delirium were observed between groups of 50 delirious and 
50 nondelirious patients (Table 1). No difference was noted between both groups 
regarding the moment of blood withdrawal counted from ICU admission (Table 1). 
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Several pro- and antiinflammatory cytokines, PCT as marker of inflammation, stress 
response hormone cortisol, as well as several brain specific proteins differed 
significantly between delirious and nondelirious patients (Table 2). 
Table 1 Demographic variables of delirium and nondelirium ICU-patients 
    Table 1. Demographic variables of delirium and nondelirium ICU‐patients  
  Delirium 
  (n=50) 
Nondelirium 
    (n=50) 
p value 
Age in years (95%CI)  72 (38‐86)  68 (31‐84)  .10  
Gender (male, N %)  27 (46)  26 (40)  .50 
Medical patients (N,%)  14 (28)  13 (26)  .50 
Unplanned admissions (N,%)  23 (46)  7 (35%)  .34 
APACHE‐II score (point) 
(95%CI)  16 (9‐25)  15 (6‐23)  .11 
Inflamed patients (N, %)  26 (52)  20 (40)  .16 
Days on the ICU (median [IQR] 
before draw blood   1 [1‐2]  1 [1‐3]  .38 
Mean arterial blood pressure 
in mmHg (95%CI)   64 (47‐90)  65 (50‐105)  .37 
Use of sedatives (midazolam, 
propofol) (N,%)  28 (56)  16 (32)  .13 
Use of opiates (N,%)  45 (90)  42 (84)  .28 
Urea in mmol/L (95%CI)  11 (4‐29)   9 (4‐23)  .14 
Metabolic acidosis (N,%)  15 (30)  14 (28)  .50 
     Data are expressed as mean and standard deviation (±) unless other reported. 
 
Of note, all measured levels of biomarkers were well above the lower detection 
limit. Differences in biomarkers between inflamed and noninflamed delirious 
patients are illustrated in Additional file.
Inflamed patients
This group consisted of 26 delirium and 20 nondelirium ICU patients. Several pro- 
as well as antiinflammatory cytokines, PCT and cortisol were significantly higher in 
the delirium group compared to the nondelirium group (Table 3). Levels of brain 
specific proteins were comparable between the groups, except for a borderline 
significant elevated level of S100-β in the delirium group (p=0.07). In univariate 
logistic regression analysis IL-8, MCP-1, PCT, cortisol, and S100-β were significantly 
(p < .05) associated with delirium. Extended with the biomarkers TNF-α, IL-6, IL-18, 
IL-1ra and IL-10 the 10 best biomarkers associated with delirium (all p < .10) were then 
entered into a multivariate logistic regression analysis. This multivariate analysis 
demonstrated a significant association between the proinflammatory cytokine IL-8 
(odds ratio 9.0; 95%CI 1.8-44.0) with the presence of delirium in inflamed patients.
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Noninflamed patients
This group of patients consisted of 24 delirium and 30 nondelirium ICU patients. 
The proinflammatory cytokines IL-6 and IL8 as well as the antiinflammatory 
cytokines IL-1ra and IL-10 and level of PCT were significantly higher in delirious 
patients compared with the nondelirious patients. Furthermore several amyloidβ 
forms differed significantly, and Tau levels differed borderline significant between 
the two groups (Table 3). 
Biomarkers that were significantly associated with delirium were IL-8, IL-1ra, IL-
10, ratio Aβ1-42/40 and ratio AβN-42/40. Furthermore IL-6, PCT, cortisol, ratio Tau/
Aβ1-42, Aβ1-40 and AβN-40 were in total the 10 best with delirium associated 
biomarkers (all p < .10) in univariate logistic regression analysis. Multivariate logistic 
regression analyses with these biomarkers showed a significant association of ratio 
Aβ-42/40 (OR 0.03; 95%CI 0.002 - 0.50) and the antiinflammatory cytokine IL-10 
(OR 2.6; 95%CI 1.1 - 5.9) with the presence of delirium in noninflamed patients.
Correlations of biomarkers with long-term subjective cognitive failure
At a median of 18 months after ICU discharge, 10 out of the 100 ICU patients had 
died. Except for a significantly lower level of IL-1β in the survivors group, no other 
differences were found between the survivors and nonsurvivors (data not shown). 
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Table 2 Differences between delirious and nondelirious patients 
Table2.Differencesbetweendeliriousandnondeliriouspatients
 Delirium(n=50) Nondelirium(n=50) Differencespvalue
Proinflammatorycytokines  
TNFͲɲ(pg/mL) 11 [7Ͳ14] 8 [5Ͳ13] .02*
ILͲ1E(pg/mL) 3 [3Ͳ6] 3 [3Ͳ7] .63
ILͲ6(pg/mL) 61 [37–113] 37 [23Ͳ81] .01*
ILͲ8(pg/mL) 29 [20–39] 17 [9–26] <.0001*
ILͲ17(pg/mL) 3 [3Ͳ4] 3 [3Ͳ4] .17
ILͲ18(pg/mL) 99 [74–161] 86 [70–120] .11
MIF(pg/mL) 418 [300Ͳ724] 257 [157–576] .02*
Antiinflammatorycytokines  
ILͲ1ra(pg/mL) 36 [17–68] 21 [13–33] .001*
ILͲ10(pg/mL) 29 [16–51] 18 [9Ͳ39] .01*
Chemotacticcytokines    
MCPͲ1(pg/mL) 372 [248–589] 239 [179–325] <.0001
Defensin    
HNP(µg/mL) 0.06 [0.03–0.12] 0.06 [0.03–0.10] .89
Markersofinflammation  
CRP(mg/ml) 56 [35Ͳ114] 47 [32Ͳ84] .11
Procalcitonine(ng/mL) 0.35 [0.17Ͳ1.68] 0.14 [0.07–0.36] <.0001*
Stressresponsehormone  
Cortisol(µmol/L) 0.51 [0.31–0.97] 0.35 [0.09Ͳ0.62] .006*
BrainSpecificProteins    
S100ͲE(pg/ml) 132 [100–294] 135 [90Ͳ219] .40
Tau(pg/ml) 41 [24–91] 32 [17Ͳ56] .07
RatioTau/AE1Ͳ42 1.14 [0.62Ͳ2.71] 0.95 [0.47Ͳ1.69] .10
AE1Ͳ42(pg/ml) 36 [29Ͳ47] 36 [30Ͳ41] .70
AE1Ͳ40(pg/ml) 156 [129–225] 146 [113Ͳ163] .05
RatioAE1Ͳ42/40 0.23 [0.20Ͳ0.27] 0.25 [0.23Ͳ0.30] .006*
AENͲ42(pg/ml) 31 [23Ͳ40] 29 [24Ͳ36] .65
AENͲ40(pg/ml) 222 [167Ͳ276] 178 [146Ͳ220] .02*
RatioAENͲ42/40 0.15 [0.12Ͳ0.17] 0.17 [0.14Ͳ0.19] .04*
RatioAE1Ͳ42/NͲ42 1.26 [1.03Ͳ1.34] 1.29 [1.10Ͳ1.40] .48
RatioAE1Ͳ40/NͲ40 0.78 [0.69Ͳ0.85] 0.80 [0.73Ͳ0.92] .28
DataareexpressedasmedianandIQR.DifferencesweretestedwithMannͲWhitneyUͲ
test.*pͲvalue<.05

 
In total, 52 (58%) patients out of the 90 survivors returned the CFQ, 23 (44%) of 
these were delirious during their ICU stay. No important differences were noted 
between nonresponders and responders concerning age (69±8 versus 73±6; p = .12), 
APACHE-II (16±3 versus 15±4; p = .31), gender (male 46% versus 54%; p = .45), 
delirium (46% versus 44%; p = .60) and inflamed (55% versus 40%; p = .29).
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Table 3 Differences between delirium and nondelirium patients in inflamed 
 and noninflamed patients 
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We found no correlation between S100-β, total human Tau, cortisol or any of the 
other measured inflammatory mediators, CFQ, age, APACHE-II score, and mean 
blood pressure. In addition, we found no correlations between CFQ and age, 
APACHE-II score and length of stay in the ICU.
The patient number per subgroup were too low and therefore did not allow us to 
perform correlation analyses between biomarkers and the different subgroups for 
reasons of lack of statistical power. 
Discussion
This study shows that differences exist in various inflammatory mediators associated 
with delirium between inflamed and noninflamed patients. After multivariate 
regression analysis, IL-8 was associated with delirium in inflamed patients, whereas 
in noninflamed patients, IL-10 and Aβ-42/40 were associated with delirium. These 
differences between inflamed and noninflamed ICU patients in delirium-associated 
biomarkers suggest that the underlying mechanism governing the development of 
delirium in inflamed patients differs from that in noninflamed patients. Furthermore, 
we demonstrated that, in contrast to inflammatory mediators, different forms of 
amyloidβ significantly correlate with long-term subjective cognitive problems in ICU 
patients, illustrating that the underlying mechanism of delirium is relevant for its 
long-term cognitive consequences.
This is the first study investigating plasma amyloidβ (Aβ) levels and human Tau in 
critically ill patients in relation to the presence of delirium. In view of the reported 
increased incidence of dementia following ICU/hospital admission (16), our 
findings could provide a possible mechanistic link, because noninflamed delirium is 
associated with Aβ, but this must be confirmed in a longitudinal study focusing on 
these biomarkers combined with more-extensive cognitive testing. Furthermore, 
Aβ is associated with sustained long-term subjective cognitive dysfunction in ICU 
patients. Studies comparing plasma levels of Aβ between Alzheimer (AD) and non-
Alzheimer dementia patients and controls (17;18;32) have yielded conflicting results 
with respect to levels of different forms of Aβ. Increased levels of Aβ1-42 (17) as well 
as increased levels of Aβ1-40 (18) were found in dementia patients (32). In addition, 
increased levels of Tau/Aβ1-42 ratio have been found in cerebrospinal fluid (CSF) of 
patients with cerebral amyloid deposition (33), but this has not yet been investigated 
in plasma. In the present study, the difference in levels of total Tau and the Tau/
Aβ1-42 ratio between noninflamed delirious patients and noninflamed nondelirious 
patients approached statistical significance. It is known that plasma levels of Aβ are 
age dependent (34), however, this could not have confounded our results because 
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there were no differences in age between delirious and nondelirious patients in our 
study. Additionally, the patients investigated in this study were not recognized with 
a history of cognitive impairment by patients’ medical history and information from 
their relatives, which could explain differential Aβ levels. The lower Aβ1-42/40 ratio, 
probably due to an increase of Aβ1-40 at a constant Aβ1-42 level, in combination 
with a significant correlation with long-term cognitive failure on several domains 
of the CFQ are in accordance with findings that elevated levels of Aβ1-40 increases 
the risk of developing dementia (16;18). Importantly, this finding of early lower Aβ1-
42/40 ratio and ratio Aβ1-40/N-40 in delirious patients without signs of serious 
previous cognitive impairment is tempting to speculate that this represents the first 
sign of an imbalance in the Aβ metabolism. To our knowledge, these early findings 
of imbalance in Aβ metabolism have not been reported before. Our findings might 
therefore shed new light on the important question whether delirium plays a 
causative role in the development of dementia in later life, or if delirium is the first 
sign of dementia. Because deposition of Aβ in the brain is generally considered 
to be a long-term process and samples in our study were drawn shortly after the 
onset of delirium, it is more plausible that delirium may be the first sign of an early 
dementia process. However, a cause-effect relationship cannot be determined in a 
cross sectional observational study like ours. This hypothesis of early imbalance in 
Aβ metabolism in delirious patients need to be confirmed in future studies.
Previously, it has been demonstrated that delirium is associated with elevated 
levels of IL-6, IL-8 and S100-β in non-ICU patients (9;10) and with IL-6 and S100-β 
in septic ICU patients (13). IL-8 levels were not measured in these septic patients. 
We showed, by using a multivariate logistic regression analysis, that levels of IL-8 in 
inflamed patients were associated with delirium but IL-6 was not. A possible reason 
for this discrepancy might be that we determined biomarkers directly after the first 
positive delirium screening, whereas it has been shown that the highest levels of 
IL-6 occur in the later phase of delirium (10). 
Several limitations of our study should be addressed. First, we used the CAM-ICU 
to diagnose delirium in ICU patients instead of the gold standard: the DSM-IV criteria 
(35). It is recognized that it is not feasible to use this gold standard in ICU patients, and 
therefore the CAM-ICU is an accepted alternative to diagnose delirium in the ICU. The 
CAM-ICU has the highest sensitivity and specificity rate of all delirium assessment tools 
(36;37) and is well implemented in the daily practice of our nurses with a high interrater 
reliability (26). In addition, to strengthen the delirium diagnosis, all medical and nurse 
files of the patients were analyzed, and patients were not included when in doubt 
of the delirium diagnosis. Second, we did not use a validated cognitive assessment 
tool such as the informant questionnaire on cognitive decline short form (IQCODE-
sf), which is a surrogate evaluation to determine if the patient suffered from serious 
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cognitive impairment prior to ICU admission. Instead of this, we used information 
from medical records and the next of kin of the patients to identify whether the patient 
had a history of cognitive impairment. In case of any reference to or sign of cognitive 
impairment, patients were not included in our study. Furthermore, as a measure of 
patients’ cognitive function 18 months after ICU discharge, we used the validated 
CFQ, which is a self-evaluated questionnaire to detect cognitive-based failures and 
not dementia and is also not a specific psychometric test, which may result in more-
objective data. Although this can be considered a limitation of our study, our findings 
are the results of patient’s own perception of cognitive functioning and are therefore 
informative and relevant. Third, in this study we measured biomarkers only at one 
point in time. In a longitudinal biomarker study (9), a difference in cytokine levels 
before and during delirium was found. In the absence of biomarker data in critically ill 
patients with delirium, we chose to perform an exploratory study to investigate which 
biomarkers were most strongly associated with delirium immediately after the onset 
of delirium. This was an exploratory hypothesis-generating study, of which the results 
may facilitate hypotheses for future research. Fourth, potential covariates need to 
be considered as a potential limitation of the study, in contrast to a randomized trial 
in which possible covariates are likely to be equally divided between the groups. 
Although baseline patient characteristics were comparable between the delirium 
and nondelirium groups, unbalanced influence of covariates cannot be ruled out 
in such an observational study as we performed. Last, we measured levels of brain 
biomarkers in peripheral blood and not directly in material derived from the brain or 
cerebrospinal fluid. It is recognized that levels of Aβ1-42 in cerebrospinal fluid of AD-
patients are decreased (38), but studies on plasma Aβ forms have yielded ambiguous 
results (18;39-43). A large prospective study showed that increased plasma levels of 
Aβ1-40 increased the risk for dementia, especially when the concentration of Aβ1-42 
was increased (18). This results in a decrease of ratio Aβ1-42/40  (40). A combination of 
different brain specific proteins, such as a combination of Aβ with Tau concentrations 
in CSF, improves discrimination between AD patients and controls (44). Although it 
has been recommended to determine these biomarkers in CSF rather than in plasma 
(45), our results are in accordance with these findings. Interestingly, levels of Tau, 
ratio Tau/Aβ1-42, and Aβ1-40 were increased in inflamed delirious and nondelirious 
patients and in delirious noninflamed patients, but appear to be lower in nondelirious 
noninflamed patients. It can be argued that a blood barrier change during systemic 
inflammation may play a role. This may also suggest that determining neuronal 
biomarkers in plasma can be used instead of only CSF samples. Obviously, CSF samples 
are not routinely obtained in our ICU patients. To our knowledge, a study investigating 
the correlation between CSF and plasma levels of Aβ  has yet to be performed. 
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Conclusion
In inflamed patients, the proinflammatory cytokine IL-8 was independently 
associated with delirium, whereas in noninflamed patients, the ratio Aβ1-42/40 and 
IL-10 were independently associated with delirium, as determined by multivariate 
regression analyses. This suggests that the underlying mechanism governing the 
development of delirium in inflamed patients differs from that in noninflamed 
patients. These findings illustrate the relevance of distinguishing between inflamed 
and noninflamed when investigating biomarkers in delirious patients. Finally, 
elevated levels of amyloidβ correlated with long-term cognitive impairment. These 
findings are in line with the notion that delirium in noninflamed ICU patients may 
represent the first sign of a (subclinical) dementia process. Future research into 
the relation of delirium, amyloid forms, and long-term cognitive function should 
include more-extensive tests of cognitive function.
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Additional file
Differences between inflamed and noninflamed delirium patients  
Additionalfile.Differencesbetweeninflamedandnoninflameddeliriumpatients
 Deliriumpatients
 Inflamed(n=26) Noninflamed(n=24) pͲvalue
Proinflammatorycytokines  
TNFͲɲ(pg/mL) 13 [10Ͳ16]  8 [5Ͳ13] .03*
ILͲ1E(pg/mL) 3 [3Ͳ6] 3 [3Ͳ6] .61
ILͲ6(pg/mL) 73 [38–143] 50 [29–90] .58
ILͲ8(pg/mL) 31 [24–44] 20 [12–32] .04*
ILͲ17(pg/mL) 4 [3Ͳ7] 3 [3Ͳ4] .15
ILͲ18(pg/mL) 136 [88–187] 82 [66Ͳ141] .004*
MIF(pg/mL) 438 [294–796] 334 [214–561] .66
Antiinflammatorycytokines  
ILͲ1ra(pg/mL) 48 [27–74] 24 [17–51] .02*
ILͲ10(pg/mL) 23 [13–47] 28 [12–44] .15
Chemotacticcytokines    
MCPͲ1(pg/mL) 516 [295–822] 268 [192–398] .01*
Defensin     
HNP(µg/mL) 0.06 [0.03–0.13] 0.06 [0.04–0.10] .72
Markersofinflammation  
CRP(mg/ml) 84 [56Ͳ190] 42 [29Ͳ65] .002*
Procalcitonine(ng/mL) 1.0 [0.23Ͳ2.0] 0.22 [0.11Ͳ0.55] <.0001*
Stressresponsehormone  
Cortisol(µmol/L) 0.59 [0.34–0.98] 0.46 [0.23–0.72] .44
BrainSpecificProteins    
S100ͲE(pg/ml) 172 [113–409] 128 [87–210] .09
Tau(pg/ml) 42 [26–131] 40 [21Ͳ78] .35
RatioTau/AE1Ͳ42 1.03 [0.62Ͳ3.45] 1.17 [0.60Ͳ2.52] .84
AE1Ͳ42(pg/ml) 41 [31Ͳ52] 34 [26–43] .07
AE1Ͳ40(pg/ml) 158 [132–229] 148 [109–223] .45
RatioAE1Ͳ42/40 0.23 [0.20Ͳ0.28] 0.22 [0.19–0.26] .31
AENͲ42(pg/ml) 31 [26Ͳ43] 28 [20Ͳ37] .23
AENͲ40(pg/ml) 200 [167Ͳ283] 225 [168Ͳ273] .94
RatioAENͲ42/40 0.16 [0.13Ͳ0.18] 0.13 [0.10Ͳ0.17] .04*
RatioAE1Ͳ42/NͲ42 1.28 [1.00Ͳ1.39] 1.24 [1.04Ͳ1.33] .64
RatioAE1Ͳ40/NͲ40 0.82 [0.74Ͳ0.89] 0.72 [0.65Ͳ0.84] .03*
DataareexpressedasmedianandIQR.DifferencesweretestedwithMannͲWhitneyUtest
*pͲvalue<.05

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Delirium in Intensive Care Patients
Delirium in critically ill patients is receiving more and more attention, as illustrated 
by an almost exponential increase in the number of scientific publications (Figure 1). 
This thesis investigated several missing gaps and in this final chapter we will discuss 
our findings in view of other studies, discuss possible pitfalls and give directions for 
future research. 
Figure 1 Numbers of publications in Pubmed: ‘Delirium AND Intensive Care’
In this thesis, we showed and confirmed that the incidence of delirium in critically 
ill patients is high and associated with serious short- and long-term health-related 
problems. 
In the following discussion we will subsequently focus on the detection of delirium, 
the clinical impact of delirium, the possibilities for early prediction and prevention 
and the role of biomarkers.
Detection of Delirium in Intensive Care Patients
The gold standard to diagnose delirium is examination by a psychiatrist, 
neurologist, or geriatrician using the DSM-IV criteria (1), but in daily clinical ICU 
practice ICU nurses assess patients for delirium using validated delirium assessment 
tools. Although the performance of the most frequently used delirium assessment 
tool, the CAM-ICU, in original validation studies was excellent (2;3) using the CAM-
ICU is no guarantee that every patient with delirium will be detected. An important 
potential reason for this is suboptimal screening by the nurses. To achieve an 
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optimal performance of the CAM-ICU it is therefore important to first determine 
barriers and facilitators for successful implementation and second, to use a tailored 
evidence based implementation strategy as described in chapter 2 (4). In our study 
we found that lack of delirium knowledge and general availability of the screening 
tool were the main barriers and that leadership, education and the use of key-nurses 
played the most important role in our successful implementation. Importantly, this 
is a single centre study implying that the content of the interventions is likely to 
be different in other centres. It is further appears imperative that the attending 
intensivist evaluates the results of the assessment several times a day and results in 
clinical consequences (5). 
Recent studies suggest that the CAM-ICU has a lower performance, in particular a 
lower sensitivity (5-7) in daily ICU practice. Despite this limitation, we also used the 
CAM-ICU to determine if patients were delirious or not. However, we additionally 
screened all medical and nursing files daily for signs of delirium (8) to confirm the 
diagnosis. Moreover, our delirium diagnosis was based on all CAM-ICU screenings 
during patients’ complete ICU stay, increasing the sensitivity of the test. Therefore, 
we believe we have not underestimated the number of patients with delirium in 
our studies.
Even though the performance of the CAM-ICU is lower than in the original 
validation studies (2;3), it is still superior to that of an observational assessment 
tool such as the ICDSC (7). However, there is a clear need for further improvement. 
Notably, there are clear indications that early recognition (4) and treatment (9) of 
delirium could be beneficial for an individual patient supporting the importance of 
early detection. 
There are several possibilities that, besides the compliance of the nurses to assess 
the patients for delirium, could improve the performance of delirium detection. The 
fluctuating course of delirium can be missed by the testing tools when the screening 
is performed in between periods of confusion. This issue becomes even more 
relevant when patients are screened less frequently, e.g. twice a day instead of 
three times a day. It appears likely that an observational tool, such as the Intensive 
Care Delirium Screening Checklist (ICDSC) (10) does not have this problem or at 
least to a lesser extent, as the observational period covers a longer period of time, 
most frequently one shift of 8 hours. However, some features such as attention and 
disorganized thinking are difficult to detect by observation alone and may therefore 
be easily missed by nurses, explaining the relatively low specificity of this test (10). A 
combination of the CAM-ICU and ICDSC could enhance the performance of delirium 
detection, but this has not been investigated yet.
Apart from the screening tools, other ways to diagnose delirium would be helpful. 
We explored the possibility to detect specific markers for the diagnosis of delirium in 
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urine (using a proteomics technique), but were unable to find a specific fingerprint 
(11). This may be explained by the multifactorial pathogenesis of delirium (12-
14). Another interesting area that warrants further study is to examine whether 
electroencephalography (EEG) of delirious patients shows specific abnormalities. In 
patients suffering from sepsis-associated delirium specific EEG abnormalities have 
been observed (15) and similar abnormalities were found in small studies in medical 
and trauma patients with delirium as well (16). How these findings may facilitate 
delirium diagnosis needs to be further explored. Naturally it is not feasible to perform 
electroencephalography in all intensive care patients continuously. Perhaps, when 
typical EEG abnormalities for delirium are found, a specific EEG algorithm could 
be developed resulting in a less labor intensive EEG method that is more suitable 
to use in daily practice. Another approach to detect delirium in the future could 
be the development of a movement algorithm for motor activity patterns that 
may be typical for delirium (17-19). These patterns were recently studied using on-
body-accelerometers (20-25). Importantly, the used accelerometers, such as the 
Actiwatch, have the critical disadvantage that they only measure movements of 
one limb of the body. Video-based actigraphy monitoring may represent a more 
promising method because of the advantage that altered motions of the whole body 
can be detected and analysed without additional on-body sensors. Several studies 
have described the use of computer vision techniques to assess agitation in sedated 
(ICU) patients (26-28). Currently we are conducting a study with Philips Research 
to determine if it is possible to build an algorithm that analyses movements and 
thereby detect delirium using video camera observation.
To summarize, there are various options to improve the detection of delirium. 
First, to combine a screening tool with an observational assessment tool could 
improve sensitivity. The best option is likely to combine the CAM-ICU with the 
ICDSC and to determine the performance of the new tool compared to the CAM-
ICU alone. Importantly, this can be done relatively easy and fast, as both methods 
are currently used in daily practice. Second, to determine whether or not specific 
EEG abnormalities occur in ICU patients suffering from delirium. If so, an EEG 
algorithm and development of an electronic device with a limited amount of leads 
could make this technique feasible for daily clinical practice. Last, the development 
of an algorithm to automatically analyze movement, obtained by video actigraphy 
monitoring would be most feasible in daily ICU practice. It is expected that in 
the nearby future several possibilities to improve the detection of delirium will 
emerge that will improve the sensitivity and specificity of the diagnostic tools, 
and simultaneously will be less labor-intensive for caregivers than performing the 
current screening tests.
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Impact of Delirium in Intensive Care Patients
In chapter 5 we showed that delirium is associated with a poor outcome (29) and these 
findings confirm previous findings that delirium is associated with several important 
health consequences, such as prolonged duration of mechanical ventilation, ICU 
and hospital length of stay, higher incidence of re-intubations, accidental removal 
of tubes and catheters and ICU re-admissions (30-32). Furthermore, in chapter 5 
and 6 we determined that delirium is also associated with an increased mortality 
rate (29;33) which also confirms earlier findings (34;35). Despite the fact that our 
large cohort studies were performed in a single university hospital population, 
the comparability to earlier findings supports the generalizability of our findings. 
Except for one study (34), all previous studies adjusted for the severity of illness. 
However, most investigators, including us, used the Physiology and Chronic Health 
Evaluation-II (APACHE) score, which is a static severity of illness variable using 
only data collected within the first 24 hours after ICU admission. This implies that 
deterioration of patients’ health condition during his/her ICU stay is not taken into 
account. Whether poor outcome is a result of delirium or must be considered as 
an epiphenomenon of severity of illness needs to be studied more extensively, as 
without a dynamic severity of illness variable, it remains unclear if deterioration of 
patients’ health is directly due to the development of delirium or not. Therefore, we 
recommend to include a dynamic parameter such as the sequential organ failure 
assessment (SOFA) score (36) as a covariate in future delirium-associated outcome 
studies to obtain more insight in the course-effect relationship. As determined in 
chapter 6, adding delirium to the static mortality prediction model APACHE-II did 
not result in improvement of its performance (33) but it still needs to be studied if 
adding delirium to a dynamic model could improve its performance.  
Future research should also focus on radiological imaging of the brain in patients 
suffering from delirium. New techniques may be helpful to determine the relation 
between the severity of brain damage and delirium in general and more specific 
in its subtypes. Recently, a small study of eight patients showed lesions in the 
white matter of the brain using magnetic resonance imaging (MRI) techniques in 
ICU patients suffering from delirium (37). This is a first step that needs follow-up in 
more and larger studies. Imaging studies could be helpful to elucidate if short-term 
poor outcome is a direct result of brain damage related to delirium or is the result 
of secondary deterioration. In addition, imaging could also be useful in long-term 
follow-up studies. We demonstrated in chapter 7 that delirium is associated with 
long-term cognitive problems and that these problems are related to the duration 
of delirium (38). Although we did not take into account changes in disease severity 
over time, we did adjust for length of stay in the ICU as we assumed that this can be 
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considered as a surrogate measure for a dynamic severity of illness score. While we 
did not find differences in long-term health related quality of life (HRQoL) outcome 
between ICU survivors that suffered from delirium during their ICU stay and those 
who did not, it would be interesting to determine HRQoL more frequently over 
time once patients are discharged from the ICU. Other studies showed differences 
in HRQoL between delirious and non-delirious ICU survivors after 12 months (39) 
and recovery of cognition when measured over time (40). Our cognitive outcome 
results were in line with another cognitive impairment study (40), indicating that 
long-term cognitive impairment following ICU treatment is an issue of importance. 
Therefore, it would be of interest to obtain questionnaires immediately after ICU 
admission and repeatedly thereafter during follow-up to acquire more insight into 
the effects of delirium on the course of cognitive dysfunction over time. Since it 
is time consuming and may also be burdensome for the patient to use a validated 
self-evaluating cognitive questionnaire, the cognitive failure questionnaire (41) is a 
good alternative. To estimate the quality of life of a patient at ICU admission, it has 
been shown that patients’ relatives can reliably act as a surrogate to fill in a HRQoL 
questionnaire on behalf of the patient (42). For testing patients’ cognitive function 
at the time of ICU admission the Informant Questionnaire on Cognitive Decline-short 
form (IQCODE) (43) could be used for this purpose. Currently we are performing a 
long-term follow-up HRQoL study with repeated measurements starting immediately 
after ICU admission using the IQCODE and the CFQ during the follow-up.
Prediction and Prevention of Delirium in Intensive Care 
Patients
The short- and long-term consequences of ICU acquired delirium make adequate 
prevention imperative. The first step for effective prevention is to identify high risk 
patients. In chapter 8 we described the development and validation of a delirium 
prediction model (44). This prediction-of-delirium-in-ICU-patients (PREDELIRIC) 
model uses covariates that are readily available within 24 hrs following ICU 
admission and exerts a high predictive value, to predict delirium for the complete 
ICU length of stay. We validated this model in several hospitals in The Netherlands 
and showed that the predictive value remained good. However, due to treatment 
differences, generalizability to other countries is still not possible. At the moment 
we are therefore conducting an international validation study in several countries in 
Europe and also in Australia. Although the model is able to predict delirium 24 hours 
after ICU admission for the complete ICU stay, patients who develop delirium during 
the first day could therefore be missed with this model. An early prediction model 
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that predicts delirium immediately after ICU admission would be useful. Together 
with the international validation study we are also collecting data of important 
risk factors immediately after ICU admission to develop and to validate an ‘early 
prediction model’ (E-PREDELIRIC). Another point that needs to be addressed is 
that the PREDELIRIC model is a static model, meaning that the predicted chance to 
develop delirium does not change when patients’ condition deteriorates during the 
ICU admission. Adjustments of the PREDELIRIC model using early available factors 
and dynamic data during the ICU stay may further improve the predictive value of 
the model. 
After the PREDELIRIC model was developed and validated the model was 
implemented in our daily clinical practice. This enabled us to identify patients 
with a high risk for the development of delirium. We decided to use the model to 
standardize our delirium prevention policy and to treat patients with an estimated 
risk to develop delirium of 50% or more, and patients with a history of dementia or 
alcohol abuse with a low dose of haloperidol. We decided in advance to evaluate 
the results after one year. The effects were compared with a historical control group 
and a contemporary group of patients who did not receive haloperidol prophylaxis, 
mainly during the implementation phase. The results of this case control study are 
described in chapter 9 (45) showing beneficial effects of haloperidol prophylaxis 
and additionally confirming that the use of a delirium prediction model can help to 
identify high risk patients and focus our preventive measures on those patients that 
need it most. Unfortunately, the design of the study does not provide the highest 
level of evidence. The next step should be to confirm the results in a double-blinded 
randomized controlled trial in order to abandon possible bias, such as selection bias. 
Currently we are preparing this multicenter trial. Because, despite prophylaxis, the 
incidence of delirium was still rather high and given the few side-effects of low dose 
haloperidol, we are planning to also investigate the effect of a higher prophylactic 
dosage of haloperidol in a third arm of this trial. In the mean time, we are also 
developing a “delirium in intensive care app.” for smart phones and for the iPad to 
further facilitate use of the PREDELIRIC model in daily practice. 
Apart from pharmacological interventions, focus on non-pharmacological nursing 
interventions and on the ICU environment is also warranted. Concerning nursing 
interventions it has been shown that a program focusing on several risk factors, 
including cognitive impairment, sleep deprivation and immobility, resulted in a 
reduction of the delirium incidence and duration of delirium in non-ICU patients 
with a mediate or high risk for delirium (46). Nursing interventions aiming for early 
mobilization of mechanically ventilated intensive care patients resulted in a reduced 
duration of delirium (47). This promising area needs to be studied in ICU patients 
in the future. 
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Another interesting area that needs to be studied is the effect of restoring the 
circadian rhythm, since it is recognized that delirium is often accompanied by 
disruption of the sleep-wake cycle (18). Melatonin, a hormone that is produced in 
the pineal gland mainly during the night, plays an important role in the regulation 
of the sleep-wake cycle (48). Exogenous treatment with melatonin resulted in a 
reduction of delirium in elderly non-ICU patients (49), but its effectiveness in ICU 
patients is not sufficiently studied yet (50).  Another approach to affect the circadian 
pacemaker is the use of artificial light. Interestingly, it has been determined that in 
patients nursed in a room with a lack of daylight the chance to develop delirium 
is more than doubled (51). Artificially influencing the environmental light could 
therefore be effective in the prevention of delirium or reducing its negative effects 
on patients’ health. This interesting area needs to be studied in the ICU setting. At 
this moment we are studying the effect of applying artificial light on the delirium 
incidence and other delirium related outcome measures.
Role of Biomarkers related to Delirium in Intensive Care 
Patients
There is an acronym that is used to memorize the different causes of delirium: I 
WATCH DEATH (see textbox) of which the first letter ‘I’ stands for ‘Infection’. We 
showed that in patients with an infection present at the time of ICU admission the 
chances of becoming delirious are more than tripled compared to non-infectious 
patients (44). When the presence of infection during patients’ complete ICU 
admission is taken into account, the chance to develop delirium is even 18 times 
higher (52). 
Acronym ‘I watch Death’ for causes of Delirium
 Infections
 Withdrawal
 Acute metabolic diseases
 Trauma
 Central Nervous System
 Hypoxia  
 Deficiencies
 Endocrinopathies
 Acute Vascular
 Toxins or Drugs
 Heavy metals
I
W
A
T
C
H
D
E
A
T
H
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In chapter 10 we examined the role of systemic inflammation and the related 
increase in inflammatory biomarkers on brain function and cognition in the human 
endotoxemia model (53). Experimental endotoxemia results in both increases in 
inflammatory markers and in stress hormones (54). Therefore, the model could lead 
to stress hormone-related increased alertness, or to the first signs of encephalopathy 
as observed in septic patients. Although the human endotoxin model mimics the 
pathophysiological changes of septic patients in many ways (55-57), we showed that 
this short-term systemic inflammation model did not provoke the occurrence of 
septic encephalopathy. Therefore the model seems unsuitable to further study the 
onset of inflammation-induced delirium.
Administration of a high dosage of endotoxin in prion-diseased rodents resulted in 
delirium-like symptoms but this did not occur in rodents without a neurodegenerative 
disease (58). These results suggest that delirium predominantly occurs in inflamed 
patients with an underlying disease. 
In chapter 11 we studied the association of various markers of inflammation 
and brain specific proteins with delirium in patients in the presence or absence 
of infection/SIRS criteria and their relation to long-term cognitive function (59). 
While in other studies it was determined that several cytokines (60;61) and also the 
brain specific protein S100-β (a marker for astrocyte damage) (62) were associated 
with delirium, these studies were performed in non-ICU patients. In addition, no 
distinction was made between infectious and non-infectious delirious patients. 
Patients who suffered from delirium during their hospital stay have an increased risk 
for dementia on the long-term (63). This raises the question which one comes first; 
delirium as the first sign of a subclinical dementia syndrome, or dementia as a long-
term consequence of brain damage evoked by delirium. It is known that patients 
with dementia have increased plasma levels of some amyloidβ  forms (64-66) and 
increased levels of Tau/Aβ1-42 ratio in cerebrospinal fluid (67). We showed that it is 
relevant to distinguish between ICU patients with and without inflammation when 
studying the role of biomarkers in the development of delirium and its long-term 
cognitive consequences (59). 
We found that inflammatory markers were associated with delirium in ICU 
patients with clinical signs of infection/inflammation, while amyloidβ1-42/40 and 
the anti-inflammatory cytokine IL-10 was associated with delirium in patients 
without inflammation. In addition, elevated levels of amyloidβ were associated 
with long-term cognitive impairment while inflammatory markers were not. 
This could suggest that in patients with inflammation delirium is a result of the 
underlying inflammatory process while delirium in patients without inflammation 
may represent the first sign of a (subclinical) dementia syndrome. However, this 
complicated issue needs further investigation.
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Based on our results future research should focus on these relevant pro- and anti-
inflammatory cytokines and brain specific proteins in delirious patients with and 
without inflammation and measure these biomarkers at the time of ICU admission 
and serially over time. In addition, combined with serially measured cognitive 
function or even with radiological imaging, as suggested in part two of this chapter, 
this may further elucidate the mechanism of the onset of delirium and the long-
term consequences on cognitive functioning. 
Delirium in Intensive Care Patients
217
References
1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 4th ed. 
Washington D.C.: 1994.
2. Ely EW, Inouye SK, Bernard GR, Gordon S, Francis J, May L, et al. Delirium in mechanically ventilated 
patients: validity and reliability of the confusion assessment method for the intensive care unit (CAM-ICU). 
JAMA 2001 Dec 5;286(21):2703-10.
3. Ely EW, Margolin R, Francis J, May L, Truman B, Dittus R, et al. Evaluation of delirium in critically ill patients: 
validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). Crit Care Med 2001 
Jul;29(7):1370-9.
4. van den Boogaard M., Pickkers P., van der Hoeven J.G., Roodbol G., van Achterberg T., Schoonhoven L. 
Implementation of a delirium assessment tool in the ICU can influence haloperidol use. Crit Care 2009 Aug 
10;13(4):R131.
5. van Eijk MM, van den Boogaard M., van Marum RJ, Benner P, Eikelenboom P, Honing ML, et al. Routine Use 
of the Confusion Assessment Method for the Intensive Care Unit: A Multicenter Study. Am J Respir Crit Care 
Med 2011 May 11;184(3):340-4.
6. Reade MC, Eastwood GM, Peck L, Bellomo R, Baldwin I. Routine use of the Confusion Assessment Method 
for the Intensive Care Unit (CAM-ICU) by bedside nurses may underdiagnose delirium. Crit Care Resusc 2011 
Dec;13(4):217-24.
7. van Eijk MJ, van Marum RJ, Klijn I, de Wit N., Kesecioglu J, Slooter AJC. Comparison of delirium assessment 
tools in a mixed intensive care unit. Critical Care Medicine 2009;37(6):1881-5.
8. Inouye SK, Leo-Summers L, Zhang Y, Bogardus ST, Jr., Leslie DL, Agostini JV. A chart-based method for 
identification of delirium: validation compared with interviewer ratings using the confusion assessment 
method. J Am Geriatr Soc 2005 Feb;53(2):312-8.
9. Heymann A, Radtke F, Schiemann A, Lutz A, MacGuill M, Wernecke KD, et al. Delayed treatment of delirium 
increases mortality rate in intensive care unit patients. J Int Med Res 2010 Sep;38(5):1584-95.
10. Bergeron N, Dubois MJ, Dumont M, Dial S, Skrobik Y. Intensive Care Delirium Screening Checklist: evaluation 
of a new screening tool. Intensive Care Med 2001 May;27(5):859-64.
11. van den Boogaard M., van Swelm R.P., Russel F.G., Heemskerk S., van der Hoeven J.G., Masereeuw R., et al. 
Urinary protein profiling in hyperactive delirium and non-delirium cardiac surgery ICU patients. Proteome 
Sci 2011;9(9):13.
12. Flacker JM, Lipsitz LA. Neural mechanisms of delirium: current hypotheses and evolving concepts. J Gerontol 
A Biol Sci Med Sci 1999 Jun;54(6):B239-B246.
13. Maclullich AM, Ferguson KJ, Miller T, de Rooij SE, Cunningham C. Unravelling the pathophysiology of 
delirium: a focus on the role of aberrant stress responses. J Psychosom Res 2008 Sep;65(3):229-38.
14. van Gool WA, van de Beek D., Eikelenboom P. Systemic infection and delirium: when cytokines and 
acetylcholine collide. Lancet 2010 Feb 27;375(9716):773-5.
15. Ebersoldt M, Sharshar T, Annane D. Sepsis-associated delirium. Intensive Care Med 2007 Jun;33(6):941-50.
16. Plaschke K, Hill H, Engelhardt R, Thomas C, von HR, Scholz M, et al. EEG changes and serum anticholinergic 
activity measured in patients with delirium in the intensive care unit. Anaesthesia 2007 Dec;62(12):1217-23.
17. Bellelli G, Speciale S, Morghen S, Torpilliesi T, Turco R, Trabucchi M. Are fluctuations in motor performance a 
diagnostic sign of delirium? J Am Med Dir Assoc 2011 Oct;12(8):578-83.
18. Gupta N, de JJ, Schieveld J, Leonard M, Meagher D. Delirium phenomenology: what can we learn from the 
symptoms of delirium? J Psychosom Res 2008 Sep;65(3):215-22.
19. Meagher DJ, Moran M, Raju B, Gibbons D, Donnelly S, Saunders J, et al. Motor symptoms in 100 
patients with delirium versus control subjects: comparison of subtyping methods. Psychosomatics 2008 
Jul;49(4):300-8.
20. Godfrey A, Conway R, Leonard M, Meagher D, Olaighin GM. Motion analysis in delirium: a wavelet based 
approach for sub classification. Conf Proc IEEE Eng Med Biol Soc 2008;2008:3574-7.
General discussion, Conclusions, Future directives
12
218
21. Godfrey A, Conway R, Leonard M, Meagher D, Olaighin G. A classification system for delirium subtyping with 
the use of a commercial mobility monitor. Gait Posture 2009 Aug;30(2):245-52.
22. Godfrey A, Leonard M, Donnelly S, Conroy M, Olaighin G, Meagher D. Validating a new clinical subtyping 
scheme for delirium with electronic motion analysis. Psychiatry Res 2010 Jun 30;178(1):186-90.
23. Godfrey A, Conway R, Leonard M, Meagher D, Olaighin GM. Motion analysis in delirium: a discrete 
approach in determining physical activity for the purpose of delirium motoric subtyping. Med Eng Phys 2010 
Mar;32(2):101-10.
24. Leonard M, Godfrey A, Silberhorn M, Conroy M, Donnelly S, Meagher D, et al. Motion analysis in delirium: a 
novel method of clarifying motoric subtypes. Neurocase 2007 Aug;13(4):272-7.
25. Osse RJ, Tulen JH, Bogers AJ, Hengeveld MW. Disturbed circadian motor activity patterns in postcardiotomy 
delirium. Psychiatry Clin Neurosci 2009 Feb;63(1):56-64.
26. Becouze P, Hann CE, Chase JG, Shaw GM. Measuring facial grimacing for quantifying patient agitation in 
critical care. Comput Methods Programs Biomed 2007 Aug;87(2):138-47.
27. Chase JG, Agogue F, Starfinger C, Lam Z, Shaw GM, Rudge AD, et al. Quantifying agitation in sedated ICU 
patients using digital imaging. Comput Methods Programs Biomed 2004 Nov;76(2):131-41.
28. Gholami B, Haddad WM, Tannenbaum AR. Agitation and pain assessment using digital imaging. Conf Proc 
IEEE Eng Med Biol Soc 2009;2009:2176-9.
29. van den Boogaard M, Schoonhoven L, van der Hoeven J.G., van Achterberg T., Pickkers P. Incidence and 
short-term consequences of delirium in critically ill patients: a prospective observational cohort study. 
International Journal of Nursing Studies 2011;Accepted.
30. Dubois MJ, Bergeron N, Dumont M, Dial S, Skrobik Y. Delirium in an intensive care unit: a study of risk 
factors. Intensive Care Med 2001 Aug;27(8):1297-304.
31. Ely EW, Gautam S, Margolin R, Francis J, May L, Speroff T, et al. The impact of delirium in the intensive care 
unit on hospital length of stay. Intensive Care Med 2001 Dec;27(12):1892-900.
32. Ouimet S, Kavanagh BP, Gottfried SB, Skrobik Y. Incidence, risk factors and consequences of ICU delirium. 
Intensive Care Med 2007 Jan;33(1):66-73.
33. van den Boogaard M., Peters S.A., van der Hoeven J.G., Dagnelie P.C., Leffers P., Pickkers P., et al. The impact 
of delirium on the prediction of in-hospital mortality in intensive care patients. Crit Care 2010;14(4):R146.
34. Ely EW, Shintani A, Truman B, Speroff T, Gordon SM, Harrell FE, Jr., et al. Delirium as a predictor of mortality 
in mechanically ventilated patients in the intensive care unit. JAMA: Journal of the American Medical 
Association 2004 Jul 14;292(2):168-9.
35. Pisani MA, Kong SY, Kasl SV, Murphy TE, Araujo KL, Van Ness PH. Days of delirium are associated with 1-year 
mortality in an older intensive care unit population. Am J Respir Crit Care Med 2009 Dec 1;180(11):1092-7.
36. Vincent JL, De MA, Cantraine F, Moreno R, Takala J, Suter PM, et al. Use of the SOFA score to assess the 
incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. 
Working group on “sepsis-related problems” of the European Society of Intensive Care Medicine. Crit Care 
Med 1998 Nov;26(11):1793-800.
37. Morandi A, Gunther ML, Vasilevskis EE, Girard TD, Hopkins RO, Jackson JC, et al. Neuroimaging in delirious 
intensive care unit patients: a preliminary case series report. Psychiatry (Edgmont ) 2010 Sep;7(9):28-33.
38. van den Boogaard M., Schoonhoven L, Evers AW, van der Hoeven JG, van Achterberg T, Pickkers P. Delirium 
in critically ill patients: Impact on long-term health-related quality of life and cognitive functioning. Crit Care 
Med 2011 Sep 15.
39. Van Rompaey B., Schuurmans MJ, Shortridge-Baggett LM, Truijen S, Elseviers M, Bossaert L. Long term 
outcome after delirium in the intensive care unit. J Clin Nurs 2009 Dec;18(23):3349-57.
40. Girard TD, Jackson JC, Pandharipande PP, Pun BT, Thompson JL, Shintani AK, et al. Delirium as a predictor of 
long-term cognitive impairment in survivors of critical illness. Crit Care Med 2010 May 13;38(7):1513-20.
41. Broadbent DE, Cooper PF, FitzGerald P, Parkes KR. The Cognitive Failures Questionnaire (CFQ) and its 
correlates. Br J Clin Psychol 1982 Feb;21 (Pt 1):1-16.
42. Hofhuis J, Hautvast JL, Schrijvers AJ, Bakker J. Quality of life on admission to the intensive care: can we 
query the relatives? Intensive Care Med 2003 Jun;29(6):974-9.
Delirium in Intensive Care Patients
219
43. Jorm AF, Jacomb PA. The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): socio-
demographic correlates, reliability, validity and some norms. Psychol Med 1989 Nov;19(4):1015-22.
44. van den Boogaard M., Pickkers P., Slooter A.J.C., Kuiper M.A., Spronk P.E., van der Voort P.H.J., et al. PRE-
DELIRIC, PREdiction of DElirium in ICu patients; development and validation of a delirium prediction model 
for Intensive Care patients. BMJ 2011.
45. van den Boogaard M, Schoonhoven L, van Achterberg T., van der Hoeven J.G., Pickkers P. Effects of 
prophylactic use of haloperidol in critically ill patients with a high risk for delirium. Submitted 2011.
46. Inouye SK, Bogardus ST, Jr., Charpentier PA, Leo-Summers L, Acampora D, Holford TR, et al. A 
multicomponent intervention to prevent delirium in hospitalized older patients. N Engl J Med 1999 Mar 
4;340(9):669-76.
47. Schweickert WD, Pohlman MC, Pohlman AS, Nigos C, Pawlik AJ, Esbrook CL, et al. Early physical and 
occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial. Lancet 
2009 May 30;373(9678):1874-82.
48. Dahlitz M, Alvarez B, Vignau J, English J, Arendt J, Parkes JD. Delayed sleep phase syndrome response to 
melatonin. Lancet 1991 May 11;337(8750):1121-4.
49. Al-Aama T, Brymer C, Gutmanis I, Woolmore-Goodwin SM, Esbaugh J, Dasgupta M. Melatonin decreases 
delirium in elderly patients: a randomized, placebo-controlled trial. Int J Geriatr Psychiatry 2011 
Jul;26(7):687-94.
50. Bourne RS, Mills GH. Melatonin: possible implications for the postoperative and critically ill patient. 
Intensive Care Med 2006 Mar;32(3):371-9.
51. Van Rompaey B., Elseviers MM, Schuurmans MJ, Shortridge-Baggett LM, Truijen S, Bossaert L. Risk factors 
for delirium in intensive care patients: a prospective cohort study. Crit Care 2009 May 20;13(3):R77.
52. Aldemir M, Ozen S, Kara IH, Sir A, Bac B. Predisposing factors for delirium in the surgical intensive care unit. 
Crit Care 2001 Oct;5(5):265-70.
53. van den Boogaard M., Ramakers B.P., van Alfen N., van der Werf S.P., Fick W.F., Hoedemaekers C.W., et al. 
Endotoxemia-induced inflammation and the effect on the human brain. Crit Care 2010;14(3):R81.
54. Kox M, Stoffels M, Smeekens S.P, van Alfen N, Gomes M, Eijsvogels M.H, et al. The influence of 
concentration/meditation on autonomic nervous system activity and the innate immune response: a case 
study. Accepted 2011.
55. Heemskerk S, Pickkers P, Bouw MP, Draisma A, van der Hoeven JG, Peters WH, et al. Upregulation of renal 
inducible nitric oxide synthase during human endotoxemia and sepsis is associated with proximal tubule 
injury. Clin J Am Soc Nephrol 2006 Jul;1(4):853-62.
56. Pleiner J, Mittermayer F, Schaller G, Marsik C, MacAllister RJ, Wolzt M. Inflammation-induced 
vasoconstrictor hyporeactivity is caused by oxidative stress. J Am Coll Cardiol 2003 Nov 5;42(9):1656-62.
57. Suffredini AF, Fromm RE, Parker MM, Brenner M, Kovacs JA, Wesley RA, et al. The cardiovascular response 
of normal humans to the administration of endotoxin. N Engl J Med 1989 Aug 3;321(5):280-7.
58. Cunningham C, Campion S, Lunnon K, Murray CL, Woods JF, Deacon RM, et al. Systemic inflammation 
induces acute behavioral and cognitive changes and accelerates neurodegenerative disease. Biol Psychiatry 
2009 Feb 15;65(4):304-12.
59. van den Boogaard M, Kox M, Quinn K.L., van Achterberg T., van der Hoeven J.G., Schoonhoven L, et al. 
Biomarkers associated with delirium in critically ill patients and their relation with long-term subjective 
cognitive dysfunction; indications for different pathways governing delirium in inflamed and non-inflamed 
patients. Crit Care 2011;15(6):R297.
60. de Rooij SE, Van Munster BC, Korevaar J, Levi M. Cytokines and acute phase response in delirium. J 
Psychosom Res 2007 May;62(5):521-5.
61. Van Munster B.C., Korevaar J.C, Zwinderman AH, Levi M, Wiersinga WJ, de Rooij SE. Time-course of 
cytokines during delirium in elderly patients with hip fractures. J Am Geriatr Soc 2008 Sep;56(9):1704-9.
62. Van Munster B, Bisschop P, Zwinderman A, Korevaar J, Endert E, Wiersinga W, et al. Cortisol, interleukins 
and S100B in delirium in the elderly. Brain Cogn 2010;Epub ahead of print.
General discussion, Conclusions, Future directives
12
220
63. Witlox J, Eurelings LS, de Jonghe JF, Kalisvaart KJ, Eikelenboom P, van Gool WA. Delirium in Elderly Patients 
and the Risk of Postdischarge Mortality, Institutionalization, and Dementia: A Meta-analysis. JAMA 2010 Jul 
28;304(4):443-51.
64. Le Bastard N., Leurs J, Blomme W, De Deyn PP, Engelborghs S. Plasma amyloid-beta forms in Alzheimer’s 
disease and non-Alzheimer’s disease patients. J Alzheimers Dis 2010 Jan;21(1):291-301.
65. Pesaresi M, Lovati C, Bertora P, Mailland E, Galimberti D, Scarpini E, et al. Plasma levels of beta-amyloid (1-
42) in Alzheimer’s disease and mild cognitive impairment. Neurobiol Aging 2006 Jun;27(6):904-5.
66. van Oijen M., Hofman A, Soares HD, Koudstaal PJ, Breteler MM. Plasma Abeta(1-40) and Abeta(1-42) and the 
risk of dementia: a prospective case-cohort study. Lancet Neurol 2006 Aug;5(8):655-60.
67. Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM, Mach RH, et al. Cerebrospinal fluid tau and ptau(181) 
increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical 
trials of Alzheimer’s disease. EMBO Mol Med 2009 Nov;1(8-9):371-80.
Delirium in Intensive Care Patients
221
General discussion, Conclusions, Future directives
12

13
Summary
223
Summary
Delirium is a psycho-organic disorder with an acute onset, disturbances in 
consciousness and altered cognition. The term psycho-organic disorder implies 
that there is always a physical cause such as an infection, dehydration, electrolyte 
disturbances or renal failure, underlying the onset of delirium. Three subtypes of 
delirium are described: a hyperactive subtype with symptoms of hyperalertness or 
agitation, a hypoactive subtype featured with signs of hypoalertness or lethargy 
and the alternating or mixed subtype, characterized by alternating hyper- and 
hypoactive symptoms. 
This thesis has four main research aims that are addressed in separate parts: 
• To gain more insight into the diagnosis of delirium in ICU patients using the 
confusion assessment tool and to explore if delirium could be diagnosed with 
tools other than existing delirium assessment tools 
• To determine the impact of delirium on several short- and long-term health 
related consequences 
• To determine if delirium in intensive care patients can be predicted and 
prevented
• To explore the role of (inflammatory) biomarkers in delirium in ICU patients
In PART ONE we focussed on the Detection of Delirium in Intensive Care Patients. 
Following a general and background description of delirium in Chapter 1 we 
described a tailored strategy to implement the confusion assessment method- ICU 
(CAM-ICU) in our daily practice focused on potential barriers, using several evidence 
based implementation interventions in chapter 2. We evaluated our strategy and 
measured CAM-ICU compliance, interrater reliability, and delirium knowledge 
as measures for success. Furthermore we compared haloperidol use, as a proxy 
for delirium incidence, before and after the implementation. In four months, the 
CAM-ICU compliance, the delirium knowledge of the ICU-nurses, and the interrater 
reliability increased significantly. In addition, more patients were treated with 
haloperidol, however with a lower dose and for a shorter period of time. Our 
conclusion was that using this tailored implementation strategy, the CAM-ICU was 
successfully introduced in the ICU and the main goals were achieved rapidly. The 
observation that more patients were treated with haloperidol with a lower dose 
and for a shorter period of time following the successful implementation of the 
CAM-ICU suggests that delirium is detected in an earlier phase during which the 
patient is more sensitive to the treatment with haloperidol.
In Chapter 3 a multicentre study in the Netherlands was described examining the 
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performance of the CAM-ICU when used by ICU-nurses in daily practice. Two teams 
of three delirium experts including psychiatrists, geriatricians and neurologists 
visited ten ICUs. Based on cognitive examination, inspection of medical files and 
DSM-IV-TR criteria for delirium, the expert teams classified patients as awake and 
not delirious, delirious, or comatose. This served as ‘gold standard’. The CAM-ICU as 
performed by the bedside ICU-nurses in 181 patients was compared with the ‘gold 
standard’. We found a lower performance of the CAM-ICU compared to the original 
validation studies of the CAM-ICU. Although the specificity of the CAM-ICU in all 
participating ICUs was high, the sensitivity of the CAM-ICU was rather low and there 
were noticeable differences between the participating ICUs. Furthermore, when 
stratifying the data, the sensitivity was lowest in the hypoactive delirium subgroup, 
and the sensitivity was poor in neurocritical care patients. Our finding that the 
specificity of the CAM-ICU as performed in routine practice appears to be high, but 
that sensitivity is low hampers early detection of delirium by the CAM-ICU. 
In the last chapter of part one, Chapter 4, we described a prospective study in 
which we explored the possibility to find a fingerprint of delirium markers in the 
urine of patients following cardiac surgery using urinary proteomics. While urinary 
proteomics has successfully been applied to identify novel biomarkers associated 
with various disease states, its value in delirious patients was not investigated. For 
this study cardiac surgery ICU patients who suffered from hyperactive delirium 
were included and matched with non-delirium patients on relevant variables. 
Urine was collected within 24 hours after the onset of delirium. Matrix-assisted 
laser desorption/ionisation-time of flight mass spectrometry (MALDI-TOF MS) was 
applied to detect differences in the urinary proteome associated with delirium 
in these ICU patients. We included 10 hyperactive delirium and 10 meticulously 
matched non-delirium post-cardiac surgery patients, but no relevant differences in 
the urinary excretion of proteins were observed. We concluded that MALDI-TOF 
MS of urine does not reveal a clear hyperactive delirium proteome fingerprint in 
ICU patients.
PART TWO concentrated on the Impact of Delirium in Intensive Care Patients 
and in Chapter 5 we determined the overall delirium incidence and duration of 
delirium, per delirium subtype and per ICU admission diagnosis. Additionally, 
we determined the short-term consequences of delirium. In a large prospective 
observational study all adult consecutive patients admitted to our ICU during 
one year were included. Delirium was assessed using the CAM-ICU and divided 
in three subtypes: hyperactive, hypoactive and mixed subtype. As measures for 
short-term consequences we registered duration of mechanical ventilation, re-
intubations, incidence of unplanned removal of tubes, length of (ICU) stay and in-
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hospital mortality. In total 1,613 patients were included of whom 26% developed 
delirium. The incidence rates in the neurosurgical (10%) and cardiac surgery group 
(12%) were the lowest; incidence was higher in medical patients (40%) and highest 
in neurological patients (64%). The mixed subtype of delirium occurred most 
frequently and the hyperactive subtype had the lowest incidence in ICU patients. 
The median duration of delirium was two days and was significantly longer in the 
mixed subtype. Concerning short-term consequences, delirious patients were more 
likely to be mechanically ventilated and if so, for longer periods of time, and were 
more likely to remove their tubes and catheters. Also, they stayed in the ICU and 
hospital for a longer time, and had a six times higher chance of dying compared to 
non-delirious ICU patients, even after adjusting for their severity of illness score. 
We concluded that the delirium incidence in a mixed ICU population is high and 
differs importantly between ICU admission diagnoses and the subtypes of delirium. 
Patients with delirium had a significantly higher incidence of short-term health 
problems, independent of their severity of illness and this was most pronounced in 
the mixed subtype of delirium. 
In Chapter 6 we examined if adding delirium, present within 24 hours after ICU 
admission, as an additional variable to the acute physiology and chronic health 
evaluation (APACHE-II) score, would improve the predictive estimate of the model. 
In this prospective cohort study 2,116 adult patients were screened for delirium and 
1,740 patients were included for analysis of whom  332 (19%) were delirious at the 
time of ICU admission or within 24 hours after admission. We found that delirium 
was significantly associated with in-hospital mortality. However, the predictive 
accuracy of the APACHE-II did not improve after adding delirium, both in the total 
group as well as in the subgroup excluding cardiac surgery patients. We concluded 
that, although delirium is a significant predictor of mortality in ICU patients, adding 
delirium as an additional variable to the APACHE-II model does not improve its 
predictive estimate.
In Chapter 7 we examined the impact of delirium on long-term health related 
quality of life (HRQoL) and cognitive functioning of ICU survivors. In this prospective 
follow-up study at a median of 18 months after ICU discharge, HRQoL questionnaires 
were sent to 1292 ICU survivors with (21%) and without (79%) delirium during their 
ICU stay. We used the short form-36v1 (SF-36), checklist individual strength (CIS-)
fatigue and cognitive failure questionnaire (CFQ) to measure patients’ perceived 
HRQoL and cognitive functioning. A total of 915 (71%) patients responded, of which 
171 (19%) patients suffered from delirium during their ICU stay. After adjusting for 
covariates, no differences were found between delirium and non-delirium survivors 
in the SF-36 and CIS-fatigue scores. However, survivors who had suffered from 
delirium reported that they made significantly more social blunders and their 
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overall cognitive function was significantly impaired compared to survivors who had 
not been delirious. Survivors of mixed type and hyperactive delirium performed 
significantly worse on the domain mental health compared to the hypoactive 
delirium subtype patients. Furthermore, we found that the duration of delirium was 
significantly correlated to problems with memory and remembering names. In this 
study we concluded that ICU survivors who suffered from delirium during their ICU 
stay have a similar adjusted health related quality of life evaluation, but significantly 
more cognitive problems than those who did not suffer from delirium, even after 
adjusting for relevant covariates. In addition, the duration of delirium is related to 
long-term cognitive problems.
In PART THREE we focused on the Prediction and Prevention of Delirium in Intensive 
Care Patients and in Chapter 8 we described the development and validation of 
a delirium prediction model for ICU patients. In this prospective study the model 
was developed in our hospital and subsequently validated in five intensive care 
units in the Netherlands (two university hospitals and three university-affiliated 
teaching hospitals). In this large study more than 3,000 patients were evaluated. 
The developed model consists of ten predictors that are readily available within the 
first 24 hours after patients’ ICU admission. The developed prediction of delirium 
in ICU (PRE-DELIRIC) model showed a good performance, which remained good 
during the temporal and the external validation. Interestingly, the prediction of 
attending nurses’ and physicians’ was significantly less adequate compared with 
the PRE-DELIRIC model, illustrating the additional value of the model. The model 
allows for early delirium prediction and the initiation of preventive measures. The 
prediction model was then integrated in our patient data management system and 
implemented in our daily clinical practice. 
In Chapter 9 we evaluated the effects of prophylactic treatment of delirium 
using a low dose of haloperidol in ICU patients with a high (≥50%) predicted risk 
for delirium using the PRE-DELIRIC model, or ICU patients with a history of alcohol 
abuse or dementia. Primary outcome measures were delirium incidence, delirium 
free days without coma and 28-day mortality. Results of prophylactic treatment 
were compared with a historical control group and a contemporary group that did 
not receive haloperidol prophylaxis mainly due to non-compliance to the protocol 
during the implementation phase. We prospectively decided to evaluate our 
policy after 12 months. After 1 year, a total of 177 patients received prophylactic 
haloperidol treatment. The historical control group consisted of 299 patients and the 
contemporary group that was not preventively treated with haloperidol consisted 
of 59 patients. Delirium prophylaxis with haloperidol resulted in a significantly lower 
delirium incidence and more delirium free days. Cox-regression analysis adjusted 
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for sepsis showed a relative reduction of 20% of 28-day mortality in patients 
who received prophylactic treatment with haloperidol. Furthermore, haloperidol 
prophylaxis resulted in less ICU re-admissions and unplanned removal of tubes/
lines. The 59 patients who were not treated during the intervention period showed 
similar results compared to the untreated control group, further substantiating 
these beneficial effects of haloperidol. Few side-effects were reported, all of which 
were evaluated not severe. We concluded that prophylactic treatment with low 
dose haloperidol in patients with a high risk for delirium exerts several beneficial 
effects. 
In the last part of this thesis, PART FOUR, we examined the Role of Biomarkers 
related to Delirium in Intensive Care Patients. In Chapter 10 we studied the effects 
of inflammation on brain function and cognitive function during experimental 
human endotoxemia. In 15 healthy male volunteers we measured levels of several 
cytokines, cortisol and brain specific proteins (BSP), the electroencephalography 
(EEG) changes and cognitive function tests (CFTs) prior to and during endotoxemia. 
The administration of 2 ng/kg E. Coli endotoxin resulted in a significant increase 
of circulating pro- and anti-inflammatory cytokines, and cortisol. The measured 
BSP remained within the normal range, but a statistically significant change in 
neuron specific enolase (NSE) and S100-β changed was observed. Quantitative EEG 
analysis showed a higher state of alertness which was related to the increase of 
cortisol. The observed CFTs changes during endotoxemia were found to be due to a 
practice effect. Furthermore we found that several biomarkers were correlated with 
improvement of some cognitive functions, i.e. of working memory and psychomotor 
speed capacity. No other significant correlations between cytokines, cortisol, EEG, 
CFT and BSP were found. We concluded that short-term systemic inflammation 
does not provoke or explain the occurrence of septic encephalopathy, but primarily 
results in an inflammation-mediated increase in cortisol and alertness.
In Chapter 11 we determined plasma biomarkers in delirious and non-delirious 
ICU patients and examined the role of these biomarkers on long-term cognitive 
function to improve our insight in the relation between these markers and delirium.
In this exploratory observational study, ICU patients with or without delirium 
were divided in groups with (“inflamed”) or without (“non-inflamed”) evidence 
of an infection/SIRS to further elucidate the role of systemic inflammation. Within 
24 hours following the onset of delirium, blood was obtained for biomarker 
analysis and in non-delirious patients we draw blood after a similar ICU length of 
stay compared to the group of delirious patients. Furthermore, 18 months after 
ICU discharge, a cognitive failure questionnaire (CFQ) was distributed to the ICU 
survivors. In this study 50 delirious and 50 non-delirious patients were included. 
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In inflamed delirious patients the proinflammatory cytokine interleukin (IL)-8 was 
independently associated with delirium, while IL-10 and amyloidβ1-42/40 were 
associated with non-inflamed delirious patients, as determined with multivariate 
regression analysis. Furthermore, levels of several amyloidβ forms, but not pro-
inflammatory cytokines, human Tau or S100-β, were significantly correlated with 
self reported cognitive impairment 18 months after ICU discharge. These results 
suggest that proinflammatory cytokines are involved in the development of delirium 
in inflamed patients without long-term cognitive consequences, while amyloidβ is 
related to delirium in non-inflamed patients and associated with impaired cognitive 
functioning in the long-term. The results further support that the underlying 
mechanisms governing the development of delirium in inflamed patients differ from 
those in non-inflamed patients. The fact that elevated levels of amyloid-β correlated 
with long-term cognitive impairment suggests that development of delirium in non-
inflamed patients may represent the first sign of a (subclinical) dementia process, 
but this needs to be confirmed in further studies.
In the final Chapter 12 we summarized our findings and discussed the results of 
this thesis in view of several methodological issues and we elaborated on the clinical 
consequences of our results and aims for future research. 
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Delirium is een psycho-organische stoornis met een acuut begin gepaard gaande 
met bewustzijnstoornissen en een veranderde cognitie waarbij de verschijnselen 
kunnen fluctueren over de dag. De term psycho-organische stoornis houdt in 
dat er altijd een lichamelijke oorzaak zoals een infectie, dehydratie, verstoorde 
elektrolytenbalans of nierfalen, aan ten grondslag ligt aan het delirium. 
We onderscheiden drie subtypen van delirium: een hyperactief subtype met 
symptomen van hyperalertheid of agitatie, een hypoactief subtype gekenmerkt 
door tekenen van hypoalertheid of lethargie en het gemengde subtype waarbij de 
hyper- en hypoactieve symptomen elkaar afwisselen.
Dit proefschrift had vier onderzoeksdoelen die werden behandeld in afzonderlijke 
delen:
• Verkrijgen van meer inzicht in de diagnose delirium bij intensive care (IC-)
patiënten gebruikmakend van het delirium screeningsinstrument de 
‘Confusion Assessment Method-ICU’ (CAM-ICU) en het onderzoeken of de 
diagnose delirium op een andere manier kan worden vastgesteld
• Vaststellen van de impact van delirium op verschillende korte- en lange 
termijn gezondheidsconsequenties 
• Bepalen of delirium bij de IC-patiënten kan worden voorspeld en kan worden 
voorkomen
• Onderzoek naar de rol van (ontsteking) biomarkers bij IC-patiënten met 
delirium 
In DEEL EEN hebben we ons gericht op de Detectie van Delirium bij Intensive 
Care Patiënten. Na een algemene en achtergrond beschrijving van delirium in 
Hoofdstuk 1 beschrijven we in Hoofdstuk 2 de implementatie van een op maat 
gemaakte strategie om de CAM-ICU in onze dagelijkse praktijk in te voeren. Deze 
strategie richtte zich op potentiële belemmeringen waarbij we gebruik hebben 
gemaakt van verschillende evidence based implementatie interventies. We 
evalueerden onze strategie aan de hand van de compliantie aan de CAM-ICU, de 
interbeoordelaarsbetrouwbaarheid, en kennis op het gebied van delirium van de 
IC-verpleegkundige als maat voor succes. Verder hebben we gekeken naar het 
effect van het gebruik van de CAM-ICU op het haloperidol gebruik, welke diende 
als vervangende maat voor de deliriumincidentie, voor en na de implementatie. 
In vier maanden was de compliantie aan de CAM-ICU, de kennis op het gebied 
van delirium en de interbeoordelaarbetrouwbaarheid significant toegenomen. 
Daarnaast stelden we vast dat meer patiënten behandeld werden met haloperidol, 
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maar voor een kortere periode en met een lagere dosering. Onze conclusie was 
dat het gebruik van deze op maat gemaakte implementatiestrategie heeft geleid 
tot een succesvolle introductie van de CAM-ICU in onze IC-praktijk en dat de 
belangrijkste doelstellingen snel waren bereikt. De observatie dat meer patiënten 
met haloperidol werden behandeld, maar met een lagere dosis en voor een kortere 
tijd na de succesvolle implementatie van de CAM-ICU suggereert dat delirium eerder 
werd gedetecteerd in een fase waarin de patiënt gevoeliger is voor de behandeling 
met haloperidol.
In Hoofdstuk 3 beschrijven we een multicenter studie uitgevoerd op tien IC-
afdelingen in Nederland waarbij onderzocht werd in welke mate de CAM-ICU 
delirium bij de patient kon vaststellen wanneer deze wordt gebruikt door IC-
verpleegkundigen in de dagelijkse praktijk. Twee teams van drie delirium experts 
waaronder psychiaters, geriaters en neurologen bezochten de tien intensive 
care afdelingen twee keer. Op basis van cognitief onderzoek, het bestuderen van 
de medische dossiers en door gebruik te maken van de DSM-IV-TR criteria voor 
delirium, werden de patiënten door de expert teams aangemerkt als patiënten die 
wakker zijn en niet delirant, delirant, of comateus. Deze beoordeling diende als 
‘goud standaard’ voor de diagnose delirium. De CAM-ICU uitgevoerd door de IC-
verpleegkundigen bij 181 patiënten werd op deze manier vergeleken met deze ‘goud 
standaard’. De CAM-ICU, wanneer gebruikt door IC-verpleegkundigen, presteerde 
duidelijk minder goed dan in de oorspronkelijke validatie studies uitgevoerd door 
onderzoeksverpleegkundigen. Hoewel de specificiteit van de CAM-ICU bij alle 
deelnemende centra hoog was, bleek de sensitiviteit van de CAM-ICU laag te zijn 
en er waren opvallende verschillen tussen de deelnemende centra. Bovendien, 
wanneer de data werden gestratificeerd bleek dat de sensitiviteit het laagst was 
in de hypoactieve delirium subgroep en de sensitiviteit was slecht in groep van 
neurologie patiënten. Onze bevinding dat de specificiteit van de CAM-ICU, zoals 
gebruikt in de dagelijkse praktijk, hoog lijkt te zijn, maar dat de sensitiviteit laag is 
belemmert vroege detectie van delirium door de CAM-ICU.
In het laatste hoofdstuk van deel één, Hoofdstuk 4, beschrijven we een prospectieve 
studie waarin we de mogelijkheid hebben onderzocht om een ‘fingerprint’ van 
delirium markers te vinden in de urine van de patiënten na een hartoperatie met 
behulp van urineproteomics. Hoewel urineproteomics onderzoek eerder met 
succes werd toegepast om nieuwe biomarkers te identificeren die geassocieerd 
zijn met diverse andere ziektebeelden, werd de waarde hiervan bij delirante IC-
patiënten nog niet eerder onderzocht. Voor dit onderzoek werden IC-patiënten 
die na een hartoperatie een hyperactief delirium hadden ontwikkeld geïncludeerd 
en vergeleken met niet-delirante IC-patiënten na een hartoperatie. Urine werd 
verzameld binnen 24 uur na het ontstaan van het delirium. Matrix-assisted laser 
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desorptie/ionisatie-time of flight massaspectrometrie (MALDI-TOF MS) techniek 
werd toegepast om verschillen in de eiwituitscheiding in de urine te detecteren 
die mogelijk geassocieerd waren met delirium bij IC-patiënten. We includeerden 
10 hyperactief delirium patiënten en 10 vergelijkbare niet-delirum patiënten na 
een hartchirurgische operatie. Er werden geen relevante verschillen in de urinaire 
excretie van eiwitten waargenomen. We concludeerden dat, gebruikmakend van de 
MALDI-TOF MS techniek, geen duidelijk hyperactief deliriumproteoom ‘fingerprint’ 
in de urine van IC-patiënten aantoonbaar is.
DEEL TWEE concentreerde zich op de Impact van Delirium bij Intensive Care 
Patiënten en in Hoofdstuk 5 hebben we de incidentie en duur van delirium 
vastgesteld, per delirium subtype en per IC opnamediagnose. Daarnaast hebben 
we de korte termijn gevolgen van delirium onderzocht. In een grote prospectieve 
observationele studie werden alle volwassen IC-patiënten geïncludeerd die 
gedurende één jaar werden opgenomen op onze IC afdeling. Delirium werd 
vastgesteld met de CAM-ICU en patiënten met een delirium werden ingedeeld 
in hyperactief, hypoactief of in het gemengde delirium subtype. Als maat voor de 
korte termijn gevolgen gebruikten we de duur van de mechanische beademing, de 
incidentie van re-intubaties, incidentie van onbedoeld verwijderen van tubes en 
katheters, opnameduur op de IC en in het ziekenhuis, en de ziekenhuismortaliteit. 
In totaal werden 1613 patiënten geïncludeerd, waarvan 26% een delirium 
ontwikkelde tijdens de IC-periode. De incidentie in de groep neurochirurgische 
patiënten (10%) en hartchirurgische patiënten (12%) was het laagst; de incidentie 
was hoger in de groep medische patiënten (40%) en het hoogst in de groep 
neurologie patiënten (64%). Het gemengde delirium subtype kwam bij IC-patiënten 
het meest frequent voor en het hyperactieve subtype het minst. De mediane 
duur van delirium was twee dagen en de duur was significant langer in de groep 
patiënten met het gemengde delirium subtype. Wat betreft de korte termijn 
gevolgen stelden we vast dat mechanische beademing bij deliriumpatiënten vaker 
noodzakelijk was, de beademingsduur langer was en deze patiënten vaker tubes 
en katheters verwijderden. Ook was de opnameduur op de IC en in het ziekenhuis 
langer en patiënten met een delirium hadden, na correctie voor ziekte-ernst, een 
zes keer grotere kans te overlijden vergeleken met niet-delirante IC-patiënten. We 
concludeerden dat de deliriumincidentie op een gemengde IC afdeling hoog is en 
verschilt per IC opnamediagnose en per delirium subtype. Patiënten met delirium 
hadden significant meer last van nadelige korte termijn gevolgen, onafhankelijk van 
de ziekte-ernst. Dit was het meest uitgesproken voor het gemengde subtype van 
het delirium.
In Hoofdstuk 6 onderzochten we of het toevoegen van de diagnose delirium, 
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aanwezig binnen 24 uur na IC opname, als een extra variabele aan de ziekte-ernst 
score, de APACHE-II, de nauwkeurigheid van de sterfteschatting van de APACHE-II 
zou kunnen verbeteren. In deze prospectieve cohort studie werden 2116 volwassen 
patiënten gescreend op delirium en 1740 patiënten werden geïncludeerd voor 
analyse. Hiervan waren 332 (19%) patiënten al delirant tijdens de opname op de 
IC of binnen 24 uur na IC opname. Wij stelden vast dat delirium significant was 
geassocieerd met ziekenhuissterfte. Echter, de voorspellende waarde van de 
APACHE-II verbeterde niet na toevoegen van delirium, zowel in de totale groep 
patiënten als in de subgroep zonder cardiochirurgische patiënten. We kwamen tot 
de conclusie dat, hoewel delirium een significante voorspeller is van sterfte bij IC-
patiënten, het toevoegen van delirium als een extra variabele aan het APACHE-II 
model, de voorspellende waarde van het model niet verbeterde. 
In Hoofdstuk 7 onderzochten we de impact van delirium op de lange termijn 
gezondheidsgerelateerde kwaliteit van leven en het cognitief functioneren van de 
IC- overlevenden. In deze prospectieve follow-up studie werden na een mediane 
duur van 18 maanden na IC ontslag, kwaliteit van leven vragenlijsten verstuurd naar 
1292 IC overlevenden waarvan 21% met, en 79% zonder delirium tijdens hun IC 
opname. We gebruikten de SF-36v1 (SF-36) vragenlijst, de CIS-vermoeidheid en de 
CFQ (cognitieve vragenlijst) om de door de patiënten ervaren kwaliteit van leven en 
hun cognitief functioneren te evalueren. In totaal reageerden 915 (71%) patiënten, 
waarvan er 171 (19%) patiënten delirant waren geweest tijdens de IC opname. Na 
correctie voor verschillende covariabelen, werden geen verschillen gevonden tussen 
delirium en niet-delirium overlevenden in de SF-36 en de CIS-vermoeidheid scores. 
Echter, overlevenden die een delirium hadden doorgemaakt meldden significant 
vaker dat ze vergissingen op sociaal gebied maakten en hun algemene cognitieve 
functie was significant slechter in vergelijking met overlevenden die niet delirant 
waren geweest tijdens de IC-opname. Overlevenden die een gemengd of een 
hyperactief subtype delirium hadden doorgemaakt scoorden aanzienlijk slechter 
op het domein geestelijke gezondheid in vergelijking met de overlevenden na een 
hypoactief delirium subtype. Verder vonden we dat de duur van een delirium sterk 
was gecorreleerd met geheugenproblemen en het onthouden van namen. In deze 
studie concludeerden we dat de IC overlevenden die delirant waren geweest tijdens 
hun IC opname een vergelijkbare score hadden op de  kwaliteit van leven, maar 
hadden aanzienlijk meer cognitieve problemen dan degenen die niet delirant waren 
geweest, ook na correctie voor relevante covariabelen. Daarnaast was de duur van 
het delirium gerelateerd met de lange termijn cognitieve problemen.
In DEEL DRIE hebben we ons gericht op de Voorspelling en Preventie van Delirium 
bij Intensive Care Patiënten en in Hoofdstuk 8 beschrijven we de ontwikkeling en 
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validatie van een delirium predictiemodel voor IC-patiënten. In een prospectieve 
studie werd het model  ontwikkeld in ons ziekenhuis en vervolgens gevalideerd op 
vijf intensive care units (twee universitaire ziekenhuizen en drie grote regionale 
ziekenhuizen) in Nederland. In deze grote studie werden ruim 3000 patiënten 
geïncludeerd. Het ontwikkelde model bestaat uit tien voorspellers/predictors die 
eenvoudig beschikbaar zijn binnen 24 uur na IC-opname. Het IC delirium predictie 
(PRE-DELIRIC) model had bij de ontwikkeling ervan een goede voorspellende waarde, 
die goed bleef tijdens de interne en de externe validatie. Interessant is dat de 
voorspelling van de zorgverleners (verpleegkundigen en artsen) significant minder 
goed was in vergelijking met het PRE-DELIRIC model, wat aantoont dat het model 
van toegevoegde waarde is. Het model zorgt voor een vroege deliriumvoorspelling 
en het kunnen initiëren van preventieve maatregelen. Het PRE-DELIRIC model 
werd vervolgens geïntegreerd in ons patiënt-data-management-systeem en 
geïmplementeerd in onze dagelijkse klinische praktijk.
In Hoofdstuk 9 onderzochten we de effecten van delirium profylaxe met een 
lage dosis haloperidol bij IC-patiënten met een voorspelt hoog risico (≥ 50%) op 
het ontwikkelen van delirium zoals vastgesteld met het PRE-DELIRIC model, en IC-
patiënten met een voorgeschiedenis van alcoholmisbruik of dementie. Primaire 
uitkomstmaten waren optreden van delirium, aantal deliriumvrije dagen zonder 
coma, en 28-dagen mortaliteit. De resultaten van profylactische behandeling 
met haloperidol werden vergeleken met een historische controlegroep en 
een groep patiënten die geen haloperidol profylaxe hadden gehad tijdens 
de interventieperiode, wat vooral te wijten was aan het niet naleven van het 
preventieprotocol tijdens de implementatiefase. Vooraf werd afgesproken het 
preventiebeleid na 12 maanden te evalueren. In totaal werden 177 patiënten 
profylactische behandeld met haloperidol. De historische controlegroep bestond 
uit 299 patiënten en de niet preventief behandelde interventiegroep bestond uit 59 
patiënten. Deliriumprofylaxe met haloperidol resulteerde in een significant lagere 
deliriumincidentie en toename van het aantal deliriumvrije dagen. Cox-regressie 
analyse, gecorrigeerd voor sepsis, liet een relatieve mortaliteitsreductie zien van 
20% op de 28-dagen mortaliteit bij patiënten die profylactisch waren behandeld 
met haloperidol. Bovendien resulteerde haloperidol profylaxe tot minder IC 
heropnames en onbedoeld verwijderen van tubes en katheters. De 59 patiënten die 
niet preventief werden behandeld tijdens de interventieperiode lieten vergelijkbare 
resultaten zien als de onbehandelde controle groep, hetgeen suggereert dat de 
positieve effecten vastgesteld in de behandelde groep veroorzaakt worden door het 
preventief behandelen met haloperidol en niet door een tijdsafhankelijke invloed. 
Er werden weinig bijwerkingen gemeld, die bovendien allemaal als niet ernstig 
werden geëvalueerd. We concludeerden dat profylactische behandeling met een 
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lage dosis haloperidol bij patiënten met een hoog risico op delirium resulteert in 
vooral gunstige effecten.
In het laatste deel van dit proefschrift, DEEL VIER, onderzochten we de Rol van 
Biomarkers gerelateerd aan Delirium bij Intensive Care Patiënten. In Hoofdstuk 10 
hebben we de effecten bestudeerd van een ontsteking op de hersenfunctie en 
de cognitieve functie tijdens experimentele endotoxinemie bij mensen. Bij 15 
gezonde mannelijke vrijwilligers hebben we waarden bepaald van verschillende 
ontstekingseiwitten (cytokines), het stress-hormoon cortisol en enkele 
hersenspecifieke eiwitten (HSE), de elektro-encefalografie (EEG) veranderingen en 
cognitieve functietesten (CFT’s) voorafgaand aan, en tijdens de endotoxinemie. De 
toediening van 2 ng/kg E. Coli endotoxine resulteerde in een significante stijging 
van de circulerende pro-en anti-inflammatoire cytokines en het cortisol. De 
gemeten HSE bleven allen binnen de normaal waarde, maar er was een statistisch 
significante verandering te zien van het neuron specifiek enolase (NSE) en S100-β. 
Kwantitatieve EEG analyse liet een verhoogde staat van alertheid zien, die was 
gerelateerd aan de toename van het cortisol. De waargenomen CFT’s veranderingen 
tijdens endotoxinemie bleken te worden veroorzaakt door een leereffect. Verder 
vonden we dat een aantal biomarkers waren gecorreleerd met verbetering 
van een aantal cognitieve functies, dat wil zeggen met het werkgeheugen en 
psychomotorische snelheid van reageren. Er werden geen andere significante 
correlaties tussen cytokines, cortisol, EEG, CFT en HSE gevonden. We concludeerden 
dat de kortdurende systemische ontsteking geen septische encephalopathie 
kon provoceren of het ontstaan ervan kon verklaren, maar dat de kortdurende 
systemische ontsteking vooral resulteerde in een ontsteking-gemedieerde toename 
van cortisol en alertheid.
In Hoofdstuk 11 hebben we biomarkers in bloedplasma bepaald bij delirante en 
niet delirante IC-patiënten en onderzochten we de rol van deze biomarkers op 
lange termijn cognitieve functies, om ons inzicht te verbeteren in de relatie tussen 
deze markers en delirium. In deze exploratieve observationele studie werden de 
IC-patiënten met of zonder delirium verdeeld in groepen met (“inflammatie”) of 
zonder (“niet-inflammatie”) aanwijzingen van een infectie/ontsteking om verder de 
rol van een systemische ontsteking te ontrafelen. Binnen 24 uur na het ontstaan 
van het delirium, werd bloed afgenomen voor analyse van biomarkers en van niet-
delirante patiënten werd bloed afgenomen na een vergelijkbare IC opnameduur 
als die van de patiënten met een delirium. Verder werd, 18 maanden na IC ontslag, 
een Cognitive Failure Questionnaire (CFQ) toegezonden aan de overlevenden. In 
deze studie werden 50 delirante en 50 niet-delirante IC-patiënten geïncludeerd. 
Bij de deliriumpatiënten met inflammatie was het pro-inflammatoire cytokine 
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interleukine (IL)-8 onafhankelijk geassocieerd met het optreden van delirium, terwijl 
IL-10 en amyloidβ 1-42/40 waren geassocieerd met delirium bij patiënten zonder 
inflammatie, beide bepaald middels multivariaat regressie analyse. Verder waren 
de waarden van verschillende amyloidβ vormen (maar niet de pro-inflammatoire 
cytokines, het menselijke Tau of S100-β) significant gecorreleerd met zelf-
gerapporteerde cognitieve stoornissen, 18 maanden na IC ontslag. Deze resultaten 
suggereren dat pro-inflammatoire cytokines betrokken zijn bij de ontwikkeling 
van het delirium bij patiënten met inflammatie en dat dit geen lange termijn 
cognitieve gevolgen veroorzaakt, terwijl amyloïdeβ is gerelateerd aan delirium 
bij patiënten zonder inflammatie geassocieerd met een verminderd cognitieve 
functioneren op de lange termijn. Deze resultaten ondersteunen het idee dat de 
onderliggende mechanismen van de ontwikkeling van delirium bij IC-patiënten met 
inflammatie anders is vergeleken met IC-patiënten zonder inflammatie. Het feit 
dat de verhoogde waarden van amyloidβ correleert met lange termijn cognitieve 
stoornissen suggereert dat de ontwikkeling van het delirium bij patiënten zonder 
inflammatie het eerste teken kan zijn van een (subklinisch) dementieel proces, 
maar dit moet bevestigd worden in vervolgstudies.
In het laatste Hoofdstuk 12 hebben we onze bevindingen samengevat en de 
resultaten van dit proefschrift besproken in het licht van een aantal methodologische 
zaken en zijn we ingegaan op de klinische consequenties van onze resultaten en 
doelen voor toekomstig onderzoek.
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List of abbreviations
Aβ1-42/40 Amyloidβ 1-42 and 1-40
AβN-42/40 Amyloidβ truncated-42 and 1-40
AD Alzheimer disease
APACHE-II Acute physiology and chronic health evaluation-II
AUC Area under the receiver operating characteristics curve
BSP Brain specific proteins
CABG Coronary artery bypass graft
CAM-ICU Confusion assessment method – intensive care unit
CF Cognitive function
CFQ Cognitive failure questionnaire
CI Confidence interval
CRP C-reactive protein
CSF Cerebrospinal fluid
DSM-IV Diagnostic and statistical manual of mental disorders-IV
EEG Electroencephalography
GFAP Glial fibrillary acidic protein
HL-test Hosmer-Lemeshow test
HNP Human neutrophil protein-1
IQCODE-sf Informant questionnaire on cognitive decline short form
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IQR Interquartile range
IL Interleukin
LPS Lipopolysaccharide
MALDI-TOF MS Matrix assisted laser desorption / ionisation time of flight mass 
 spectrometry
MCP Monocytes chemotactic protein-1
MDRD-GFR Modification of diet in renal disease – glomerular filtration rate
MIF Macrophage migration inhibitory factor
NSE Neurospecific enolase
OR Odds ratio
PASAT Paced auditory serial addition test
RASS Richmond agitation sedation score
S100-β S100 calcium binding protein-β
SDT Digit symbol test
SIRS Systemic inflammatory response syndrome
SOFA Sequential organ failure assessment
STAI State trait anxiety inventory
TNF-α Tumor necrosis factor-α
WAIS-III Wechsler adult intelligence scale III
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Dankwoord
Na ruim vier jaar noeste arbeid kan het hoofdstuk promoveren worden afgesloten. 
Het is een leuke, interessante en vooral leerzame weg geweest. Maar deze weg 
bewandel je nooit alleen. En dat kan ook niet. Hierbij word je begeleid en gesteund 
(direct en indirect) door vele mensen met ieder hun eigen inbreng en bijdrage. Hun 
bijdrage is voor mij altijd zeer waardevol geweest. Hoewel ik dit misschien niet altijd 
even duidelijk vertel, ben ik eenieder hier zeer dankbaar voor. Nu krijg ik de kans 
om mijn dank op papier te zetten zodat het ook vastligt. Mocht ik toch nog iemand 
vergeten zijn dan excuses hiervoor.
Prof. Pickkers, beste Peter, het was en is me een waar genoegen om door jou 
begeleid te worden. Wat een bron van inspiratie van ideeën en enthousiasme. 
Nooit zag je ergens problemen, nooit was iets teveel, altijd zag jij weer kansen en 
mogelijkheden. Zaken die wat krom waren wist jij weer recht te maken en zwakke 
punten wist jij (bijna) altijd weer om te buigen tot sterke punten. Wat heb ik veel 
van je geleerd op allerlei gebieden van de wetenschap, maar ook andere belangrijke 
en minder belangrijke  dingen in het leven. Soms is het wel eens lastig om je bij te 
houden met al je ideeën voor nieuw onderzoek maar mede dankzij al jouw ideeën 
en inspiraties is het een prachtig ‘boekje’ geworden.
Ik kan me nog goed herinneren dat je als nieuwe assistent, en later fellow-
intensivist op de AOV-IC kwam werken. We konden het al snel goed samen vinden 
en ik vond het ook maar wat leuk dat je, jullie zoon naar mij hebt vernoemd of 
was dit toch niet zo? Ik heb je enorm zien groeien in die tijd. Je vertelde me in 
die tijd dat je een prachtig sepsis-model naar Nijmegen ging halen; het LPS-model. 
Op dat moment kon ik al helemaal niet bevroeden dat ik dit model later ook zelf 
zou gaan gebruiken bij mijn onderzoek (hoofdstuk 10). Toen al spraken we geregeld 
over wetenschappelijk onderzoek. Op dat moment was ik nog bezig met mijn studie 
Verplegingswetenschap en had nog geen rol had in de uitvoering van onderzoek. We 
hadden het destijds vooral over cardiologische problemen en hartritmestoornissen. 
Iets waar ik de nodige kennis van had die ik op je kon overdragen; daar stond je altijd 
voor open. Hierna werd je stafarts en al snel groeide je verder door met als kroon 
op je werk (tot nu toe) het hoogleraarschap. In de tussentijd kwam er een vacature 
voor wetenschappelijk onderzoeker op de IC. Jij vond het maar wat belangrijk dat 
ik deze functie zou krijgen, en ik ook. Dit heeft geresulteerd in deze goede en vooral 
ook prettige samenwerking. Hopelijk voor nog een hele lange tijd. DANK (sorry, ik 
had nog allemaal superlatieven willen gebruiken maar ik moet me beperken, anders 
wordt het boekje echt te vol!)
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Prof. van der Hoeven, beste Hans, de drijvende kracht achter onze IC. Jij hebt de 
IC weten op te tillen tot het niveau waar het nu staat; het allerhoogste niveau. Het 
is een eer om met je te mogen samenwerken. Altijd heb je, ondanks je zeer drukke 
werkzaamheden, tijd voor me gehad en stimuleerde je me waar mogelijk, vaak ook 
indirect. We leerden elkaar al een beetje kennen tijdens de Venticare congressen 
waar je altijd een graag geziene, en gehoorde spreker was en bent. Hier spraken we 
voor het eerst over wetenschap en ook over Verplegingswetenschappelijk onderzoek. 
Alhoewel ik niet zeker weet of je toen al wist wat Verplegingswetenschappelijk 
onderzoek allemaal inhield  . Later, toen je in het UMC St Radboud kwam werken, 
hebben we op de AOV-IC veel direct samengewerkt. Jij maakte mogelijk dat ik, samen 
met mijn collega Corine Speelman, in 2004 het klinisch pad voor de hartchirurgie 
mocht ontwikkelen en implementeren. Dit werd een groot succes en dankzij jou kon 
ik me toen verder ontwikkelen, iets waar ik je nog steeds erg dankbaar voor ben. 
Tijdens de regelmatige stuurgroepbijeenkomsten gedurende mijn promotietraject 
hield je altijd de grote lijn in de gaten en zorgde je er ook voor dat we door al onze 
onderzoeksideeën niet teveel afweken van het pad. Tijdens onze laatste bijeenkomst 
heb ik nog laten zien wat mijn originele plan was en dat we uiteindelijk weinig hiervan 
zijn afgeweken. Ik hoop dat we nog lang mogen samenwerken.
Prof. van Achterberg, beste Theo, bijna was ik gestopt met mijn studie 
Verplegings wetenschap toen ik problemen ondervond met het zoeken naar een 
afstudeeronderwerp in mijn derde studiejaar. Mede dankzij jouw interventie heb 
ik uiteindelijk mijn studie afgemaakt. Hier ben ik je nog steeds zeer dankbaar 
voor, anders had ik dit nooit kunnen bereiken. Je zorgde er mede voor dat ik de 
European Academy of Nursing Science (EANS) summer school kon volgen. Hier 
heb ik veel geleerd en leuke internationale contacten aan overgehouden. In de 
tussentijd maakte je eveneens deel uit van mijn begeleidingsgroep tijdens mijn 
promotie onderzoek. Alhoewel onze contacten misschien wat minder intensief 
waren, je commentaren waren altijd constructief en leidde altijd tot nog betere 
manuscripten. Je inbreng was altijd met humor, maar vooral ook veel kennis en 
daardoor zeer waardevol.
Dr. Schoonhoven, beste Lisette, dank voor alle begeleiding en ondersteuning, 
die zich overigens niet beperkte tot sec de wetenschap. Altijd had je oog voor 
zowel de wetenschappelijke kant als ook het menselijk aspect. Dit is tijdens een 
promotietraject ook erg belangrijk. Ik heb me altijd verheugd op onze tweewekelijkse 
bijeenkomsten, en niet alleen vanwege de heerlijke koffie die je speciaal voor mij 
zette. Je was altijd kritisch en constructief in je commentaar, hier heb ik enorm 
veel van geleerd. Bovendien hield ook jij de rode draad van de promotielijn goed 
16
248
in de gaten om te voorkomen dat we soms niet teveel zouden afdwalen, en dat het 
‘boekje’ niet nog dikker werd.
Promoveren doe je niet alleen is een bekende uitspraak en die onderschrijf ik van 
harte. De complete begeleidingsgroep: Peter, Hans, Theo en Lisette ben ik enorm 
dankbaar voor alle ondersteuning. Zonder jullie was het zeker niet gelukt, ik verwijs 
hierbij graag naar stelling 7. Er is een zeer goede en waardevolle samenwerking 
tussen de intensive care en Verplegingswetenschap die we in de toekomst zeker 
moeten en zullen voortzetten.
Maurice Peters en Hans Coolen; dank voor jullie ondersteuning tijdens het gehele 
traject. Alhoewel jullie wat meer aan de kantlijn stonden was dit zeker niet minder 
belangrijk. Tweewekelijks zaten we om tafel om de voortgang van mijn studies te 
volgen, in het begin met Maurice, later opgevolgd door Hans. Waar mogelijk boden 
jullie ondersteuning als er ergens problemen waren of als zaken niet geheel liepen 
zoals we graag wilden. Zonder deze steun was het niet zo ‘soepeltjes’ verlopen.
Researchverpleegkundigen en Promovendi; we zijn een echt team onder de 
bezielende leiding van Peter, maar ook die van Tijn Bouw. Dank voor al je hulp, 
ondersteuning en luisterend oor. Jij hebt excellente kennis op het gebied van de 
WMO en ethische aspecten van het onderzoek die je altijd met ons allen deelt. 
Mede dankzij jou hebben ook Aarnout JansenVanRosendaal, Hetty van der Eng en 
Marieke van der A hun steentje kunnen bijdragen aan onder andere het delirium 
onderzoek. Ook speciale dank aan onze researchsecretaresse Yvonne Kaspers en 
onze decubitus en wondspecialist Wendy Groetelaers voor al jullie ondersteuning 
bij en rondom mijn onderzoeken. Ik denk dat jullie niet beseffen hoe belangrijk jullie 
voor ons onderzoekers zijn. Hoewel we het wel eens vergeten te benoemen, DANK 
voor al jullie hulp en steun.
Daarnaast hebben we een grote groep promovendi en gepromoveerden die bij 
het gehele promotietraject onmisbaar zijn. Al was het alleen maar vanwege het 
tafeltennissen (koning van de ‘bananen-ballen en diepe snijders’), fietsen (altijd 
leuk als een collega alleen je rug ziet bij het fietsen; Matthijs, maar je bent zeker 
geen wieltjeszuiger!), karten, samen naar New Kids en andere intellectuele films, 
het gezellige vrijdagmiddag borrelen en andere dingen die ik nog ben vergeten/
of geen ruimte meer voor heb. Maar ook het samen ‘kelderslaaf’ mogen zijn, 
en discussiëren over methodiek, statistiek, wetgeving en andere belangrijke 
onderzoeksgerelateerde zaken. Matthijs, Bart, Lucas, Benno, Jonne, Suzanne, 
Mirrin, Kim, Jenneke en onze jongste aanwinst in het lab Jelle; DANK voor al 
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bovengenoemde leuke en vooral ook leerzame dingen. Dankzij jullie zijn het zeker 
geen tropenjaren geweest.
Sjef van der Velde; onze expert op het gebied van de ICT. Dankzij jou is het gelukt om 
veel data op een veel eenvoudigere manier beschikbaar te krijgen voor onderzoek 
in zijn algemeenheid en in het bijzonder voor al mijn delirium onderzoeken. Zonder 
jouw hulp was ik waarschijnlijk nu nog aan het analyseren (stelling 9). Niets was 
teveel, altijd was alles mogelijk. En je zag me alweer aankomen als ik toch nog 
iets veranderd wilde hebben in de elektronische CAM-ICU versie, en later ook het 
PRE-DELIRIC model. Mede dankzij jou is dit allemaal geïntegreerd in ons IC-web/
PDMS. Ik ben je hier zeer dankbaar voor. Ging het aanvankelijk nog over delirium 
en onderzoek, later kwamen hier ook meer persoonlijke dingen bij zoals vakanties 
en whisky. Ik heb je kennis op velerlei zaken hoog zitten, behalve Retsina ‘wijn’. 
Onlangs kwam Maikel Couwenberg erbij die voor mijn latere deliriumstudies erg 
belangrijk is geweest. DANK
Verder wil ik ook alle verpleegkundigen en hoofdverpleegkundigen, het 
secretariaat, intensivisten, fellow-intensivisten en arts-assistenten bedanken voor 
hun hulp, steun en adviezen. En Jennie, jou wil ik in het bijzonder bedanken. Jou 
zadelde ik iedere keer weer op met de lastige taak om een stuurgroepbijeenkomst 
te plannen met al mijn begeleiders en hun overvolle agenda’s. Geen sinecure dus, 
maar het lukte je iedere keer weer; dank hiervoor. Mede ook dankzij jullie is het een 
goede en uiterst prettige leer- en werkomgeving.
Dr. de Laat, beste Erik, onze samenwerking dateert nog van de tijd dat ik als ic-
verpleegkundige op de AOV-IC begon. We hebben veel samengewerkt, alleen nooit 
samen ‘aan het bed’ gestaan. Al snel na mijn aanstelling op de AOV-IC in 1996 
kwam ik, samen met en door jou in de redactie van Cordiaal waar ik veel van je heb 
geleerd. Later zaten we ook samen in de redactieraad van Nursing. Mede dankzij 
jouw inzet mocht ik bij Verplegingswetenschap in Utrecht mijn colloquium doctum 
doen om daarna te mogen starten met mijn studie Verplegingswetenschap. Hierna 
werd je mijn begeleider tijdens mijn afstudeerfase. Alhoewel je rol tijdens het 
promotietraject beperkt was, bleef je altijd geïnteresseerd in de voortgang. Dank 
voor al je hulp, adviezen en je niet aflatende enthousiasme.
Choco+ leden; beste studiegenoten Eline (en Bart), Miranda, Leo (en Joke), Anne-
Margreet (en Frits) en Mia, we deelden tijdens onze studie al snel een tweede liefde 
naast het onderzoek, en dat was chocolade. Ik keek altijd uit naar onze choco+ 
bijeenkomsten meerdere keren per jaar. Vaak hebben we onze bijeenkomsten 
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gecombineerd met de uitvoering van ander zinvol onderzoek; het blind testen van 
chocolade/bonbons/truffels en andere choco-producten. Ook keek ik altijd uit naar 
onze jaarlijkse, immer leuke en gezellige, kampeerweekenden. Dank voor al jullie 
interesse en support, niet alleen tijdens mijn promotietraject maar ook ervoor. Wie 
is de eerstvolgende?
Paranimfen Marius en Frank; ik vind het werkelijk bijzonder dat mijn twee beste 
vrienden vandaag naast me staan tijdens deze belangrijke dag. De start van onze 
vriendschap dateert alweer van enige tijd geleden. Voor Marius al tijdens onze 
inservice A-opleiding in Boxmeer in 1983. Hier beleefden we gouden tijden in 
de ‘huiskamer’, biljarten bij ‘schele Herman’, de DOKA om foto’s te ontwikkelen, 
alle ontgroeningen die we uitvoerden of waar we aan mee hielpen etcetera. 
Prachtig. Maar ook bij belangrijkere werkzaamheden als in de leerlingenraad en 
de ondernemingsraad. De vriendschap tussen ons vieren, met jouw vrouw Anja 
en mijn vrouw Lilian, is altijd in stand gebleven en zelfs nog intensiever geworden. 
Recentelijk hebben we ons 25-jarig jubileum gevierd; op naar de volgende 25 jaar. 
Frank, wij kennen elkaar ook alweer 15 jaar en onze vriendschap is ontstaan tijdens 
onze samenwerking op de AOV-IC. Het klikte meteen, ook later met Alice erbij. Het 
was altijd een gezellig samenzijn met veel wederzijdse belangstelling voor elkaar, 
meestal onder het genot van een heerlijk glas wijn. Toen ik begon als onderzoeker 
wist jij het meteen: ‘dit gaat jou glansrijk lukken’, en ik wist meteen dat jij het absoluut 
zou maken als fotograaf toen jij je uniform inruilde om vakfotograaf te worden. Het 
is je gelukt, en zie daar, een prachtige door jou gemaakte coverfoto op mijn boekje.
Verder wil ik alle medeauteurs bedanken die het mogelijk hebben gemaakt om de 
delirium onderzoeken uit te voeren. De samenwerking met meerdere centra, onder 
andere met Utrecht (Arjen Slooter), Leeuwarden (Michael Kuiper), Apeldoorn 
(Peter Spronk), Amsterdam (Peter van der Voort), Den Bosch (Koen Simons en Peter 
de Jager) zijn zeer belangrijk en waardevol voor me geweest, en nog.
En niet te vergeten, en zeker niet op de laatste plaats, ook mijn (schoon-)ouders, 
broer, zwagers, schoonzussen, neven en nichtjes en andere niet genoemde vrienden. 
Jullie wil ik ook bedanken voor jullie interesse en begrip, vooral als ik weer eens iets 
vergeten was. Of geen tijd had omdat ik nog moest werken om onderzoeksgegevens 
te verzamelen of data te analyseren of artikelen te schrijven. Gerco en Agnes 
dank voor alle heerlijke en gezellige etentjes met jullie, gecombineerd met jullie 
interesse en support voor en tijdens mijn promotie. Ronald, dank voor de vele uren 
ontspanning waar jij aan bijdroeg tijdens het racefietsen en ATB-en. Hopelijk volgen 
nog vele tochten. 
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Lieve Lilian, het beste moet je altijd voor het laatste bewaren. Ik kan het niet vaak 
genoeg zeggen; zonder jou was dit zeker nooit gelukt. Ik ben je eeuwig dankbaar. Al 
tijdens mijn studie Verplegingswetenschap zorgde jij ervoor dat ik de ruimte kreeg 
om te studeren en hierna ook nog eens tijdens mijn promotietraject kreeg ik alle 
tijd en ruimte. Je kwam met een subliem voorstel; laten we voor iedere publicatie 
voor je proefschrift uit gaan eten. Zo heb ik warme herinneringen overgehouden 
aan etentjes bij onder andere De Schat (Nijmegen), Puur (Berg en Dal), Kaatje bij de 
Sluis (Blokzijl) en last but not least, Bridges (Ubud, Bali). Mede hierdoor vond jij het 
ook beslist niet bezwaarlijk dat er iets meer hoofdstukken in mijn proefschrift staan. 
Altijd was jij mijn sociale antenne en agenda, zorgde dat thuis alles op rolletjes 
liep, regelde en bereidde onze vakanties voor en deed alles wat ik nu vergeet. Het 
is gewoon teveel om op te noemen.  DANK, DANK en DANK… we fietsen samen een 
mooie toekomst tegemoet. 
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Curriculum vitae 
Mark van den Boogaard werd geboren op 8 februari 1965 in 
Nijmegen. Na zijn middelbare school (Merletcollege te Cuijk) 
startte hij in 1983 met de Verpleegkundige inservice-A opleiding in 
het Maasziekenhuis te Boxmeer gevolgd door Militaire Dienstplicht 
in het Militair Revalidatie Centrum te Doorn. Vervolgens rondde 
hij succesvol de Coronary Care Unit opleiding af in het Westeinde 
Ziekenhuis te Den-Haag (1988-1990), gevolgd door de intensive care opleiding in 
ziekenhuis de Weezenlanden te Zwolle (1990-1992). In 1996 ging hij werken als IC 
verpleegkundige op de hartchirurgische intensive care unit van het UMC St Radboud 
te Nijmegen. Van 1994 tot 2000 was hij daarnaast tevens gastdocent hartritme-
geleidingsstoornissen aan het Deltion college te Zwolle en St. Antonius Academie 
te Nieuwegein en ambulance verpleegkundige bij de GG&GD te Nijmegen van 1995 
tot 2000. 
Nadat hij zijn colloquium doctum had behaald in 1998 volgde hij een wiskunde 
opleiding aan het James Boswell instituut van de Universiteit Utrecht. Vervolgens 
studeerde hij Gezondheidswetenschappen afstudeerrichting Verplegings-
wetenschap aan de Universiteit Utrecht en behaalde in 2005 zijn masters diploma. 
Hij studeerde af op een gerandomiseerde studie over subacute wonden waarbij het 
effect op de wondgenezing werd bestudeerd van twee wondbehandelingsmethoden.
In 2007 werd hij aangenomen als promovendus/wetenschappelijk onderzoeker 
op de Intensive Care. Het samenwerkingsverband tussen de afdelingen Intensive 
Care (prof. Hans van der Hoeven, prof. Peter Pickkers) en de afdeling IQ Healthcare 
(prof. Theo van Achterberg, dr. Lisette Schoonhoven) heeft geresulteerd in  de 
totstandkoming van dit proefschrift over Delirium bij Intensive Care Patiënten. 
Tijdens zijn onderzoeksperiode won hij de prijs voor beste mondelinge presentatie 
bij het NVIC-congres 2010 over het delirium predictie model. Verder waren twee 
van zijn artikelen genomineerd voor de Anna-Reynvaan wetenschapsprijs in 2010 
en in 2011.
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Naast zijn werk als wetenschappelijk onderzoeker is Mark bestuurslid van Venticare 
en het tijdschrift Kritiek en is lid van de programmacommissie van Venticare, lid 
en secretaris van het Delirium Consortium Intensive Care, Scholar of the European 
Academy of Nursing Science, extern lid van de kenniskring van het lectoraat Acute 
en Intensieve Zorg aan de HAN, lid van de European Delirium Association en is hij 
lid van de Working Group Postoperative Delirium and Cognitive Dysfunction van de 
European Society of Intensive Care Medicine. 
Na zijn promotie zal Mark zich verder bekwamen in de epidemiologie (onder 
andere door het volgen van de Summer Course Epidemiology in de V.S. en van 
de Masteropleiding Epidemiologie aan de Radboud Universiteit Nijmegen) en 
verbonden blijven aan de afdeling intensive care als wetenschappelijk onderzoeker.
Mark is getrouwd met Lilian Peters en woont in Nijmegen.
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